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1.1 The spleen
The spleen is the largest secondary lymphoid organ in the mammalian body and exerts
a large array of functions. The spleen maintains the erythrocyte population, captures
blood-borne pathogens and facilitates the induction of both innate and adaptive immune
responses1. The unique structure of the spleen facilitates the plethora of functions the
spleen exerts. In Box 1 the anatomy of the spleen is discussed. The immune system
has developed several mechanisms to combat pathogens. The T cell dependent humoral
immune response, which involves the activation of B cells by T cells and induces high
afnity antibody production and life-long memory, takes place in lymph nodes and the
white pulp of the spleen, and plays a key role in the destruction of extracellular pathogens.
However, this mechanism needs more than one week to become fully effective. There
are numerous pathogens that have the capacity to cause severe pathology and even death
within this time. Therefore there are other mechanisms within the immune system that are
active early after pathogen encounter. One of these mechanisms is independent of T cells
and is called the T-independent (TI) immune response. TI antigens can be divided into 2
groups. TI-I antigens, such as lipopolysaccharide (LPS) , are polyclonal stimulators that
are totally independent of T cells in evoking a response, whereas TI-II antigens, such as
Ficoll, the Streptococcus pneumoniae-epitope phosphorylcholine (PC) and dextran, are
independent of T cell help but still need T cell derived factors 2–5. TI-II antigens are
molecules with multiple, repeating subunits and upon intravenous administration target
the marginal zone of the spleen 6,7. Several studies have been performed to investigate
the role of cells in the marginal zone of the spleen in TI immune responses. It has been
described that marginal zone B cells (MZB) are pivotal to the TI immune response against
the model TI antigen Ficoll 8. In addition, marginal zone macrophages (MZM) are also
involved in the TI immune response as they capture TI-II antigens and the anti-Ficoll
response is diminished upon elimination of MZM by liposomes 9. Hence both MZM and
MZB are crucial to the TI-II immune response. However, depletion of MZM using ERTR-
9 for targeting, did not result in a decrease in the TI immune response, suggesting that the
function of the MZM in the marginal zone is less straightforward 10,11. Still, the unique
situation of this cell population in the marginal zone that enables the capture of blood-
borne pathogen and the close proximity to MZB cells point towards the involvement of
MZM in the TI immune response 12.
Recently it was discovered that the MZM-specic monoclonal antibody ERTR-9 rec-
ognizes a murine specic intercellular adhesion molecule- (ICAM-)grabbing nonintegrin
related 1 (mSIGNR1) 13,14 . mSIGNR1 is a C-type lectin that is exclusively expressed
by MZM and is neither expressed by marginal metallophilic macrophages (MMM) nor
the splenic red pulp macrophages. It is one of ve murine homologues of the human C-
type lectins dendritic cell-specic intercellular adhesion molecule 3 (ICAM 3)-grabbing
nonintegrin (DC-SIGN) and liver/lymph node-SIGN (L-SIGN) that play important roles
during homeostasis and pathogen recognition.
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Box 1: The spleen
The anatomy and vascularization of the spleen
The spleen has a central position in the blood circulation and has an ingenious vascularization.
The afferent splenic artery enters the spleen in the region of the hilus and branches into a number
of central or penicillar arterioles that terminate as end arterioles in the red pulp (Fig. 1.1). Central
arterioles branch into numerous small follicular arterioles in the white pulp 15–17. These lymphoid
areas have a white appearance at the macroscopic level and are therefore referred to as the white
pulp. The white pulp follicles display a high resemblance to lymph nodes, since in both lymphoid
organs B cells are located in follicles surrounded by a T cell area where the central arteriole is
located. This anatomical organization facilitates an optimal interaction between T and B cells,
which is pivotal for the induction of a potent immune response.
The red pulp surrounds the white pulp areas and consists of venous sinuses and pulp cords (Fig.
1.1). The red pulp mediates the filtering of the blood by the spleen. The cords contain fibroblasts
that maintain a network of reticular fibers. In addition, numerous macrophages are found within
this area of the spleen. In contrast to the cords, which form an open blood system and thus
are devoid of any endothelial lining 18, the venous sinuses are lined by a discontinuous layer of
endothelial cells oriented along the longitudinal axis of the sinus. These endothelial cells contain
stress fibers and are kept together by annular fibers, which are part of the extracellular matrix.
Upon contraction of the stress fibers, an intercellular space appears. Blood enters the pulp cord
by terminal arterioles and is filtered by the passage through the network of reticular fibers in the
cord and the passage through the endothelial slits surrounding the venous sinuses (Fig. 1.1).
Moreover, the quality of the erythrocyte population is monitored; “old” erythrocytes, which have
a rigid membrane, are not able to deform and penetrate the slits between the endothelial cells and
are phagocytosed by the numerous macrophages residing in the cords. In addition, erythrocytes
bearing intracellular inclusions or intracellular organisms such as malaria can be cleared from
these components during the passage without destruction of the erythrocyte. The membranes of
the cells close and the cells pass into the sinuses while the phagocytic cells will clear the inclusions
and the aged erythrocytes 19,20. Hence, the red pulp of the spleen functions as an ingenious filter
system pivotal for the quality of the erythrocyte population and the clearance of intracellular
inclusions. As described, a large part of the arterial blood traverses the white pulp, reaches the
venous sinuses and leaves the spleen. However, a proportion of the terminal arterioles ends in
a sinus in a distinguishable concentric area that separates the white and red pulp; the marginal
zone 21,22. In contrast to mice, which have one marginal zone, humans have an inner and an outer
marginal zone, which is surrounded by a large perifollicular zone. The blood flow in the marginal
sinus is low and the marginal zone is an important transit area for recirculating B and T cells that
are leaving the bloodstream and entering the white pulp 23 (Fig. 1.1). In addition to being a transit
area, the marginal zone contains a large number of resident cells. These cell populations are
marginal metallophilic macrophages (MMM), marginal zone B cells (MZB) and marginal zone
macrophages (MZM) (Fig 1.1). Together these cells are involved in the screening of the blood for
pathogens, debris and foreign particles.
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Figure 1.1: The anatomy and vascularization of the spleen
Schematic overview of the structure and vascularization of the spleen based on the figures drawn
by G. Kraal 1.
Cells in the marginal zone of the spleen
Between the white pulp and the sinus, sialic acid-binding immunoglobulin-like lectin-1 (Siglec-
1) expressing MMM are situated 24 (Fig. 1.1). MMM display a high affinity for silver and hence
are called metallophilic cells, and are strategically positioned along the borders of the marginal
sinus, ideal for the uptake of blood-borne antigens 16. However, in spite of their acid phosphatase
activity and ability to take up iron compounds, they do not phagocytose well 16.
At the outer face of the marginal sinus, bordering the red pulp, the MZM reside (Fig. 1.1). MZM
are big cells with long cell processes. These cells form a ring of two or three layers dispersed
throughout the marginal zone. They are highly phagocytic, and often contain, when examined at
the ultrastructural level, phagolysosomes with necrotic erythrocytes and cellular debris 25. This
unique macrophage subpopulation is characterized by the expression of the macrophage receptor
with a collagenous structure (MARCO) and ERTR-9 antigen 25,26. Upon systemic administra-
tion of bacteria or LPS, MARCO expression is induced within the red pulp macrophage popu-
lation whereas ERTR-9 staining remains a specific marker for the MZM 27. In contrast to other
macrophages, MZM do not express MHC class II 7. Consequently, MZM are not involved in the
priming of T cells but may be involved in the activation of B cells. Indeed, MZM appear to have
close contacts with a specific B cell population.
There are two splenic B cell populations; the mature recirculating follicular B cells are located
in the B-lymphoid follicles in spleen and lymph nodes, and MZB, which can be found in the
marginal zone. The MZB population comprises about 5% of all peripheral B cells. These cells
are long-lived, apparently naive B cells with a partially activated phenotype 28–30. MZB localize
in the spleen to the marginal zone in the vicinity of the marginal sinus and in close proximity to the
MZM, and do not readily recirculate 31. MZB are in close approximation to the marginal sinus to
facilitate interaction with blood-borne antigens (Fig. 1.1). MZB can be activated to become IgM-
secreting plasmablasts within hours, which is vital to their function in the innate immune response
32. Hence, MZB appear to constitute a first line of defense against blood-borne pathogens.
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1.2 C-type lectins
C-type lectins are pathogen receptors expressed by antigen presenting cells, which are the
sentinels of the immune system that sense danger signals such as infected or transformed
cells and subsequently prime naive T cells to induce an adaptive immune response. Anti-
gen presenting cells acquire antigen, and process this for presentation on MHC molecules
to T cells and are hereby instrumental in the induction of T cell responses 33. An impor-
tant route of antigen uptake occurs through C-type lectin receptors that internalize anti-
gens for processing and antigen presentation on MHC molecules by targeting the antigen
to MHC II-positive late endosomes for degradation and subsequent antigen presentation
34,35
. C-type lectins contain one or multiple carbohydrate recognition domains (CRD)
that enable them to bind to carbohydrate structures, which are present on the surface of
many pathogens but are also expressed by self-antigens (Fig. 1.2). Thus, C-type lectins
are not only involved in pathogen recognition but can also function in homeostasis 36,37.
Antigen binding to C-type lectins does not lead to immune activation, rather these re-
ceptors induce immune tolerance by default, and require simultaneous signaling through
Toll-like receptors (TLR) that specically recognize signature structures of pathogens to
trigger pathogen-specic immune responses during infection 38,39.
The SIGN family of C-type lectins consists of DC-SIGN, L-SIGN and LSECtin
(liver and lymph node sinusoidal endothelial cell C-type lectin) in human and the ve
homologues mDC-SIGN and mSIGNR1 to mSIGNR4 in mice. All SIGN members are
type II C-type lectins that contain one CRD region that denes the ligand specicity of
the receptor (Fig. 1.2).
1.2.1 The human SIGN molecules
Human DC-SIGN is located on chromosome 19p13 in close proximity to the CD23 gene.
Two homologues L-SIGN (DC-SIGNR) and LSECtin are located adjacent to the DC-
SIGN gene40–42. L-SIGN shares 77% amino acid sequence identity with DC-SIGN 40,42,
whereas LSECtin has only 31% identity to DC-SIGN.
DC-SIGN (CD209) was the rst SIGN molecule identied and found to be expressed
at high levels on monocyte-derived dendritic cells (DC) 43 (Fig. 1.2). In situ, DC-SIGN is
present on subsets of immature DC at dermal and mucosal sites in the periphery, and on
both immature and mature DC in lymphoid tissue such as tonsils, lymph nodes, and spleen
43–45
. DC-SIGN is not expressed on DC subsets of blood, except for a subpopulation of
CD14+ cells with DC-like phenotype 35. Other DC subsets such as plasmacytoid DC, and
Langerhans cells do not express DC-SIGN.
Recently, it was shown that upon infection with Mycobacterium tuberculosis and My-
cobacterium leprae, DC-SIGN expression is induced on alveolar and leprosy skin lesion
macrophages with a tolerant phenotype respectively, suggesting expression of DC-SIGN
on macrophage subsets 46,47.
The expression pattern of L-SIGN and LSECtin is strikingly different from that of
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Figure 1.2: Schematic overview of the structure and expression of DC-SIGN and its human
and murine homologues
All SIGN homologues are transmembrane receptors, except for mSIGNR2, which is a soluble re-
ceptor. The percentage amino-acid-homology of the CRD of the different homologues compared
to DC-SIGN are depicted above the CRD. Within the CRD the highly conserved EPN sequence is
essential for recognizing mannose-containing structures. All SIGN homologues contain the EPN
motif, except for mSIGNR4, which has a QPN motif, indicating that mSIGNR4 may have another
ligand specificity compared to the other SIGN molecules. In contrast to DC-SIGN that contains
7 complete and one incomplete repeat, the number of repeats of L-SIGN is variable and varies
between 3 and 9 which is indicated with arrows. Within the cytoplasmic tail several internaliza-
tion motifs are found. The di-leucin (LL) motif is thought to be important for internalization of
DC-SIGN. The tyrosine-based motif and the tri-acidic cluster are also involved in internalization.
However, the internalization capacities of the homologues of DC-SIGN have not been extensively
explored. Based on its expression pattern, mSIGNR1 seems more similar to the homologue of
L-SIGN rather than DC-SIGN whereas the expression of mDC-SIGN seems more homologous to
DC-SIGN, although they are expressed by different DC subtypes.
DC-SIGN. In contrast to DC-SIGN, L-SIGN and LSECtin are neither expressed by DC in
vivo nor by monocyte-derived DC cultured in vitro 40,41, rather both L-SIGN and LSECtin
are expressed in liver on liver sinusoidal endothelial cells (LSEC) and in lymph node (Fig.
1.2)40,41. Whereas DC-SIGN is expressed on lymph node DC, L-SIGN is found on cells
underneath the subcapsular sinus of the lymph node that express the endothelial markers
LIVE-1 and CLEVER-1( 44). These cells are in direct contact with afferent lymph that
not only carries antigens bound to DC, but also transports soluble antigens to the lymph
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node. In addition, L-SIGN is expressed by placenta endothelial cells 48.
Both DC-SIGN and L-SIGN contain repeats within the neck domain. In contrast to
DC-SIGN that contains 7 complete and one incomplete repeat, the number of repeats
of L-SIGN is variable and varies between 3 and 9 (Fig. 1.2) 40. These neck domains
enable multimerization of DC-SIGN and L-SIGN, and both receptors form tetramers 49,50.
Tetramerization of DC-SIGN and L-SIGN may strengthen interactions with ligand by
enabling high-avidity binding. Since alleles encoding L-SIGN have variable numbers of
repeats in heterozygotic individuals, this may affect proper tetramerization of L-SIGN,
and abrogate or modulate ligand binding to L-SIGN. Indeed, Chan et al. observed that
cells expressing L-SIGN molecules with similar numbers of tandem repeats display a
higher ligand binding capacity than cells expressing heterozygous L-SIGN with different
numbers of tandem repeats 51.
Through the binding of various pathogens, DC-SIGN also functions as an antigen
receptor that internalizes upon binding of antigen, and targets bound antibody to the late
endosomal/lysosomal compartment for processing and presentation to T cells 35. Thus far
it is unknown whether L-SIGN has an antigen presenting function.
L-SIGN has considerable homology to DC-SIGN in the cytoplasmic tail and the di-
leucine motif, which is essential for internalization through DC-SIGN 52,53, is conserved
in L-SIGN, indicating that also L-SIGN functions as an internalization receptor (Fig. 1.2).
Indeed, similar to DC-SIGN, L-SIGN mediates internalization of hepatitis C virus (HCV)
particles to the endosomal compartment 52.
Binding specificity of DC-SIGN and L-SIGN
The CRD of the SIGN receptors determines their binding specicity. Within the
CRD the highly conserved sequences are essential in recognizing mannose-, fucose- or
galactose-containing structures. The CRD of DC-SIGN contains an EPN motif, resulting
in a high afnity for mannose-type carbohydrates (Fig. 1.2) 54. DC-SIGN also specically
binds non-sialylated Lewis antigens such as Lewisa, Lewisb, Lewisx, and Lewisy and this
has led to the identication of several pathogens and cellular ligands that are recognized
by these receptors55,56. DC-SIGN recognizes viruses such as human immunodeciency
virus type 1 (HIV-1) , Dengue virus, human cytomegalovirus, Ebola and HCV, Mycobac-
terium tuberculosis, but also parasites such as Schistosoma Mansoni and cellular ligands
such as ICAM-2, expressed by endothelial cells, and ICAM-3 present on T cells, through
high mannose glycans 43,45,55,57–61.
The interaction of DC-SIGN with cellular ligands such as ICAM-2 and ICAM-3 in-
dicates that DC-SIGN serves as an adhesion receptor to establish cellular interactions be-
tween DC and T cells, DC-SIGN/ICAM-3, or DC and endothelial cells, DC-SIGN/ICAM-
2( 43,45). In addition, DC-SIGN expressed by DC was observed to interact with neutrophils
through Lewisx expressed by Mac-1 and CEACAM1( 56,62). Both ligands are upregulated
upon neutrophil activation. Strikingly, DC-SIGN specically interacts with Mac-1 ex-
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pressed by neutrophils in contrast to Mac-1 expressed by other cells. This interaction,
through the production of TNFα by the neutrophil, results in DC maturation. Upon mat-
uration, the DC produce interleukin (IL)-12, which skews the concomitant immune re-
sponse to induce a helper T cell (Th) 1 response. Hereby the neutrophil inuences the
immune response through DC-SIGN.
The highest degree of homology between DC-SIGN and L-SIGN is found within the
CRD, indicating that L-SIGN and DC-SIGN have similar ligands (Fig. 1.2). Indeed, L-
SIGN, similar to DC-SIGN, recognizes high mannose glycans, and binds high mannose-
containing ligands. Similar to DC-SIGN, L-SIGN is able to bind ICAM-3( 40), and may
establish cellular interactions with ICAM-3-expressing T cells allowing activated T cells
to leave the circulation and enter the liver and lymph nodes.
Strikingly, L-SIGN does not bind to the fucose-containing Lewisx antigen in contrast
to DC-SIGN. The difference in the carbohydrate recognition prole of DC-SIGN and L-
SIGN has been traced to a single amino acid mutation: Val351 in DC-SIGN to Ser363
in L-SIGN63,64. Protein modeling indicates that Val351 forms a hydrophobic pocket that
is required to t Lewisx into DC-SIGN and to stabilize binding. Lewisx binding to L-
SIGN is disrupted since a hydrophilic serine is present in L-SIGN. This suggests that
L-SIGN-expressing endothelial cells of liver and lymph node are not involved in capture
of Lewisx expressed by pathogens nor self structures. Possibly the differential recognition
of Lewisx is involved in the capacity of L-SIGN to discriminate between two Leishmania
parasite strains. Whereas DC-SIGN binds both L. pifanoi and L. infantum, which induce
cutaneous and visceral leismaniasis respectively, L-SIGN specically recognizes only L.
infantum65, suggesting that the interaction between L-SIGN expressed by LSEC and L.
infantum may be involved in the infection of juxtaposing Kupffer cells, the target cells of
L. infantum.
DC-SIGN and L-SIGN as a pathogen receptor for viruses
Several viruses, such as HIV-1, severe acute respiratory syndrome coronavirus, Den-
gue virus and Sindbis virus, were found to interact with DC-SIGN and L-SIGN, result-
ing in infection48,60,61,66–68. However the structures involved in the specic interaction
with DC-SIGN and L-SIGN have not yet been identied. For the viruses HIV-1, HCV,
and Ebola it has been established that L-SIGN and DC-SIGN bind these viruses through
recognition of high mannose moieties 40,57,69–71. Strikingly, some viruses use the binding
to DC-SIGN for transport and a more efcient infection of other target cells. This mech-
anism was rst identied for HIV-1. Immature DC-SIGN+ DC are located underneath
mucosal epithelium at sites of HIV-1 transmission. After capture of HIV-1 by DC-SIGN
on DC, DC may travel to the lymph nodes where CD4+ T cells reside and present HIV-
1 for in-trans infection of T cells 61. After internalization through DC-SIGN, HIV-1 is
routed to non-lysosomal compartments which allows HIV-1 to escape lysosomal degra-
dation and remain virulent within DC for prolonged times 72,73. This mechanism may
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also be used by other viruses since DC-SIGN also binds and internalizes Dengue virus,
human cytomegalovirus, Ebola and HCV for in-trans infection of target cells 57–60. More-
over, these viruses directly infect DC through interactions with DC-SIGN 57,60. L-SIGN
mediates in-trans infection of target cells with similar efciency as DC-SIGN 40,57,59. In
particular, L-SIGN interaction with viruses may be of importance for transmission of
hepatotropic viruses such as HCV. Indeed, L-SIGN expressing LSEC have been shown to
capture HCV from the blood and transmit the virus to neighboring hepatocytes, in which
HCV can replicate52,74. Thus, viruses target both DC-SIGN and L-SIGN to facilitate the
infection of target cells.
Besides these similarities in the binding to pathogens, DC-SIGN and L-SIGN also
display unique binding capacities. Davis et al. showed that human cell-derived West
Nile virus is specically recognized by L-SIGN while it was recognized to a much lesser
extent by DC-SIGN, indicating that human cell-derived West Nile virus contains a yet
unidentied ligand that is specically bound by L-SIGN but not by DC-SIGN 75.
DC-SIGN and L-SIGN as a pathogen receptor for bacteria and parasites
Although M. tuberculosis primarily infects macrophages, it also binds DC through in-
teractions of its cell wall component ManLAM with DC-SIGN 76,77. Moreover, ManLAM
is secreted by M. tuberculosis-infected cells, and ManLAM binding to DC-SIGN on DC
blocks Toll-like receptor-induced maturation of DC and induces the immunosuppressive
cytokine IL-10( 76). This indicates that binding of ManLAM to DC-SIGN triggers in-
hibitory signals by which M. tuberculosis suppresses immune activation signals through
TLR signaling. Recently, probiotic bacteria such as the Lactobacillus species L. reuteri
and L. casei were found to also exert immune suppression through engagement of DC-
SIGN on DC. However, in contrast to M. tuberculosis, these bacteria of the normal gut
ora do not inhibit DC maturation, but instruct DC to induce IL-10-producing regulatory
T cells that suppress T cell responses 78. Thus, bacteria use DC-SIGN binding to modulate
the immune response.
Non-sialylated Lewis antigens are expressed on LPS of Helicobacter pylori and on
soluble egg antigens of the parasite Schistosoma mansoni and indeed these pathogens
bind to DC-SIGN55,76,79. Although interaction of Lewis antigen-expressing H. pylori
with DC-SIGN also results in immune regulation, this is different from the immune mod-
ulation exerted by M. tuberculosis, L. reuteri and L. casei. DC-SIGN binding Lewisx+/y+
H. pylori induce a mixed Th1/2 response, whereas Lewis− H. pylori that do not bind
DC-SIGN trigger a Th1 response 80. Since H. pylori can spontaneously switch the ex-
pression of the Lewis antigen on LPS, H. pylori can evade the recognition by DC-SIGN
by down-regulating the Lewis expression. In addition, the phase shift may enable the few
Lewis+ H. pylori in a predominant Lewis− H. pylori population to suppress protective
Th1 responses, and may provide an explanation for the induction of chronic gastritis by
H. pylori infection. The parasite S. mansoni also triggers Th2 responses, however, it is
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presently unknown whether the interaction of Lewis antigens on the parasite with DC-
SIGN on DC is involved in the modulation of the evoked immune response towards a Th2
prone response81.
In conclusion, pathogen binding by DC-SIGN can result in the modulation of the im-
mune response facilitating persistence of the pathogen. Possibly, L-SIGN is also involved
in the immune-suppressive mechanisms induced by pathogens.
1.2.2 The murine SIGN homologues
Five murine DC-SIGN homologues have been cloned and have been characterized by
several groups14,82–84; as a consequence, some of these homologues received differ-
ent names. The ve homologues of DC-SIGN will be addressed here as mDC-SIGN,
mSIGNR1 (SIGN-Related), mSIGNR2, mSIGNR3 and mSIGNR4. These ve homo-
logues of DC-SIGN are situated on adjacent regions of mouse chromosome 8 A1.2-1.3.
Similar to human DC-SIGN, the mDC-SIGN gene is located in close proximity to the
CD23 gene, and similar to human L-SIGN, mSIGNR1, 2 and 3 are located near the mDC-
SIGN gene.
The ve murine homologues display various deviations from the general structure of
DC-SIGN (Fig. 1.2). Despite a similarity ranging from 65% to 70% to the amino acids
in the CRD region of human DC-SIGN, the murine homologues have a much shorter
membrane proximal neck domain compared to their human homologues, with a lesser
degree of homology.
Soluble forms of murine DC-SIGN homologues
The murine homologue mSIGNR2 is expressed as a soluble form, since it lacks the
cytosolic and the transmembrane domain (Fig. 1.2) 84. Also, two alternative splicing
products of mSIGNR1 were found. One of these products lacked the transmembrane
region84. The cellular fate and the function of the homologues lacking the transmembrane
domain are unknown. These soluble proteins may remain in the cytoplasm and/or may be
secreted85. The presence of soluble DC-SIGN homologues in the cytoplasm can be useful
in the recognition of viral pathogens that have infected the cell, similarly as has been
shown for soluble mannose-binding lectin 86. Secretion of soluble murine homologues of
DC-SIGN may act as extracellular antagonists of the membrane-expressed homologues
as has been reported for CD23, CD72 and mast cell function-associated antigen 87–89.
Although mSIGNR2 mRNA has been detected in testis and LPS-stimulated B cells none
of these soluble molecules have been detected at the protein level yet.
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mSIGNR3 and mSIGNR4
mSIGNR3 mRNA has been detected at low levels in spleen and lymph node. At a
cellular level, some mSIGNR3 RNA could be detected at low levels in DC, and at even
lower levels in T and B cells 84. However, expression of mSIGNR3 at the protein level
remains elusive. Using a soluble IgG-Fc mSIGNR3 chimera, a binding specicity for
mannose-, fucose- and N-acetylglucosamine-terminating oligosaccharides was demon-
strated90. The fucose recognition was demonstrated by the binding to Lewis antigens
Lewisa/b and Lewisx/y. In addition, mSIGNR3 expressed by transfectants displayed a
specicity for both dextran and zymosan 91.
mSIGNR4 mRNA was detected at high levels in testis, similar to mSIGNR2, and at
very low levels in spleen. No RNA was detected in either DC, T cells or B cells 84. In con-
trast to the other murine SIGN receptors, mSIGNR4 has a QPN motif instead of an EPN
motif, indicating that mSIGNR4 preferentially binds galactose-containing carbohydrates
(Fig. 1.2)54,84.
Although there are ve murine homologues of DC-SIGN present at DNA level, only
mDC-SIGN and mSIGNR1 are expressed by cells of the immune system. Hence, research
has focused on mDC-SIGN and mSIGNR1 and little is known so far of the other murine
homologues.
mDC-SIGN
All murine homologues were rst identied by RT-PCR from murine spleen DC,
whereas only mDC-SIGN has been shown to be expressed by DC 83. By RNA blot
analysis, mDC-SIGN mRNA was detected at high levels in spleen, lung, and bone mar-
row, and at moderate levels in kidney, heart, thymus and lymph node 83,84. Assessment
of the mDC-SIGN RNA at the cellular level showed that mDC-SIGN RNA was abun-
dantly present in DC, at low levels in B cells, but not in T cells 83. CD8α− DC express
higher levels of mDC-SIGN RNA than CD8α+ DC83. Similar to human DC-SIGN on
DC, the expression of mDC-SIGN is down-regulated upon DC activation and matura-
tion83. Interestingly, mDC-SIGN is expressed on plasmacytoid preDC that differentiate
into CD8+CD205− DC upon activation with microbial stimulus (Fig. 1.2) 92. These data
suggest that, although the DC subsets are different, mDC-SIGN being DC-specic most
closely resembles DC-SIGN.
Recent studies have shown that mDC-SIGN is not equipped to bind to multivalent
pathogen ligands such as Ebolavirus glycoprotein and HIV-1 gp120 (our unpublished
observations)93. Using murine and human DC-SIGN chimeras it was shown that both the
neck domain, as well as the CRD, prevents interaction of mDC-SIGN with multivalent
ligands. Therefore, despite the similarity in expression and the homology of amino acids
in the CRD, mDC-SIGN does not appear to be suited to function as a model for further
investigations into the in vivo function of DC-SIGN. However, mDC-SIGN can be used
as a tool to specically target the CD8− DC population94.
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mSIGNR1
The most extensively studied of the 5 murine homologues of DC-SIGN is mSIGNR1.
mSIGNR1 mRNA has been demonstrated at high levels in lymph nodes, moderate levels
in both spleen and testis, but little or no expression in other tissues 13,84. Hardly any or
no mSIGNR1 expression was found on DC, alveolar macrophages, B cells and T cells
13,95
. Identication of mSIGNR1 as the antigen for the MZM-specic antibody ERTR-
9, led to a more detailed investigation of its expression pattern 14. mSIGNR1 protein
was found to be expressed in lymph node, spleen and liver. In addition, Taylor et al.
demonstrated that mSIGNR1 is expressed on resident peritoneal macrophages 95, whereas
thioglycollate elicited macrophages do not express mSIGNR1( 96). Besides mSIGNR1,
resident peritoneal macrophages also express the C-type lectin Dectin-1. Both mSIGNR1
and Dectin-1 are involved in the capture of the yeast component zymosan 95. In the lymph
node, mSIGNR1 is expressed on the medullary and subcapsular macrophages 14 (Fig.
1.2). In humans, L-SIGN is expressed by cells located underneath the subcapsular sinus
of the lymph node44. Possibly, both L-SIGN and mSIGNR1 are involved in the capture
of antigen from circulating lymph.
In the liver the expression of mSIGNR1 is similar to L-SIGN as they are both ex-
pressed by liver LSEC 14, which are specialized endothelial cells that are localized be-
tween the liver sinusoids and hepatocytes. Here, these fenestrated endothelial cells,
which lack a basal membrane, function as a barrier to protect the hepatocytes from blood-
borne harmful components while allowing for exchange of nutrients 97. These specialized
endothelial cells with antigen presenting cell characteristics internalize components via
receptor-mediated endocytosis and are able to transcytose these agents across the created
barrier. Lohse et al. have described that LSEC are able to present antigen to, and prime,
naive CD4+ T cells similar to DC98. Strikingly, LSEC induce immune tolerance 99.
Recently it has been described that murine LSEC are able to cross-present food anti-
gens on their MHC I molecules within 2 hours after ingestion 100. Similar to CD4+ T cells,
the functional outcome of CD8+ T cell stimulation by cross-presenting LSEC is tolerance
101
. Therefore it seems that LSEC are a liver-specic antigen presenting cell population
that is organ resident and induces immune tolerance. LSEC are known for their highly
efcient receptor-mediated endocytosis of macromolecules. The expression of pattern
recognition receptors by LSEC facilitates the internalization of substantial amounts of
molecules for MHC-restricted presentation to T cells. Pattern recognition receptors ex-
pressed by LSEC are the mannose receptor and scavenger receptors. However, these
receptors are expressed quite ubiquitously. In contrast, the C-type lectin L-SIGN and its
murine homologue mSIGNR1 are specically expressed by LSEC and not by other liver
resident immune cells such as Kupffer cells 14,40,48,84. The function of these C-type lectins
during homeostasis is currently unclear. Future experiments on the function of mSIGNR1
expressed by LSEC will unravel its in vivo function and may serve as a model for the in
vivo function of L-SIGN.
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1.3 The in vivo function of the SIGN molecules
Although mSIGNR1 is not expressed by DC but by specic macrophage subsets, its func-
tion has been studied in more detail than mDC-SIGN. mSIGNR1 has a binding activity
for hICAM-2 and hICAM-3 similar to human DC-SIGN 14,82. Thus, mSIGNR1 can func-
tion as an adhesion receptor. However, mice do not express an ICAM-3 homologue and
therefore binding of mSIGNR1 to ICAM-3 is not physiologically relevant. mSIGNR1
also interacts with murine ICAM-2, which is widely expressed on murine lymphocytes,
and could therefore mediate contact between mSIGNR1-positive cells and leukocytes in
mice102.
Besides being a gateway for migrating lymphocytes, the splenic marginal zone is also
important as a defense against pathogens (reviewed by Kraal 103). Because of their po-
sition adjacent to the marginal sinuses, MZM are among the rst cells to interact with
blood-borne antigens and are presumed to have a critical role in host defense against bac-
terial pathogens. The fact that mSIGNR1 is abundantly expressed by MZM 13,14 hints to
a function as a pathogen recognition receptor. Indeed, mSIGNR1 is able to capture the
model polysaccharide antigen dextran, and mannan, the major constituent of the yeast-
derived particle zymosan directly from blood 13,14. Hence, mSIGNR1 functions as a
pathogen receptor contributing to the lter function of the spleen. The spleen is known to
be pivotal for the clearance of blood-borne pathogens such as Streptococcus pneumoniae,
lymphocytic choriomeningitis virus, ectromelia virus and Sindbis virus 104–108. It remains
to be seen whether mSIGNR1 merely scavenges the pathogens from the blood or whether
mSIGNR1 is also involved in the presentation of these captures antigens to closely situ-
ated marginal zone B cells (Fig. 1.1). The situation of the MZM and MZB, which reside
in close contact to each other, would allow for such interactions, resulting in a role for
mSIGNR1 in the TI immune response.
1.4 Outline of this thesis
The binding characteristics of murine SIGNR1 was investigated and compared to both hu-
man homologues; DC-SIGN and L-SIGN (Chapter 2) 109. Both DC-SIGN and mSIGNR1
share a preference for multi-mannose coupled to the lipoarabinomannan (LAM) structure
of mannose-capped LAM (ManLAM) , a capsular component of Mycobacterium tuber-
culosis (Chapter 3)110. To investigate the in vivo consequences of the recognition of M.
tuberculosis by mSIGNR1, mSIGNR1-decient mice were studied in an infection model
with M. tuberculosis in Chapter 4. Although the immunosuppressive cytokine IL-10 was
induced upon in vitro stimulation of peritoneal macrophages with ManLAM, and en-
hanced early systemic immune response in the mSIGNR1-decient mice was observed,
no differences in pathology were apparent. Our results indicate that mSIGNR1 does not
play a crucial role in M. tuberculosis pathology since mSIGNR1 is not expressed in the
lungs but at sites remote from the site of infection. Therefore we investigated the in vivo
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function of mSIGNR1 during infection with a pathogen known to depend on the spleen
for an effective immune response; S. pneumoniae 111.
First the interaction of DC-SIGN with Streptococcus pneumoniae was investigated
(Chapter 5)112. From a panel of S. pneumoniae serotypes we demonstrated that DC-SIGN
specically interacted with 2 serotypes; serotype 3 and 14 and not with serotype 19. The
binding of S. pneumoniae serotype 14 was mediated through the capsular polysaccharide.
For serotype 3 the ligand bound by DC-SIGN remains unidentied. Similar to DC-SIGN,
mSIGNR1 recognizes S. pneumoniae. This is of specic interest since the spleen plays
an important role in the immune defense against encapsulated Gram-positive S. pneumo-
niae; this bacterium is notorious for its overwhelming post-splenectomy infections and
has been observed to target the marginal zone of the spleen where the mSIGNR1 express-
ing marginal zone macrophages reside (Fig. 1.1). We therefore set out to investigate
in Chapter 6 the in vivo function of mSIGNR1 during infection with S. pneumoniae 113.
Upon infection with S. pneumoniae, we observed a striking difference in pathology be-
tween wild type and mSIGNR1-decient mice. The mSIGNR1-decient mice displayed
more severe pathology with a larger inux of cells and a larger outgrowth of the bac-
teria in various organs. In addition, the amount of early IgM antibodies reactive with
PC, expressed by S. pneumoniae, was analyzed and was very low in mSIGNR1-decient
mice compared to wild-type mice, indicating a possible role of mSIGNR1 in the pro-
duction of early anti-PC antibodies. Likely, these early anti-PC antibodies are produced
by marginal zone B cells, which reside in close contact with the mSIGNR1-expressing
marginal zone macrophages of the spleen (Fig. 1.1). In Chapter 7 we investigated the
interaction between mSIGNR1 and marginal zone B cells more closely. Indeed we ob-
served that mSIGNR1 is able to interact with marginal zone B cells. Although a decrease
in the amount of marginal zone B cells was observed in mSIGNR1-decient mice de-
spite a normal location of this specic cell population, the functional consequences of
this interaction are not fully understood yet.
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Abstract
C-type lectins are important receptors expressed by antigen presenting cells that are in-
volved in cellular communications as well as in pathogen uptake. An important C-type
lectin family is represented by DC-SIGN and its homologues in human and mouse. Here
we have investigated the carbohydrate specicity of cellular mSIGNR1 and compared it
with DC-SIGN and L-SIGN. mSIGNR1 has a similar specicty as human DC-SIGN for
high mannose-containing ligands present on both cellular and pathogen ligands. However,
the SIGN molecules differ in their recognition of Lewis antigens; mSIGNR1 interacts not
only with Lewisx/y and Lewisa/b antigens similar to DC-SIGN, but also with sialylated
Lewisx, a ligand for selectins. The differential recognition of Lewis antigens suggests
differences between mSIGNR1 and DC-SIGN in the recognition of cellular ligands and
pathogens that express Lewis epitopes.
2.1 Introduction
Antigen presenting cells such as macrophages and dendritic cells (DC) express C-type
lectins that are involved in pathogen capture, processing and antigen presentation to in-
duce immune responses against these pathogens 1. However, it is becoming clear that
several lethal pathogens have evolved to subvert the function of some C-type lectins to
escape immune surveillance 2. An important C-type lectin family is represented by DC-
SIGN and its homologues in both human and mouse.
The SIGN family of C-type lectin receptors (CLR) consists of DC-SIGN and L-
SIGN in human and the ve murine homologues mDC-SIGN, mSIGNR1 to mSIGNR4.
Human DC-SIGN is expressed by DC 2,3, whereas L-SIGN is expressed on specialized
liver and lymph node endothelial cells that possess antigen presentation capacity 4–6. In
mouse, only mDC-SIGN is expressed by DC 7, whereas the mSIGNR1-4 molecules dis-
play a differential tissue distribution 8. The most extensively studied of these murine
homologues is mSIGNR1, which is expressed on marginal zone macrophages (MZM) 8,9
and peritoneal macrophages 10.
DC-SIGN has been demonstrated to interact with various viruses such as HIV-1 11,
human cytomegalovirus 12, and Dengue virus13 and microbes including M. tuberculosis
14,15 and Leishmania parasites 16. DC-SIGN has been shown to mediate internalization
of ligands for antigen presentation 17. Strikingly, HIV-1 exploits this feature of DC-SIGN
to gain access to CD4+ T cells that are the primary target cells of infection 11. Similarly,
other viruses have been shown to use DC-SIGN to enhance viral transmission to target
cells2, whereas M. tuberculosis and Helicobacter pylori target DC-SIGN to modulate DC
function14,18. Thus, several pathogens target DC-SIGN to escape immune surveillance.
Identication of the carbohydrate specicity of DC-SIGN for high mannose glycans and
non-sialylated fucose-containing Lewis (Le) antigens, such as Lea,Leb,Lex and Ley 19–21,
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has led to the identication of both pathogens and self-antigens that are recognized by this
receptor. The high degree of homology between the carbohydrate recognition domains of
DC-SIGN and L-SIGN is reected by their similar ligand specicity. L-SIGN, similar to
DC-SIGN, recognizes high mannose glycans, and binds high mannose-containing ligands
such as HIV-1 and HCV 4,22. However, L-SIGN does not bind to the fucose-containing
Lewis antigens in contrast to DC-SIGN 23.
The carbohydrate specicity of mSIGNR1 demonstrated specicity for mannose- and
fucose-terminating oligosaccharides 24,25. By using a soluble recombinant chimera of
mSIGNR1 fused to an Fc domain, Galustian et al. demonstrated that mSIGNR1 binds
to the Lewis antigens Lex/y and Lea/b, similar to DC-SIGN24. Although the use of Fc
chimeras provides information about the binding characteristics of C-type lectins, studies
into their binding specicity should also be performed with the C-type lectins expressed
on cells due to their multimerization and possible clustering, which is crucial to the carbo-
hydrate binding specicity. Indeed, mSIGNR1-Fc did not interact with the polysaccharide
dextran, whereas cellular-expressed mSIGNR1 interacts with dextran as demonstrated by
several groups8,9,24.
Here, we have investigated and compared the carbohydrate binding specicity of cel-
lular mSIGNR1 with its human homologues DC-SIGN and L-SIGN. DC-SIGN, L-SIGN
and mSIGNR1 have a similar specicity for mannose-containing carbohydrates present
on both cellular and pathogen ligands. However, the three receptors differ in their recog-
nition of fucose-containing Lewis antigens. mSIGNR1 interacts not only with Lex/y and
Lea/b antigens similar to DC-SIGN, but also with sialylated Lex. The differential recog-
nition of Lewis antigens suggests differences between mSIGNR1 and DC-SIGN in the
interaction with Lewis antigen-containing cellular and pathogen ligands.
2.2 Materials and Methods
Antibodies, reagents and cells
The following antibodies were used: ERTR-9 (anti-mSIGNR1) 9, AZN-D1 (anti-DC-
SIGN), AZN-D2 (anti-L-SIGN/DC-SIGN) 3, Raji-1 (previously referred to as THP-1 cells
26) transfectants expressing wild-type DC-SIGN, L-SIGN or mSIGNR1 were generated
by transfection with 10 µg pRc/CMV-DC-SIGN plasmid by electroporation as previously
described3,4,9. ManLAM was obtained from J.T. Belisle, the TB Vaccine Testing and
Reseach Materials Contract NIAID N01-AI-40091, Colorado State University, CO. Puri-
ed lipopolysaccharide (LPS) from H. pylori was obtained from M. Monteiro (National
Research Council, Ottawa, Canada).
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Fluorescent bead adhesion assay
Carboxylate-modied TransFluorSpheres (488/645 nm, 1.0 µm; Molecular Probes,
Eugene, OR) were coated with HIV-1 gp120 and ICAM-2 as described 11. Mannan was
covalently coupled to the beads according to the manufacturers protocol. Streptavidin
was covalently coupled to the beads as described and streptavidin-coated beads were in-
cubated with biotinylated PAA-linked glycoconjugates (50 pmol; Syntesome, Munich,
Germany). The uorescent bead adhesion assay was performed as described 27. Cells
were preincubated for 30 minutes at 37◦C with inhibitors (mannan, 1 mg/ml or EGTA, 10
mM). Next, ligand-coated uorescent beads (20 beads/cell) were added to the cells for 45
minutes at 37◦C, washed and analyzed by ow cytometry (FACScan, Becton Dickinson,
Oxnard, CA), by measuring the percentage of cells that had bound uorescent beads.
2.3 Results
In order to investigate the interaction of mSIGNR1 with different carbohydrates and to
compare its ligand specicity with the human homologues DC-SIGN and L-SIGN, we
stably transfected Raji-1 cells with these receptors (Fig. 2.1A). The cells express high
levels of the different C-type lectins (Fig. 2.1A). The expression level of mSIGNR1
was measured with a different antibody (ERTR-9) than the human homologues (AZN-
D2) and due to differences in afnity the expression levels cannot be compared to each
other. Recently, we have demonstrated that human DC-SIGN and L-SIGN and murine
SIGNR1 interact with mycobacteria through mannose-capped lipoarabinomannan (Man-
LAM)25. Both homologues have the highest afnity for the (man)3-ara structure present
on ManLAM, similar to DC-SIGN 25. Therefore we compared the interaction of the three
cell-lines with ManLAM. The binding activity of the transfectant expressing mSIGNR1
to ManLAM is similar to that observed for the two human homologues DC-SIGN and
L-SIGN (Fig. 2.1B), indicating that the different transfectants have comparable expres-
sion levels of the three C-type lectins and can be used to compare their carbohydrate
specicity.
Next, we investigated the interaction with the poly mannose-containing polysaccha-
ride mannan. This polysaccharide has been extensively used as an inhibitor of DC-SIGN
and other C-type lectins that have specicity for high mannose structures because this
ligand is multivalent and mannose-specic C-type lectins have a high afnity for this
polysaccharide28. Here we have coated uorescent beads with mannan through chem-
ical cross-linking in order to investigate the interaction with mSIGNR1. As demon-
strated, DC-SIGN and its homologues bind strongly to the poly mannose-containing
carbohydrate. The interaction is specic since the mock transfectant does not interact
with mannan (Fig. 2.1B) and blocking studies demonstrate that this interaction can be
inhibited by the calcium chelator EGTA (data not shown). As reported earlier, DC-
SIGN also binds to less complex mannose-containing glycoconjugates i.e. mannose and
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Figure 2.1: Cellular mSIGNR1 interacts with high mannose-containing polysaccharides
(A) Raji-1 transfectants express high levels of DC-SIGN, L-SIGN and mSIGNR1. Open histograms
represent the isotype controls, dotted lines represent mock transfectants and filled histograms indi-
cate specific antibody staining. (B) Cellular mSIGNR1 interacts specifically with high mannose
epitopes present on polysaccharides and glycoproteins. Binding of the SIGN transfectants to the
different ligands was determined using the fluorescent bead adhesion assay. Standard deviation
for the fluorescent bead adhesion assay was < 5%. One representative experiment out of three is
shown.
α1→3,α1→6mannotriose 19,20. We observed a similar binding of mSIGNR1 to α1→3,α1
→6mannotriose-coated beads, as was observed with DC-SIGN and L-SIGN. These data
support previous studies demonstrating that mSIGNR1 has a similar binding specicity
for both high mannose and less complex mannose-containing carbohydrate structures.
These data suggest that mSIGNR1 interacts similarly to cellular ligands and pathogens
containing these mannose structures. Indeed, mSIGNR1 interacts with high mannose-
containing ligands of DC-SIGN, such as ICAM-2/-3 9, HIV-1 gp12029, zymosan30 and
mycobacteria10,25 (Fig. 2.1B).
Although L-SIGN and DC-SIGN recognize high mannose glycans, L-SIGN does not
bind to fucose-containing Lex antigens in contrast to DC-SIGN 21. Using Fc chimera of
mSIGNR1, Galustian et al. demonstrated that mSIGNR1, similar to DC-SIGN, binds
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Figure 2.2: Cellular mSIGNR1 interacts with sialylated Lex, in contrast to its human homo-
logues
The three DC-SIGN homologues differ in their recognition of fucose-containing carbohydrates; all
three C-type lectins bind fucose (A), whereas DC-SIGN and mSIGNR1, in contrast to L-SIGN,
bind Lex (B). The recognition of Lex-rich LPS from H. pylori by DC-SIGN and mSIGNR1 is de-
termined by their carbohydrate specificity (C). Binding of the SIGN transfectants to the different
ligands was determined using the fluorescent bead adhesion assay. Specificity was determined by
measuring binding in the presence of mannan. Standard deviation for the fluorescent bead adhesion
assay was < 5%. One representative experiment out of three is shown.
to the Lewis antigens Lex/yand Lea/b ( 24). Here we have investigated the interaction of
cellular mSIGNR1 with the Lewis antigens. Similar to DC-SIGN and L-SIGN, cellular
mSIGNR1 interacts with αL-fucose through its C-type lectin domain, since the binding
is inhibited by both mannan (Fig. 2.2A) and EGTA (data not shown). A screening of the
different Lewis antigens coated on uorescent beads demonstrate that cellular mSIGNR1
interacts to Lewis blood group antigens (Lex,Ley,Lea,Leb) that contain fucose residues in
different anomeric linkages, similar to DC-SIGN (Table 2.1). Moreover, sulfation of these
Lewis antigens does not abrogate binding (Table 2.1). Strikingly, mSIGNR1 interacts
with sialylated Lex, an L-, E- and P-selectin ligand, whereas sialylation of Lex completely
abrogates the recognition by DC-SIGN (Fig. 2.2B; Table 2.1). A more detailed analysis
demonstrates that the interaction of mSIGNR1 with sialyl-Lex is mediated by the C-type
lectin domain since it can be inhibited by both mannan and EGTA (Fig. 2.2 B and data
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not shown).
These data demonstrate that although mSIGNR1 has a similar specicity for high
mannose-containing ligands as DC-SIGN and L-SIGN, the SIGN family differs in its
recognition of Lewis antigens; mSIGNR1, in contrast to DC-SIGN and L-SIGN, interacts
with sialylated Lex, whereas L-SIGN does not bind Lex. Lewis antigens are expressed
on various cells and pathogens and our data indicate that mSIGNR1 may be an impor-
tant receptor on macrophages to facilitate the interaction with sialyl-Lex expressed by
endothelial cells and T cells, as well as with Lewis antigen-expressing pathogens such as
the gram-negative bacterium H. pylori, which induces peptic ulcers and gastric carcinoma
31
, and the worm parasite Schistosoma mansoni (the causal agent of schistosomiasis) 32.
Indeed, mSIGNR1, similar to DC-SIGN, interacts with LPS from H. pylori that is rich in
Lex, whereas L-SIGN does not interact with this Lex-rich LPS (Fig. 2.2C).
2.4 Discussion
Here we have investigated the carbohydrate specicity of cellular mSIGNR1, since mul-
timerization and clustering on the cell surface is essential for ligand recognition and in-
teractions. We demonstrate that although mSIGNR1 has a similar binding specicity for
high mannose-containing ligands as the human homologues DC-SIGN and L-SIGN, it
differs in its interaction with Lewis antigens. Both DC-SIGN and mSIGNR1 interact
with Lex in contrast to L-SIGN, but only mSIGNR1 interacts with sialylated Lex. These
data suggest that mSIGNR1 may share its ligands with P-, L- and E-selectin, which are
able to interact with sialylated Lewis antigens. Both DC-SIGN and L-SIGN recognize
high mannose glycans as well as fucose-containing Lewis antigens.
L-SIGN does not bind to the fucose-containing Lex antigens in contrast to DC-SIGN.
The difference in the carbohydrate recognition prole of DC-SIGN and L-SIGN has been
traced to a single amino acid mutation: Val351 in DC-SIGN to Ser363 in L-SIGN 23,33.
Protein modelling indicates that Val351 forms a hydrophobic pocket that is required to t
Lex into DC-SIGN and to stabilize binding. Since a hydrophilic serine is present in L-
SIGN, Lex binding to L-SIGN is disrupted. mSIGNR1 contains a hydrophobic isoleucine
at the corresponding site (Ile289) indicating that this C-type lectin is also able to form a
hydrophobic pocket for Lex binding.
Galustian et al. demonstrated using a Fc chimera of mSIGNR1 that mSIGNR1 has
specicity for mannose- as well as fucose-terminating oligosaccharides, as demonstrated
by the ability to interact with high mannose N-glycans and proteins containing N-linked
glycans such as invertase and soybean agglutinin 24. The fucose recognition was demon-
strated by binding of mSIGNR1-Fc chimera with Lewis antigens Lex/y and Lea/b. We
have used uorescent beads coated with the Lewis antigen and demonstrate that cellu-
lar mSIGNR1 is indeed able to interact with Lewis antigens as well as their sulphated
forms (Table 2.1). In contrast to Galustian et al. 24, we observe a strong binding of sialy-
lated Lex to mSIGNR1 suggesting that possible multimerization and clustering of cellular
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Ligand∗ DC-SIGN L-SIGN mSIGNR1
Lex + - +
Ley + + +
Lea + + +
Leb + + +
Sialyl Lex - - +
Sialyl Lea - - +/-
Sulfo Lex + +/- +
Sulfo Lea + + +
αL-fucose + + +
Table 2.1: Binding specificity of DC-SIGN, L-SIGN and mSIGNR1 for Lewis antigens
∗ Binding was determined by coating the carbohydrates on fluorescent beads and performing the
bead adhesion assay with Raji-1 transfectants expressing the C-type lectins (0-10% = -, 10-20% =
+/-, 20-50% = +).
mSIGNR1 enhances the interaction/recognition of these structures. Moreover, the anti-
gens were coated on beads and are presented to the receptor as a multivalent structure
thereby further increasing the interaction. Thus, although the use of Fc chimeras pro-
vides information about the binding characteristics of the CLR, studies into their binding
specicity should also be performed with the CLR expressed on cells due to their multi-
merization and possible clustering. Low afnity interactions may not be detected by Fc
chimeras.
Knowledge about the carbohydrate specicity of mSIGNR1 will help identify poten-
tial ligands of mSIGNR1 and the in vivo role of this receptor. Lewis antigens are ex-
pressed on various cells, especially sialylated Lewis antigens that act as ligands for P-, E-
and L-selectins. These selectins play a major role in migratory processes of monocytes,
neutrophils and lymphocytes across endothelial cells and mSIGNR1 may be involved
in the migration of macrophages, since this C-type lectin is expressed by macrophages.
Similarly, DC-SIGN has been demonstrated to function as an adhesion receptor on DC
that mediates both rolling on and migration across endothelial cells 34. The expression
of mSIGNR1 on the MZM that are in close contact with blood suggests that this recep-
tor may also be involved in migration of cells from blood into the spleen. Interestingly,
lymphocyte migration from blood to the white pulp may be dependent on C-type lectin
interactions since polysaccharides such as mannan, a ligand for mSIGNR1 (Fig. 2.1)
inhibit this process35–37.
Besides being a gateway for migrating lymphocytes, the splenic marginal zone is
also important as a defense against pathogens. Because of their position adjacent to the
marginal sinuses, MZM are among the rst cells to interact with blood-borne antigens
and are presumed to have a critical role in host defense against bacterial pathogens 38. The
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fact that mSIGNR1 is abundantly expressed by MZM 8,9 hints to a function as a pathogen
recognition receptor. High mannose structures are expressed by various pathogens, in-
cluding viral glycoproteins as well as mycobacteria 10,14,25. The Lewis-specicity of
mSIGNR1 may be important for its interaction with pathogens such as H. Pylori (Fig.
2.2C) and certain Klebsiella pneumoniae strains through Lex-containing LPS structures
18
, and parasites such as S. mansoni as has been demonstrated for DC-SIGN 19,21. Further
studies will demonstrate the role of mSIGNR1 in both infections and adhesion events.
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Abstract
Mycobacterium tuberculosis represents a worldwide health risk, and although macropha-
ges are primarily infected, dendritic cells (DC) are important in inducing cellular immune
responses against M. tuberculosis. Recent studies have demonstrated that M. tubercu-
losis targets the DC-specic C-type lectin DC-SIGN to inhibit the immunostimulatory
function of DC through the interaction of the mycobacterial mannosylated lipoarabino-
mannan (ManLAM) to DC-SIGN, which prevents DC maturation and induces the im-
munosuppressive cytokine IL-10. This may contribute to survival and persistence of M.
tuberculosis. Here we have identied the specic pathogen-derived carbohydrate struc-
ture on ManLAM that is recognized by DC-SIGN. We have synthesized the mannose cap
oligosaccharides man-ara, (man)2-ara and (man)3-ara, and demonstrate that these neo-
glycoconjugates are specically bound by DC-SIGN. Moreover, we demonstrate that the
human and murine DC-SIGN homologue L-SIGN and SIGNR1, respectively, also inter-
act with mycobacteria through ManLAM. Both homologues have the highest afnity for
the (man)3-ara structure, similar to DC-SIGN. This study provides information about the
specic carbohydrate structures on pathogens that are recognized by DC-SIGN, and may
provide strategies to develop vaccines against these pathogens. Moreover, the identica-
tion of mSIGNR1 as a receptor for ManLAM will enable in vivo studies to investigate the
role of DC-SIGN in M. tuberculosis pathogenesis.
3.1 Introduction
Tuberculosis has been a major worldwide cause of death for centuries. One-third of the
world population is infected with Mycobacterium tuberculosis, which causes 2 million
deaths per year. Although macrophages, and not dendritic cells (DC), are the primary
targets for infection by mycobacteria, DC are important for the cellular immune response
and recent data demonstrate that DC function is modulated by M. tuberculosis 1,2, which
may account for pathogen survival and persistence.
Immature DC express several receptors that have been demonstrated to act as recep-
tors on macrophages, such as the mannose receptor (MR), CD11b and CD11c 3,4. How-
ever, recent data demonstrate that DC-specic C-type lectin DC-SIGN is the major recep-
tor for M. tuberculosis on DC 1,5. DC-SIGN interacts with M. tuberculosis through its cell
wall component mannosylated lipoarabinomannan (ManLAM) 1. Strikingly, M. tubercu-
losis modulates the immune function of DC through the interaction of DC with ManLAM
1,2
. ManLAM interacts with DC-SIGN on immature DC thereby blocking LPS-induced
maturation and inducing the anti-inammatory cytokine interleukin (IL)-10( 1).
Moreover, Nigou et al. demonstrated that ManLAM binding to immature DC via an-
other C-type lectin, MR, blocks IL-12 production 2. These data suggest that ManLAM can
interfere with Toll-like receptor (TLR)4 signaling on DC by binding to the C-type lectin
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DC-SIGN, since DC maturation by LPS is mediated through TLR4( 6). The cell wall
component ManLAM is also secreted in vivo by macrophages infected with M. tubercu-
losis7,8, indicating that mycobacteria may secrete ManLAM to interfere with bystander
DC. Both DC and macrophages express various C-type lectins that capture and internalize
pathogens, and recent studies suggest that C-type lectins may also inuence the immune
response through signaling cross talk especially with TLR 2,9,10. Recent studies suggest
that pathogens may exploit this cross talk to interfere with TLR signaling, thereby modu-
lating immune responses 9–11.
DC-SIGN functions as an adhesion receptor on immature DC that mediates DC inter-
actions with T cells and endothelial cells 12,13. However, it is becoming clear that several
pathogens target DC-SIGN to escape immunosurveillance 11. DC-SIGN plays a key role
in the dissemination of HIV-1 by DC through HIV-1 gp120 binding 14. Resident mucosal
DC may capture HIV-1 through DC-SIGN, and DC-SIGN does not mediate infection of
DC but protects the virus during migration to the lymphoid tissues, where DC-SIGN fa-
cilitates the transmission of HIV-1 to T cells 14. Clinical strategies targeting C-type lectins
such as DC-SIGN could succeed in combating M. tuberculosis infections by shifting the
precarious balance between immune activation and suppression to favor the elimination
of mycobacteria. More knowledge about the specic pathogen structures recognized by
DC-SIGN will be very useful to design strategies to prevent pathogen interactions.
C-type lectins have a high afnity for carbohydrate structures 15. Although the car-
bohydrate specicity of DC-SIGN has been intensively characterized 15–19, the specic
carbohydrate structures, present on pathogens, that are recognized by DC-SIGN are not
well characterized. Here, we have identied the specic carbohydrate structures on Man-
LAM that are recognized by DC-SIGN. Moreover, we have investigated the interaction
of ManLAM with the human DC-SIGN homologue L-SIGN and the murine homologue
SIGNR1. Both L-SIGN and mSIGNR1 specically interact with ManLAM and rapidly
internalize ManLAM similar to DC-SIGN.
Therefore, identication of the specic carbohydrate structure recognized by DC-
SIGN and its homologues will provide strategies to combat M. tuberculosis interactions
with these receptors. Moreover, similar binding characteristics of murine SIGNR1 and
human DC-SIGN will enable in vivo studies into the role of DC-SIGN in M. tuberculosis
infections and the efcacy of vaccines.
3.2 Materials and Methods
Antibodies
The following antibodies were used: ERTR-9 (anti-SIGNR1) 20, AZN-D1 (anti-DC-
SIGN), AZN-D2 (anti-L-SIGN/DC-SIGN) 12, F30.5 (anti-LAM; A. Kolk (Royal Tropical
Institute, Amsterdam)).
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Cells
THP-1 and K562 transfectants expressing wild-type DC-SIGN, L-SIGN or mSIGNR1
were generated by transfection with 10 µg pRc/CMV-DC-SIGN plasmid by electropora-
tion as previously described 14,20–22.
Synthesis of LAM oligosaccharides
The synthesis of LAM oligosaccharides has been described previously 23. In brief,
glycosylation reactions were carried out with thioglycoside donors in dichloromethane
using activation by N-iodosuccinimide and silver triate. The oligosaccharides carry an
octylamine spacer at the reducing terminus to allow coupling to carriers to produce poly-
valent antigens. Various structures have been synthesized: 8-Aminooctyl-5-O-{3,5-di-O-
(2-O-[β-D-arabinofuranosyl]-α-D-arabinofuranosyl)-α-D-arabinofuranosyl}-α-D-arabi-
nofuranoside, in short (ara)6, 8-Aminooctyl-β-D-arabinofuranoside, in short ara; 8-Ami-
nooctyl-5-O-(α-D-mannopyranosyl)-β-D-arabinofuranoside, in short man-ara; 8-Amino-
octyl-5-O-((2-O-α-D-mannopyranosyl)-α-D-mannopyranosyl)-β-D-arabinofuranoside, in
short (man)2-ara; 8-Aminooctyl-5-O-(2-O-(2-O-(α-D-mannopyranosyl)-α-D-mannopy-
ranosyl)-α-D-mannopyranosyl)-β-D-arabinofuranoside, in short (man)3-ara (Fig. 3.1A
and B).
Synthesis of biotin labeled polyacrylamide (PAA-biotin) neoglycoconjugates
Biotin-labeled polymeric glycoconjugates were synthesized by coupling of aminooc-
tyl glycosides and biotin-NH(CH2)6NH2 with poly(4-nitrophenyl acrylate) as described
by Bovin et al.24. In brief, biotin-labeled (5%) arabinose (20%) polyacrylamide (PAA)
conjugate was prepared. A solution of poly(4-nitrophenyl acrylate) (20 mg/ml in DMF,
242 µl, 25 µM on monomer unit), containing 5 mol% of biotin-NH(CH2)6NH2, and Et3N
(7 µl) was added to a solution of Ara-O(CH2)8NH2 (1.4 mg, 5 µM) in DMSO (100
µl). The mixture was kept 24 hours at 40◦C, then 35 µl of ethanolamine was added
and the mixture was kept 15 hours at room temperature. Conjugation was monitored by
thin layer chromatography. The resulting conjugate was isolated on a 1.5 cm2×25 cm
Sephadex LH-20 column in a MeCN/H2O (1:1, v/v) mixture. The lyophilised yield was
3.9 mg (90%). The average degree of polymerization of the (non-substituted) poly(N-2-
hydroxyethylacrylamide) carrier was estimated by gel-permeation chromatography. The
apparent molecular weight was 30 kDa, equivalent to a polymerization degree of ∼260.
From our earlier studies we know that the reaction of PAA with amino-linked oligosaccha-
ride or biotin runs to completion, and hence the degree of substitution was calculated from
the input. It was thus calculated that the PAA neoglycoconjugates contain 50 oligosac-
charide and 10 biotin residues per polymeric chain.
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Fluorescent bead adhesion assay
Carboxylate-modied TransFluorSpheres (488/645 nm, 1.0 µm; Molecular Probes,
Eugene, OR) were coated with the glycolipid forms of LAM as follows. Streptavidin-
coated beads25 were incubated with biotinylated F(ab)2 fragment goat anti-mouse IgG (6
µg/ml; Jackson Immunoresearch) followed by an overnight incubation with mouse-anti-
LAM antibody (F30.5) at 4◦C. The beads were washed and incubated with 250 ng/ml
puried glycolipid LAM overnight at 4◦C. The biotin-labeled PAA neoglycoconjugates
(0.5 µg/ml) were incubated with the streptavidin-coated uorescent beads for 3 hours at
37◦C to directly coat the neoglycoconjugates on the uorescent beads. The uorescent
beads adhesion assay was performed as described by Geijtenbeek et al. 25.
Soluble DC-SIGN-Fc adhesion assay
DC-SIGN-Fc consists of the extracellular portion of DC-SIGN (amino acid residues
64-404) fused at the C-terminus to a human IgG1-Fc fragment 22. The soluble DC-SIGN
adhesion assay was performed as follows. Soluble ligands were coated onto ELISA plates
(1 µg/well) for 18 hours at room temperature, followed by blocking with 1% BSA for 2
hours at 37◦C. Soluble DC-SIGN-Fc supernatant was added for 30 minutes at 37◦C. Un-
bound DC-SIGN-Fc was washed away and binding was determined by anti-IgG1 ELISA.
Specicity was determined in the presence of either 50 µg/ml blocking antibodies, 50
µg/ml mannan or 5 mM EGTA.
Immunofluorescence microscopy
Cells were incubated at 37◦C with ManLAM (10 µg/ml). After 3 hours the cells
were washed and incubated for an additional hour at 37◦C. The cells were xed in 3%
paraformaldehyde in PBS for 15 minutes and permeabilized in PBS/0.1% saponin prior to
staining. Cells were stained in PBS/0.5% BSA with antibodies against ManLAM (F30.5)
and LAMP-1 and subsequently with Alexa Fluor 488 or 594-conjugated secondary an-
tibodies. Next, cells were allowed to adhere to poly-L-lysine coated glass slides and
mounted in anti-bleach reagent. Fixed slides were imaged with a Nikon Eclipse E800
uorescence microscope and pictures were captured with a digital NIKON DXM1200
camera at 40× objective. Images were acquired in three independent series/sessions. Pic-
tures were analyzed with Jasc Paint Shop ProTM software.
3.3 Results
DC-SIGN interacts with the mannose cap of ManLAM
Recently, we have demonstrated that DC-SIGN is a major receptor on immature DC
for mycobacteria, such as M. tuberculosis and M. bovis BCG 1. The cell wall of my-
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Figure 3.1: DC-SIGN interacts with the mannose cap of ManLAM
(A) The schematic structure of ManLAM. LAM of M. tuberculosis consists of a GPI anchor, a
mannose-rich oligosaccharide core and a branched arabinose polymer that ends in mannose caps
(n=0-3). AraLAM has a similar structure but does not contain the mannose cap. (B) Structures of the
synthesized oligosaccharides present in the mannose cap of ManLAM. (C) DC-SIGN specifically
interacts with (man)2-ara and (man)3-ara present in ManLAM. DC-SIGN-Fc binding to the PAA
neoglycoconjugates was determined by an Fc-specific ELISA. Standard deviation < 0.02 OD450.
One representative experiment out of three is shown. (D) Cellular DC-SIGN interacts specifically
with the PAA neoglycoconjugates (man)2-ara and (man)3-ara. The neoglcyconjugates were coated
on fluorescent beads and the adhesion to DC-SIGN transfectants was determined. The adhesion of
cells to the LAM glycans was determined using the fluorescent bead adhesion assay. Specificity was
determined by measuring binding in the presence of blocking antibodies against DC-SIGN. Stan-
dard deviation for the fluorescent bead adhesion assay was < 5%. One representative experiment
out of three is shown.
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cobacteria contains LAM that comprises a mannose-rich polysaccharide-core, containing
a highly branched arabinofuranosyl domain, and a glycosylphosphatidylinocitol (GPI)
anchor (Fig. 3.1A)8. Both M. tuberculosis and M. bovis BCG contain ManLAM and
the interaction of DC-SIGN with these mycobacterial strains was due to the binding of
DC-SIGN to the mycobacterial cell wall 1. In contrast, DC-SIGN does not bind to LAM
lacking this mannose cap (AraLAM) 1, as demonstrated by the data that show that DC-
SIGN does not interact with mycobacteria that contain AraLAM but not ManLAM, such
as M. smegmatis1,5. ManLAM isolated from M. tuberculosis contains mannose-residues
consisting exclusively of mono-, di- and trimers of α-D-mannopyranoses directly linked to
the arabinofuranosyl-termini (Fig. 3.1B), whereas AraLAM isolated from the fast grow-
ing M. smegmatis is not mannose capped 8. DC-SIGN has a high afnity for mannose-
containing carbohydrates 12,19 and the differences in binding to ManLAM and AraLAM
suggests that the mannose cap is recognized by DC-SIGN. We have synthesized specic
LAM oligosaccharides consisting of mono-, di- and trimers of α-D-mannoses directly
linked to the arabinofuranose moiety to investigate the interaction with DC-SIGN (Fig.
3.1C). These mannose structures were covalently linked to biotinylated PAA as a carrier.
The structures are called (ara)6, man-ara, (man)2-ara and (man)3-ara and the PAA carrier
contains 50 oligosaccharides per polymeric chain.
The interaction of DC-SIGN with the different synthesized neoglycoconjugates was
investigated in detail using the DC-SIGN-Fc binding assay 22. This assay is suitable to
measure low avidity interactions. As demonstrated previously, DC-SIGN interacts ef-
ciently with ManLAM but not with AraLAM (Fig. 3.1C) 1. DC-SIGN interacts specif-
ically with the (man)2-ara and (man)3-ara PAA neoglycoconjugates, whereas the C-
type lectin does not bind the man-ara nor the control (ara)6 PAA neoglycoconjugates
(Fig. 3.1C). DC-SIGN has the highest afnity for the (man)3-ara structures and even at
high concentrations DC-SIGN does not interact with the monomer of α-D-mannose (Fig.
3.1C). Next, we investigated the interaction of cellular DC-SIGN with the various syn-
thesized oligosaccharide structures. The biotin-PAA neoglycoconjugates were directly
coated on uorescent beads and the interaction with cells was investigated using the u-
orescent bead adhesion assay. THP-1 transfectants stably expressing DC-SIGN interact
with ManLAM but not with AraLAM (Fig. 3.1D). Analysis of the binding of DC-SIGN
with the various synthesized structures demonstrates that DC-SIGN interacts specically
with the (man)2-ara and (man)3-ara structures; whereas DC-SIGN does not bind the man-
ara and the control (ara)6 carbohydrates (Fig. 3.1D). The interaction with (man)2-ara and
(man)3-ara was specic, since antibodies against DC-SIGN completely blocked the inter-
action of K562-DC-SIGN to the carbohydrates. These data demonstrate that both soluble
and cellular DC-SIGN efciently interact with the (man)2-ara and (man)3-ara as present
in the mannose cap of ManLAM.
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Figure 3.2: DC-SIGN is the major receptor for the mannose cap of ManLAM on DC
(A) Immature DC express high levels of DC-SIGN and the other reported LAM receptor MR.
Open histograms represent isotype control and filled histograms indicate specific antibody staining.
(B) Immature DC bind strongly to the PAA neoglycoconjugates (man)2-ara and (man)3-ara via
DC-SIGN. Binding was determined using the fluorescent bead adhesion assay. Specificity was
determined by measuring binding in the presence of mannan, or blocking antibodies against DC-
SIGN (AZN-D2) and MR (Clone 19). Standard deviation <5%. One representative experiment out
of three is shown.
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DC-SIGN is the major C-type lectin on DC for di- and trimers of α-D-mannoses as
present in ManLAM
K562 cells do not express other receptors for mycobacteria such as MR that have been
shown to interact with ManLAM 3,4. However, immature DC express high levels of MR
(Fig. 3.2A), which may interact with the synthetic carbohydrates. Therefore, we investi-
gated the binding of DC with the various mannose-containing PAA neoglycoconjugates.
Immature DC bind strongly to ManLAM and to the (man)2-ara and (man)3-ara struc-
tures, but not to the man-ara structures (Fig. 3.2B). The binding is completely blocked
by antibodies against DC-SIGN, whereas the antibodies against MR do not block (Fig.
3.2B). The block with antibodies against DC-SIGN is similar to the inhibition with the
polysaccharide mannan that blocks mannose-specic C-type lectins (Fig. 3.2B). These
data demonstrate that DC-SIGN is the major receptor on immature DC for the PAA neo-
glycoconjugates (man)2-ara and (man)3-ara that are present in the mannose cap of Man-
LAM. Furthermore, these data demonstrate that the mannose cap present on ManLAM is
indeed the structure that interacts with DC-SIGN, and that the C-type lectin recognizes
the di- and trimers of α-D-mannoses directly linked to the arabinofuranosyl-termini, as
present in M. tuberculosis ManLAM.
L-SIGN and mSIGNR1 interact with ManLAM
DC-SIGN has a homologue called L-SIGN 21,26 that is specically expressed by liver
sinusoidal endothelial cells (LSEC), a liver-resident antigen presenting cell and by en-
dothelial cells in lymph nodes 21,27. This homologue functions as an HIV-1 trans-receptor
similar to DC-SIGN21. Moreover, L-SIGN interacts with other pathogens such as Ebola
virus28, cytomegalovirus29 and hepatitis C virus30,31 similar to DC-SIGN.
Next, we investigated the interaction of the DC-SIGN homologue L-SIGN and the
murine homologue SIGNR1 with mycobacterial LAM. mSIGNR1 is a murine homologue
of DC-SIGN that functions in vivo as a pathogen receptor for blood-borne antigens 20, and
analysis of its pathogen specicity may help developing in vivo models for investigating
the in vivo role of DC-SIGN in infections.
We have used THP-1 transfectants expressing similar levels of L-SIGN and mSIGNR1
to investigate the interaction with ManLAM and AraLAM (Fig. 3.3A). Both L-SIGN and
mSIGNR1 bind strongly to ManLAM but not to AraLAM, as was observed for DC-SIGN
(Fig. 3.3B). The interaction with ManLAM is specic for the C-type lectins, since the
mock transfectant does not bind ManLAM. Moreover, the interaction could be completely
inhibited by the polysaccharide mannan and EGTA, demonstrating that the interaction is
mediated by the C-type lectin domain of both receptors.
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Figure 3.3: Both L-SIGN and mSIGNR1 bind strongly to the mannose cap of the mycobacte-
rial component ManLAM
(A) THP-1 transfectants express similar levels of DC-SIGN, L-SIGN and mSIGNR1. Open his-
tograms represent the isotype controls, dotted line represents mock transfectant, and filled his-
tograms indicate the specific antibody staining. (B) Both L-SIGN and mSIGNR1 bind strongly to
ManLAM but not to AraLAM. The adhesion of cells to the LAM glycans was determined using
the fluorescent bead adhesion assay. Specificity was determined by the polysaccharide mannan and
the chelator EGTA. Standard deviation for the fluorescent bead adhesion assay was < 5%. One
representative experiment out of three is shown. (C) The DC-SIGN homologues bind efficiently to
the oligosaccharides (man)2-ara and (man)3-ara present on ManLAM. The adhesion of cells to the
LAM glycans was determined using the fluorescent bead adhesion assay. Standard deviation for the
fluorescent bead adhesion assay was < 5%. One representative experiment out of three is shown.
L-SIGN and mSIGNR1 interact with oligosaccharides present in ManLAM
Analysis of the interaction of the DC-SIGN homologues with the synthetic LAM
oligosaccharides in a uorescent bead adhesion assay demonstrates that both L-SIGN and
mSIGNR1 interact with (man)2-ara and (man)3-ara, similar to DC-SIGN (Fig. 3.3C).
Both homologues do not interact with man-ara and the control oligosaccharide (ara)6.
These data demonstrate that the C-type lectins L-SIGN and mSIGNR1 may act as recep-
tors for ManLAM and that the interaction is mediated by both di- and tri-D-mannoses
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present in ManLAM.
The amount of oligosaccharides coated on uorescent beads is constant and in order
to investigate the afnity of the C-type lectins for the different oligosaccharides, we used
soluble oligosaccharide-coated PAA compounds labeled with biotin (data not shown).
DC-SIGN, L-SIGN and mSIGNR1 have the highest afnity for the (man)3-ara oligosac-
charide (data not shown). These results demonstrate that the homologues of DC-SIGN,
L-SIGN and mSIGNR1, behave similarly as DC-SIGN in their interaction with the my-
cobacterial oligosaccharides.
ManLAM is internalized by L-SIGN and mSIGNR1 and targeted to lysosomes
Recently, we have demonstrated that DC-SIGN internalizes antigens and targets them
to lysosomal compartments for presentation on MHC Class II 32. Similarly, uorescent
mycobacteria and ManLAM were captured by DC-SIGN on immature DC and targeted
to the lysosomes1. Strikingly, the hepatitis C virus is targeted to the early endosomes by
DC-SIGN expressed by DC and THP-1 transfectants 31. The homologues L-SIGN and
mSIGNR1 have different cytoplasmic domains containing different intracellular signal-
ing motifs. Therefore, we investigated the fate of captured ManLAM by the DC-SIGN
homologues expressed by THP-1 transfectants. ManLAM was efciently captured and
internalized by DC-SIGN, L-SIGN and mSIGNR1 on THP-1 transfectants, but not by
mock transfectants (Fig. 3.4). Internalized ManLAM co-localized with the lysosomal
marker CD107a/LAMP-1 in both THP-L-SIGN and THP-SIGNR1, similar to THP-DC-
SIGN (Fig. 3.4) indicating that internalized ManLAM is targeted to CD107a+ lysosomes
by the DC-SIGN homologues.
3.4 Discussion
DC are vital in the defense against pathogens, but it is now becoming evident that some
pathogens subvert DC functions to escape immunosurveillance. HIV-1 targets the DC-
specic C-type lectin DC-SIGN to hijack DC for viral dissemination, whereas M. tuber-
culosis targets DC-SIGN by a mechanism that is distinct from that of HIV-1, leading to
inhibition of the cellular function of DC, resulting in pathogen survival. Moreover, re-
cent studies have demonstrated that DC-SIGN is a more universal pathogen receptor that
also recognizes Ebola virus, cytomegalovirus and hepatitis C virus 11. These studies in-
dicate that DC-SIGN may be targeted by these pathogens to modulate immune responses
in favor of their survival. Thus, a better understanding of the DC-SIGN-pathogen inter-
actions is necessary to combat infections. However, DC-SIGN is involved in important
cellular functions of the DC, such as initiating DC-T cell interactions 12 and DC migration
13
. Inhibiting DC-SIGN function by blocking antibodies against DC-SIGN may prevent
the immunological function of DC-SIGN. Preventing the DC-SIGN-pathogen interac-
tion through antibodies against pathogen-derived structures may provide an alternative
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Figure 3.4: Both L-SIGN and mSIGNR1 mediate internalization of captured ManLAM
ManLAM is internalized by DC-SIGN, L-SIGN and mSIGNR1 and targeted to the lysosomes. The
fate of captured ManLAM was followed by incubating transfectants with ManLAM (10 µg/ml) for
4 hours. ManLAM and CD107a/Lamp-1 were stained with F30.5 and H4A3, respectively. Arrows
point towards co-localization of ManLAM with Lamp-1 vesicles. One representative experiment
out of three is shown.
to DC-SIGN inhibitors. Therefore, the specic structures that are recognized by DC-
SIGN need to be identied. DC-SIGN is a C-type lectin that has a high specicity for
mannose-containing carbohydrates that are present in various pathogens 16,17,33. As re-
ported earlier, DC-SIGN binds to puried yeast mannan and high mannose-containing
viral proteins14,28,34 but also to less complex mannose-containing glycoconjugates i.e.
mannose and α1→3,α1→6mannotriose 17,19. Although these structures may be present
on pathogens, so far the specic pathogenic carbohydrate structures that are recognized
by DC-SIGN have not been identied.
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Recently, we and others have demonstrated that M. tuberculosis binds to immature
DC through DC-SIGN 1,5. DC-SIGN binding to M. tuberculosis was mediated by Man-
LAM, since DC-SIGN did not interact with M. smegmatis that does not express Man-
LAM1. Moreover, DC-SIGN binds strongly to ManLAM- but not AraLAM-coated beads
(Fig. 3.1). These data suggest that DC-SIGN interacts with the mannose cap of Man-
LAM. Indeed, removal of the mannose cap from ManLAM abrogates DC-SIGN binding
18
. ManLAM comprises a mannose-rich polysaccharide-core, containing highly branched
arabinofuranosyl side chains, and a GPI anchor (Fig. 3.1) 8. The mannose cap from M.
tuberculosis contains mannose-residues consisting exclusively of mono-, di- and trimers
of α-D-mannoses directly linked to the arabinofuranosyl-termini 8. We have synthesized
the mannose cap oligosaccharides man-ara, (man)2-ara and (man)3-ara, and covalently
linked them to a PAA carrier. In these synthetic neoglycoconjugates, the mannose residues
are bound to each other by α1→2 linkages, identical to the mannose cap of ManLAM.
Both soluble and cellular DC-SIGN strongly interact with the (man)2-ara and (man)3-ara
PAA glycoconjugates coated on uorescent beads, whereas DC-SIGN does not bind to
the man-ara glycoconjugates (Fig. 3.1). DC-SIGN has the highest afnity for the (man)3-
ara PAA neoglycoconjugate, as demonstrated by the binding assay using soluble PAA
neoglycoconjugates (data not shown). Even though DC express various C-type lectins
such as MR, the binding to the PAA neoglycoconjugates (man)2-ara and (man)3-ara is
mediated by DC-SIGN, since the antibodies against DC-SIGN completely block the in-
teraction (Fig. 3.2). These data support the role for DC-SIGN as a major receptor on
immature DC for M. tuberculosis and demonstrate that (man)2-ara and (man)3-ara may
represent targets to block the interaction of DC-SIGN with mycobacteria.
Recently, we have demonstrated that ManLAM blocks LPS-induced DC maturation
and induces IL-10 production through binding of DC-SIGN 1. In contrast, the PAA neo-
glycoconjugates did not block LPS-induced DC maturation or induce IL-10 production by
binding to DC-SIGN (unpublished observations). This indicates that ManLAM contains
more structures that are necessary for its signaling function. This is in agreement with the
data from Nigou et al. that the GPI anchor on ManLAM is necessary for the inhibition of
IL-12 production, presumably by binding of the fatty acyl chains to TLR4( 2).
L-SIGN is a homologue of DC-SIGN that is not expressed by DC but by LSEC and
endothelial cells in the lymph nodes 21,26. The mRNA of L-SIGN shows about 90% simi-
larity with DC-SIGN, and several studies have shown that L-SIGN has a similar binding
specicity as DC-SIGN. L-SIGN binds to the cellular ligands of DC-SIGN i.e. ICAM-2
and ICAM-3( 21) and to the envelope glycoproteins from HIV-1, Ebola virus, hepatitis C
virus and cytomegalovirus 21,28–31. L-SIGN has been demonstrated to function as a trans-
receptor for HIV-1, similar to DC-SIGN, and therefore pathogens may target L-SIGN to
escape immunosurveillance. Here, we have demonstrated that L-SIGN binds mycobacte-
rial ManLAM but not AraLAM, suggesting that L-SIGN may bind M. tuberculosis. Bind-
ing assays with the PAA neoglycoconjugates demonstrate that L-SIGN interacts strongly
with (man)2-ara and (man)3-ara, but not with man-ara, similar to DC-SIGN. These results
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suggest that L-SIGN may be involved in the pathogenesis of M. tuberculosis infection,
and demonstrate that L-SIGN captures ManLAM and rapidly internalizes it to the lyso-
somes. Thus, L-SIGN may be involved in the clearance of mycobacteria since L-SIGN is
expressed on those sites in lymph nodes and liver that are ideally suited for antigen cap-
ture and clearance. However, mycobacteria may target L-SIGN to invade those tissues.
More research is necessary to investigate the specic role of L-SIGN in these infections.
Therefore, we have investigated the interaction of the murine DC-SIGN homologue with
ManLAM.
mSIGNR1, a murine homologue of DC-SIGN, functions in vivo as a pathogen recog-
nition receptor on marginal zone macrophages that captures blood-borne antigens, which
are rapidly internalized and targeted to lysosomes for processing 20. The C-type lectin
domain of mSIGNR1 has a 74% similarity to DC-SIGN and also binds to HIV-1 gp120,
and the cellular ligands of DC-SIGN, i.e. ICAM-2 and ICAM-3( 20). Here, we demon-
strate that mSIGNR1 binds mycobacterial ManLAM through the mannose cap (Fig. 3.3).
Furthermore, mSIGNR1 interacts specically with the PAA neoglycoconjugates (man)2-
ara and (man)3-ara, but not with man-ara. The similar binding specicity to DC-SIGN
suggests that the binding of mSIGNR1 to M. bovis BCG is mediated by the cell wall
component ManLAM. Moreover, the similar binding characteristics of mSIGNR1 and
DC-SIGN will enable us to design and test in mouse models in vivo vaccines that will
prevent the interaction of DC-SIGN with pathogens such as mycobacteria. The func-
tion of mSIGNR1 is inhibited in vivo by the antibody ERTR-9 which will enable us to
investigate the in vivo function of mSIGNR1 in M. tuberculosis infections.
The identication of the specic carbohydrate structures on M. tuberculosis that inter-
act with DC-SIGN will enable us to develop strategies to specically interfere with this
interaction without blocking the immunological function of DC-SIGN.
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Abstract
Mycobacterium tuberculosis and the associated disease tuberculosis is a health risk caus-
ing many deaths worldwide each year in humans. M. tuberculosis targets dendritic cell-
specic intercellular adhesion molecule-3 grabbing nonintegrin (DC-SIGN) to induce im-
munosuppression, since interaction of DC-SIGN with mycobacterial mannose-capped
lipoarabinomannan (ManLAM) induces interleukin (IL)-10 and prevents DC matura-
tion. We investigated the role of a murine homologue of DC-SIGN, SIGN Related 1
(mSIGNR1), in a model of M. tuberculosis infection using mSIGNR1-decient (KO)
mice. In contrast to DC-specic DC-SIGN, mSIGNR1 is expressed by macrophage sub-
populations in lymph node, spleen and peritoneal cavity and not by alveolar macrophages
even during infection. As a consequence, we did not detect any differences between
wild-type (WT) and KO mice in mycobacterial loads of lung, spleen, liver and draining
lymph node after 1 day, 2 and 5 weeks of M. tuberculosis infection resulting in similar
survival rates. Although pulmonary levels of IL-10 and interferon (IFN)γ were similar
in both groups, we observed increased T cell activity in mSIGNR1 KO mice early dur-
ing infection and increased IFNγ production by splenocytes in mSIGNR1 KO mice early
in infection suggesting an immunomodulatory role for mSIGNR1. This is in agreement
with in vitro data demonstrating that peritoneal macrophages from mSIGNR1 KO mice
produce signicantly less IL-10 upon stimulation with ManLAM than those from WT
mice, suggesting that the interaction of ManLAM with mSIGNR1 can result in immuno-
suppression similar to its human homologue. Nevertheless, our data suggest that the role
of mSIGNR1 is limited during murine M. tuberculosis infection.
4.1 Introduction
Mycobacterium tuberculosis and the associated disease tuberculosis are main threats to
mankind, with one-third of the world population being infected 1. Over 8 million new
cases of tuberculosis and 2 million deaths from this disease occur yearly worldwide 2. Al-
though healthy persons infected with M. tuberculosis develop an immune response, this
response is not strong enough to eradicate the bacterium. Mechanisms by which M. tu-
berculosis escapes from the host immune response have been studied in detail. Although
macrophages, and not dendritic cells (DC), are the primary targets for infection by my-
cobacteria, DC are important for the cellular immune response. Recent data strongly sug-
gest that C-type lectins are involved in suppressing cellular immune responses mediated
by DC3,4.
C-type lectins recognize pathogens by binding to pathogen-specic carbohydrate resi-
dues. The human C-type lectin DC-SIGN, which is expressed by DC 5, binds to Man-
LAM, a major cell wall component of M. tuberculosis 6–8. Both membrane bound and
secreted ManLAM are considered an important virulence factor of M. tuberculosis 9,10.
4.1 Introduction 67
After binding to DC-SIGN, ManLAM stimulates the production of the anti-inammatory
cytokine interleukin (IL)-10 by DC and inhibits Toll-like receptor-induced DC maturation
6
. These ndings indicate that in humans, binding of ManLAM to DC-SIGN hampers DC
function leading to suppression of the adaptive immune response against M. tuberculosis
and thereby possibly facilitates survival of the pathogen.
It was recently shown that 70% of alveolar macrophages obtained from patients with
tuberculosis expressed DC-SIGN on their surface and this expression was not present
in alveolar macrophages from patients with non-mycobacterial lung pathologies or from
healthy controls11. Hence, DC-SIGN, expressed by DC and specic macrophage subsets,
could play a role in the immune defense against M. tuberculosis.
Five different homologue genes of DC SIGN were cloned in mice but the cellular ex-
pression has been elucidated only for two of these murine homologues: murine DC-SIGN
(mDC-SIGN) and murine SIGN Related 1 (mSIGNR1) 12–15. mDC-SIGN is expressed by
plasmacytoid pre-DC 16,17. However, no ligands for mDC-SIGN have been identied in-
cluding known ligands for human DC-SIGN, suggesting that the murine homologue is in-
active16,18,19. In contrast, mSIGNR1 is abundantly expressed in lymph node by medullary
and subcapsular macrophages, in spleen by marginal zone macrophages and in the liver
by sinusoidal endothelial cells 15. In addition, Taylor et al. demonstrated that mSIGNR1
is also expressed on resident peritoneal macrophages 14. The function and binding capac-
ities of mSIGNR1 have been studied in detail and are similar to human DC-SIGN 7,15,20.
Recently, it has been demonstrated that mSIGNR1 is important in the defense against
Streptococcus pneumoniae infection 21,22. Interestingly, like DC-SIGN, mSIGNR1 binds
to ManLAM and M. tuberculosis 7,14.
Here we set out to elucidate the in vivo function of mSIGNR1 in the immune de-
fense against M. tuberculosis. The role of mSIGNR1 in the host defense response against
M. tuberculosis was studied using mSIGNR1-decient (KO) mice 21. Upon stimulation
with ManLAM, the production of IL-10 by wild-type (WT) peritoneal macrophages was
induced. Strikingly, IL-10 production by KO peritoneal macrophages was reduced com-
pared to WT, suggesting an immunosuppressive role for mSIGNR1 upon infection with
M. tuberculosis similar to DC-SIGN. In addition, during the early stage of infection,
splenocytes from KO mice produced more interferon (IFN)γ than WT splenic T cells, sup-
porting the attenuated IL-10 response by peritoneal macrophages of KO mice in response
to ManLAM. These data suggest a more pronounced Th1-specic immune response in
the KO mice upon M. tuberculosis infection. However, no differences in susceptibility to
M. tuberculosis were observed between mSIGNR1 KO and WT mice. Our data suggest
that although mSIGNR1 is able to bind ManLAM and M. tuberculosis in vitro, its role is
limited during M. tuberculosis infection in vivo.
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4.2 Materials and Methods
Mice
C57BL/6×129 WT and mSIGNR1 KO mice were bred in the animal facility of the
VU University Medical Center under specic pathogen-free conditions, and were kept
in the animal facilities of the VU University Medical Center and the Academic Medical
Center in Amsterdam, The Netherlands. Six- to eight-week-old male mice were used in
the infection experiments. The Animal Care and Use Committee of the University of
Amsterdam approved all experiments.
Preparation of peritoneal macrophages
Peritoneal macrophages were harvested from mSIGNR1 KO and WT mice (n= 4 to
6 per strain). Mice were sacriced and peritoneal lavage was performed with 5 ml ster-
ile isotonic saline supplemented with 50 IE/ml heparin, and peritoneal lavage uid was
collected in sterile tubes using a glass Pasteurs pipet. Total cell numbers were counted
from each sample using a counting chamber. Cells were resuspended in RPMI 1640 con-
taining 1 mM pyruvate, 2 mM L-glutamine, penicillin, streptomycin and 10% FCS in a
nal concentration of 2×104 cells/200 µl. Cells were cultured in 96-well microtiter plates
(Greiner, Alphen a/d Rijn, The Netherlands) for 2 hours and washed with RPMI 1640 to
remove non-adherent cells. Adherent cells were stimulated with ManLAM (10 µg/ml; ob-
tained from Dr. J.T. Belisle from the Colorado State University, Fort Collins, CO (under
NIH Contract NO1-AI-75320)) or with medium for 24 hours in a total volume of 100 µl.
Supernatants were collected and stored at -20◦C until assayed for IL-10.
Experimental infection
A virulent laboratory strain of M. tuberculosis H37Rv (American Type Culture Col-
lection, Rockville, MA) was grown for 4 days in liquid Dubois medium containing 0.01%
Tween-80. A replicate culture was incubated at 37◦C, harvested at mid-log phase, and
stored in aliquots at 70◦C. For each experiment, a vial was thawed and washed with ster-
ile 0.9% NaCl. Tuberculosis was induced as described previously 23,24. Briey, mice
were anesthetized by inhalation with isourane (Abbott Laboratories Ltd., Kent, United
Kingdom) and infected intranasally with 105 live M. tuberculosis H37Rv bacilli in 50
µl saline, as determined by viable counts on Middlebrook 7H11 plates. Groups of eight
mice per time point were sacriced two and ve weeks after infection. Lungs, liver and
spleen were removed aseptically and homogenized in 5 volumes of sterile 0.9% NaCl.
10-fold dilutions were plated on Middlebrook 7H11 agar plates to determine bacterial
loads. Colonies were counted after 21 days at 37◦C. Numbers of colony-forming units
(CFU) are provided per gram of lungs. In order to check for infection efcacy, three mice
per group were sacriced one day post-infection. For cytokine measurements, organ ho-
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mogenates were diluted 1:2 in lysis buffer containing 300 mM NaCl, 30 mM Tris, 2 mM
MgCl2, 2 mM CaCl2, 1% Triton X-100, and pepstatin A, leupeptin and aprotinin (all 20
ng/ml; pH 7.4) and incubated on ice for 30 minutes. Homogenates were centrifuged at
1500×g at 4◦C for 15 minutes, and supernatants were sterilized using a 0.22 µm lter
(Corning Incorporated, Corning, NY) stored at -20◦C until assays were performed.
Characterization of inflammatory infiltrates in the lungs
Lung and draining mediastinal lymph node cell suspensions were obtained by crush-
ing through a 40-µm cell strainer (Becton Dickinson, Franklin Lakes, NJ) as described
previously23,24. Erythrocytes in the cell suspensions were lysed with ice-cold isotonic
NH4Cl solution (155 mM NH4Cl, 10 mM KHCO3, 0.1 mM EDTA, pH 7.4), the remain-
ing cells were washed twice with RPMI 1640 (Bio Whittaker, Verviers, Belgium), and
counted by using a hemocytometer. The percentages of macrophages, polymorphonu-
clear cells (PMNs) and lymphocytes were determined using cytospin preparations stained
with haematoxilin and eosin.
Flow cytometric analysis
Lung cell suspensions obtained from infected mice were analyzed by ow cytometry
using a FACS Calibur (Becton Dickinson Immunocytometry Systems, San Jose, CA) as
described previously 23,24. Cells were brought to a concentration of 1×107 cells per ml
of FACS buffer (PBS supplemented with 0.5% BSA, 0.01% NaN3 and 0.35 mM EDTA).
Immunostaining for cell surface molecules was performed for 30 minutes at 4◦C using
directly labeled antibodies against CD3 (CD3-phycoerythrin), CD4 (CD4-APC), CD8
(CD8− peridinin chlorophyl protein) and CD69 (CD69-FITC). All antibodies were used
in concentrations recommended by the manufacturer (Pharmingen, San Diego, CA). After
staining, cells were xed in 2% paraformaldehyde, and T cell surface molecules were
analyzed within the gate containing CD3+ cells.
Histology
Lungs were removed 2 and 5 weeks after inoculation with M. tuberculosis, xed in
10% buffered formaline for 24 hours, and embedded in parafn. Hematoxilin and eosin
stained slides were coded and scored from 0 (absent) to 4 (severe) for the following param-
eters: interstitial inammation, endothelialitis, bronchitis, oedema, granuloma formation
and pleuritis by a pathologist. In addition, the percentage of inamed lung parenchyma
was scored separately. For mSIGNR1 stainings the slides were deparafnized; endoge-
nous peroxidase activity was quenched by a solution of methanol/0.03% H2O2 (Merck,
Darmstadt, Germany). After digestion with a 10 mM sodium citrate solution, pH 6.0, non-
specic binding was blocked with TENG-T (10 mM Tris, 5 mM EDTA, 0.15 M NaCl,
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0.25% gelatine, 0.05% (v/v) Tween 20, pH 8) and then exposed to a goat anti-SIGNR1
antibody (R&D Systems, Minneapolis, MN). After washes, slides stained for mSIGNR1
were incubated with a horseradish peroxidase-labeled rabbit anti-goat IgG2a antibody
(Southern Biotech, Birmingham, AL). Slides were nally developed using 1% H2O2 and
3,3’-diaminobenzidine-tetra-hydrochloride (Sigma) in Tris-HCl and slides were counter-
stained with methyl green. The sections were mounted in glycerin gelatin. As a negative
control, spleens and lungs from mSIGNR1 KO mice were stained.
Splenocyte stimulation
Single cell suspensions were obtained by crushing spleens through a 40-µm cell strain-
er (Becton Dickinson, Franklin Lakes, NJ) as described 23,25. Erythrocytes were lysed
with ice-cold isotonic NH4Cl solution (155 mM NH4Cl, 10 mM KHCO3, 100 mM EDTA,
pH 7.4); the remaining cells were washed twice with RPMI 1640 (Bio Whittaker, Verviers,
Belgium) supplemented with 10% FCS and 1% antibiotic-antimycotic (GiboBRL, Life
Technologies, Rockville, MD). Cells were seeded in 96-well round bottom culture plates
at a cell density of 1×106 cells per well in quadruplicate, and stimulated with 20 µg/ml tu-
berculin puried protein derivative (PPD, Statens Seruminstitut, Copenhagen, Denmark).
Supernatants were harvested after incubation for 48 hours at 37◦C in 5% CO2, and cy-
tokine levels were analyzed by ELISA.
Cytokine measurements
The IL-10 in the stimulation assay was analyzed by Cytometric Bead Array (CBA,
Pharmingen, San Diego, CA) according to the manufacturers instructions. The detection
limit for IL-10 was 12.5 pg/ml. For measuring IFNγ, IL-4, tumor necrosis factor (TNF),
IL-1β, IL-10, KC and MIP-2 in lung homogenates, ELISA using matched antibody pairs
according to the manufacturers instructions was used (R&D Systems Inc., Minneapolis,
Minnesota, USA). Detection limits were 63 pg/ml for IFNγ, IL-4, IL-10, TNF, IL-1β and
MIP-2 and 15 pg/ml for KC.
Statistical analysis
All values are expressed as mean ± SEM. Comparisons were done with Mann-Whit-
ney U tests using GraphPad Prism version 4.00, GraphPad Software (San Diego, CA).
When comparing two groups at multiple time points two way ANOVA was used. Sta-
tistical analyses of bacterial counts were performed after log transformation. Values of
P<0.05 were considered statistically signicant.
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Figure 4.1: Reduced IL-10 production of mSIGNR1 KO peritoneal macrophages
Macrophages from WT (black bars) and mSIGNR1 KO (white bars) mice were harvested by lavage
of the peritoneal cavity. After adherence, macrophages were stimulated with medium or ManLAM
(10 µg/ml). After 24 hours of stimulation, IL-10 was determined in the supernatant. Data are
presented as means ± SEM of 4-6 mice per group. ∗∗P<0.01 versus WT.
4.3 Results
Reduced IL-10 production by mSIGNR1 KO peritoneal macrophages in response to
ManLAM
Previously it has been shown that ManLAM, a component of the capsule of M. tuber-
culosis, is able to bind DC-SIGN expressed by human DC and this interaction induces an
increase in IL-10 production after Toll-like receptor triggering 6. Therefore, ManLAM,
which is also secreted by M. tuberculosis, can act as an immunosuppressive agent fa-
cilitating infection of M. tuberculosis. In this study we set out to investigate the role of
mSIGNR1, a murine homologue of DC-SIGN in the immune response against M. tubercu-
losis in an infection model. Murine resident peritoneal macrophages express mSIGNR1,
which binds ManLAM 14. In order to investigate whether ManLAM binding to mSIGNR1
results in a similar immunosuppressive cytokine response as has been observed with DC-
SIGN, resident peritoneal macrophages from both WT and mSIGNR1 KO mice were
stimulated with ManLAM. Indeed, mice lacking mSIGNR1 were less able to produce IL-
10 in response to ManLAM (Fig. 4.1). Hence, ManLAM can exert its immunosuppressive
effects through mSIGNR1 on peritoneal macrophages.
No differences in M. tuberculosis growth in lung, spleen or liver
To determine the role of mSIGNR1 in antibacterial defense against tuberculosis, the
outgrowth of M. tuberculosis in lungs of mSIGNR1 KO and WT mice was determined
after 1 day, 2 and 5 weeks after intranasal inoculation (Fig. 4.2). At all time points after
infection, the numbers of CFU detected in the lung were similar in mSIGNR1 KO and WT
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Figure 4.2: Unaltered bacterial outgrowth in mSIGNR1 KO mice
WT (closed symbols) and mSIGNR1 KO mice (open symbols) were infected intranasally with 105
CFU of M. tuberculosis. One day, 2 and 5 weeks after infection, mice were sacrificed and bacterial
loads were determined in homogenates of lung, spleen and liver. Data are presented as means ±
SEM of 3 (day 1) to 6-8 mice per group per time point.
animals. To study the dissemination of M. tuberculosis, the bacterial loads in spleen and
liver were measured. No differences in bacterial growth in spleen or liver were observed
between mSIGNR1 KO and WT mice at the different time points (Fig. 4.2). To further
assess the role of mSIGNR1 in host defense against tuberculosis, 14 mSIGNR1 KO and
14 WT mice were studied during a 6 month observation period after infection. A similar
percentage of animals died (8 out of 14 in each group; data not shown). Thus, mSIGNR1
does not inuence the outgrowth or dissemination of M. tuberculosis nor does it appear
to be essential for survival after infection with this mycobacterium.
No differences in histopathology between lungs of mSIGNR1 KO and WT mice
Two weeks after infection, lungs of both WT and mSIGNR1 KO mice already dis-
played advanced tuberculosis with high scores for interstitial inammation and inam-
mation of vessels and bronchi (14.4±0.6 for WT and 14.6±1.9 for mSIGNR1 KO lungs;
Fig. 4.3). The diffuse inltrate consisted mainly of mononuclear cells and no differences
in the degree of inammation could be detected between WT and mSIGNR1 KO mice
(Fig. 4.3 and Table 4.1). After 5 weeks of infection, lung inammation scores increased
(18.8±0.6 for WT and 17.2±1.7 for mSIGNR1 KO lungs). Moreover, the percentage of
lung parenchyma involved in inammation was higher at 5 weeks post-infection and this
resulted in higher total cell counts in the lungs of both groups (Table 4.1). In contrast
to 2 weeks post-infection, the percentage of inltrated PMNs increased in the lungs of
both groups after 5 weeks of infection (Table 4.1). Based on these results it seems that
mSIGNR1 is not crucial for the inammation of the lungs and the concomitant cellular
inltration, upon infection with M. tuberculosis.
4.3 Results 73
A B
C D
Figure 4.3: In both WT and mSIGNR1 KO mice a similar degree of inflammation was ob-
served in the lung
(color reprint: Fig. A.1, pp. 154)
Representative lung histology of WT (A and C), and mSIGNR1 KO (B and D) mice, 2 (A, B) and
5 (C, D) weeks after intranasal infection with 105 CFU of M. tuberculosis. The lung sections are
representative for 6-8 mice per group per time point. H&E staining, magnification ×10.
Cells Mφs PMNs Lymphocytes
×105/ml % % %
2 weeks
WT 40±6 42±3 25±4 32±4
mSIGNR1 KO 53±11 44±5 28±3 28±4
5 weeks
WT 138±57 37±4 38±5 25±4
mSIGNR1 KO 122±43 38±7 34±7 15±3
Table 4.1: Effect of mSIGNR1 deficiency on total and differential lung cell counts
Total leukocyte counts (×105/ml) and differential cell counts in lungs of WT and mSIGNR1 KO
mice 2 and 5 weeks after intranasal infection with 105 CFU of M. tuberculosis.
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Figure 4.4: No expression of mSIGNR1 in lungs of infected WT mice
(color reprint: Fig. A.2, pp. 155)
Representative mSIGNR1 stainings of lung (A) and spleen (B) from WT mice 2 weeks after in-
tranasal infection with 105 CFU of M. tuberculosis. No mSIGNR1 positive cells were detectable in
the lung whereas marginal zone macrophages are stained positively. Sections are representative for
6-8 mice per group. Original magnification ×10.
No induction of mSIGNR1 in the lung during M. tuberculosis infection
DC-SIGN is expressed by alveolar macrophages upon infection with M. tuberculosis
11
. Therefore we investigated whether mSIGNR1 is upregulated on alveolar macrophages
during M. tuberculosis infection. Lung slides from WT and mSIGNR1 KO were stained
with a polyclonal antibody against mSIGNR1. Lungs from infected WT mice did not
demonstrate any positive staining at both 2 and 5 weeks after infection (Fig. 4.4A for
2 weeks and data not shown for 5 weeks). As expected, macrophages in the marginal
zones of spleens from WT mice stained positive (Fig. 4.4B) and no positive staining for
mSIGNR1 was visible in spleens from mSIGNR1 KO mice demonstrating the specicity
of the antibody used (data not shown). Thus, inammation due to infection by M. tu-
berculosis does not induce the expression of mSIGNR1 in macrophages of the lung and
demonstrates further that mSIGNR1 and DC-SIGN have a different expression pattern.
mSIGNR1 KO splenocytes produce increased IFNγ levels early in infection with un-
changed T cell recruitment
The Th1 response is pivotal for an adequate immune response against M. tuberculosis.
Therefore, we compared concentrations of IFNγ and IL-4 as prototypic Th1 and Th2
cytokine in lung homogenates and after splenocyte stimulation with the M. tuberculosis
specic antigen PPD (Fig. 4.5). Moreover we studied T cell subsets in lungs and local
lymph node at 2 and 5 weeks after infection (Table 4.2). Absence of mSIGNR1 resulted
in increased production of the Th1 cytokine IFNγ and reduced the production of IL-4 by
splenocytes after 48 hours of stimulation with PPD (Fig. 4.5). No differences in local
IFNγ and IL-4 concentrations were detected (Table 4.3). T cell subset recruitment was
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Figure 4.5: Enhanced early antigen specific IFNγ response by splenocytes from infected
mSIGNR1 KO mice
Splenocytes were isolated from WT (filled bars) and mSIGNR1 KO mice (open bars) 2 (A, C) and
5 (B, D) weeks after infection with 105 M. tuberculosis and stimulated with PPD for 48 hours. IFNγ
(A, B) and IL-4 (C; D) were measured in culture supernatants. Data are mean ± SEM of 6-8 mice
per group per time point. ∗P < 0.05 versus WT mice.
equal in lungs and draining lymph node of WT and mSIGNR1 KO mice (Table 4.2).
Nevertheless, the early activation status (% CD69 positive lymphocytes) of lung CD8+ T
cells and draining lymph node CD4+ T cells was increased after 2 weeks but not after 5
weeks of infection in the mSIGNR1 KO mice compared to the WT mice. The increase
in IFNγ and T cell activation status in the mSIGNR1 KO mice compared to WT mice
indicates that mSIGNR1 might be involved in the shift of the balance of the early immune
response against M. tuberculosis towards Th2.
Similar local cytokine and chemokine levels
It has been demonstrated that in vitro binding of M. tuberculosis ManLAM to DC-
SIGN expressed on DC and mSIGNR1 expressed on macrophages results in production
of the anti-inammatory cytokine IL-10( 6) (Fig. 4.1). We therefore assessed the local in-
ammatory response in WT and mSIGNR1 KO mice infected with M. tuberculosis. De-
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CD4+ CD4+/CD69+ CD4+ CD8+/CD69+
Lung % % % %
2 weeks
WT 79±3 29±2 13±2 5±1
mSIGNR1 KO 73±2 26±3 17±2 9±1∗
5 weeks
WT 82±3 29±3 11±3 5±2
mSIGNR1 KO 88±1 34±3 8±1 4±1
Lymph node
2 weeks
WT 62±2 10±1 35±2 5±1
mSIGNR1 KO 63±2 17±3∗ 31±2 5±1
5 weeks
WT 87±3 13±3 10±3 1±1
mSIGNR1 KO 83±6 14±1 10±2 2±1
Table 4.2: Effect of mSIGNR1 deficiency on T cell subsets in lungs during tuberculosis
T lymphocyte subsets in lungs or draining mediastinal lymph nodes of WT and mSIGNR1 KO
mice, 2 and 5 weeks after intranasal infection with 105 CFU of M. tuberculosis. Data are presented
as the percentage positive cells in the CD3+ gate. Data are mean ± SEM of 6-8 mice per group.
∗P<0.05 versus WT mice.
spite the fact that ManLAM induced IL-10 production by DC and peritoneal macrophages
in vitro, no differences in IL-10 production were observed in the lung during pulmonary
tuberculosis in mice decient for mSIGNR1 compared to WT mice. As shown in Table
4.3, no differences in total pulmonary cytokine and chemokine levels were observed: in
addition to IL-10, TNF, IL-1β, KC and MIP-2 concentrations were comparable in WT
and mSIGNR1 KO mice. Based on the cytokine prole measured locally, mSIGNR1 is
not involved in the induction of cytokine production to modulate the immune response.
4.4 Discussion
Early interactions between DC and M. tuberculosis are thought to be critical for mounting
a protective anti-mycobacterial immune response. Recent studies have demonstrated that
M. tuberculosis is able to bind to DC-SIGN, a C-type lectin expressed on DC 6,8. The
interaction of the M. tuberculosis cell wall component ManLAM with DC-SIGN resulted
in suppression of LPS-induced DC maturation and production of the immunosuppressive
cytokine IL-10 in vitro 6. These data suggest that M. tuberculosis targets the C-type lectin
DC-SIGN to suppress DC functions 6. In vivo studies are needed to fully understand the
role of DC-SIGN in M. tuberculosis infection.
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2 weeks 5 weeks
ng/ml WT mSIGNR1 KO WT mSIGNR1 KO
IFNγ 0.4±0.1 0.5±0.1 0.4±0.1 0.2±0.1
IL-4 0.4±0.1 0.5±0.1 0.5±0.1 0.8±0.1
IL-10 2.2±0.2 3.3±0.4 4.2±0.2 3.1±1.0
TNF 3.2±0.7 3.9±0.3 4.1±0.3 5.9±1.1
IL-1β 2.2±0.5 1.7±0.2 1.6±0.3 1.7±0.3
KC 4.7±0.9 4.0±0.7 4.3±0.8 3.4±1.0
MIP-2 0.3±0.1 0.3±0.1 0.6±0.1 0.4±0.1
Table 4.3: No effect of mSIGNR1 deficiency on pulmonary cytokine and chemokine levels
Cytokine and chemokine levels (in ng/ml) in lung homogenates of WT and mSIGNR1 KO mice 2
and 5 weeks after intranasal infection with 105 CFU of M. tuberculosis. Data are mean ± SEM of
6-8 mice per group.
Here, we have studied the role of mSIGNR1 in a model of pulmonary tuberculo-
sis. Although this homologue is capable of binding both M. tuberculosis and ManLAM,
similar to human DC-SIGN, it is expressed by macrophages and not DC. We found that
mSIGNR1 expressed by peritoneal macrophages is involved in ManLAM-induced IL-10
production. Therefore, we expected that the absence of the ManLAM induced down-
modulation of the immune response by the production of IL-10 would lead to an en-
hanced host defense response against M. tuberculosis in mSIGNR1 KO mice. In contrast
to our hypothesis, we were not able to detect any differences in local pulmonary concen-
trations of IL-10, IFNγ or other cytokines at 2 and 5 weeks post-infection. Moreover,
no differences were observed between mSIGNR1 KO and WT mice with respect to the
numbers of pulmonary CD4+ and CD8+ T lymphocytes at 2 and 5 weeks after infection.
We did observe increased activation in pulmonary CD8+ T cells and lymph node CD4+
cells early after infection in mSIGNR1 KO mice compared to the WT. However, the in-
creased expression of CD69 in these cells did not lead to increased local levels of IFNγ,
the protective cytokine necessary in host defense against M. tuberculosis 26,27.
Strikingly, at 2 weeks after infection, splenocytes from mSIGNR1 KO mice produced
more IFNγ upon stimulation with the recall antigen PPD compared to WT mice. This
indicates that the systemic immune response was enhanced at this early time-point in
mSIGNR1 KO mice compared to the WT suggesting an immunosuppressive role for
mSIGNR1. This immunosuppressive role of mSIGNR1 is conrmed by the trend that
stimulated mSIGNR1 KO splenocytes produced less IL-4 compared to WT splenocytes.
Hence, mSIGNR1 KO mice have a more Th1 dominated immune response when com-
pared to WT mice, suggesting a role for mSIGNR1 in the Th1/Th2 balance of the immune
response against M. tuberculosis. However, the increased IFNγ production by splenocytes
early in infection did not result in an enhancement of antibacterial response by mSIGNR1
78 References
KO mice.
mSIGNR1 could be involved in the binding and internalization of M. tuberculosis for
degradation, since mSIGNR1 is a receptor for M. tuberculosis. However, mSIGNR1 is not
expressed by alveolar macrophages and we did not observe any induction of mSIGNR1
expression by alveolar macrophages or inux of mSIGNR1 positive cells during infection,
suggesting that mSIGNR1 is not involved in the initial or late capture of M. tuberculosis
in the lung. Indeed, no differences were observed in the outgrowth of the bacteria and
local levels of IL-10, IFNγ or IL-4.
Recent studies have demonstrated that mSIGNR1 is involved in the early defense
against S. pneumoniae 21,22. Lanoue et al. demonstrated that, upon intraperitoneal infec-
tion of S. pneumoniae, mSIGNR1 expressed by peritoneal macrophages enhanced clear-
ance of S. pneumoniae by phagocytosis 21. Recently, we have demonstrated that upon
intranasal infection with S. pneumoniae, mSIGNR1 KO mice did not clear bacteria from
lung and blood, and displayed severely enhanced inammatory parameters compared to
the WT mice. In addition, the levels of anti-phosphorylcholine IgM did not increase dur-
ing infection in mSIGNR1 KO mice whereas the antibody level did increase during infec-
tion in the WT mice. These antibodies are essential for protection against infection with
S. pneumoniae. Hence, mSIGNR1 seems to play a role in the early antibody-mediated
immune response against S. pneumoniae. Host defense against intracellular M. tuber-
culosis infection mainly depends on cell-mediated immunity 1,28. Although in the early
phase of infection, mSIGNR1 inuences the Th1/Th2 balance of the immune response
evoked by M. tuberculosis, this shift towards a Th1 response was not enough to protect
against infection. Importantly, mSIGNR1 is not expressed by alveolar macrophages even
after infection, which can explain the minor role of mSIGNR1 in the pathogenesis of M.
tuberculosis.
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Abstract
The Gram-positive bacterium Streptococcus pneumoniae is the leading causative patho-
gen in community-acquired pneumonia. The ever-increasing frequency of antibiotic-
resistant S. pneumoniae strains severely hampers effective treatments. Thus, a better un-
derstanding of the mechanisms involved in the pathogenesis of pneumococcal disease is
needed; in particular of the initial interactions that take place between the host and the
bacterium. Recognition of pathogens by dendritic cells is one of the most crucial steps in
the induction of an immune response. For efcient pathogen recognition, dendritic cells
express various kinds of receptors, including the dendritic cell-specic C-type lectin DC-
SIGN. Pathogens such as Mycobacterium tuberculosis and HIV target DC-SIGN to escape
immunity. Here the in vitro binding of DC-SIGN with S. pneumoniae was investigated.
DC-SIGN specically interacts with S. pneumoniae serotype 3 and 14 in contrast to other
serotypes such as 19F. While the data described here suggest that DC-SIGN interacts
with S. pneumoniae serotype 14 through a ligand expressed by the capsular polysaccha-
ride, the binding to S. pneumoniae serotype 3 appears to depend on an as yet unidentied
ligand. Despite the binding capacity of the capsular polysaccharide of S. pneumoniae 14
to DC-SIGN, no immunomodulatory effects on the dendritic cells were observed. The
immunological consequences of the serotype-specic capacity to interact with DC-SIGN
should be further explored and might result in new insights in the development of new
and more potent vaccines.
5.1 Introduction
Streptococcus pneumoniae (pneumococcus) is a major cause of bacterial pneumonia, oti-
tis media, bacteremia and meningitis and is a leading cause of morbitity and mortality
worldwide1,2. Pneumococcus is surrounded by a polysaccharide (PS) capsule which pro-
tects it from phagocytosis and is pivotal for virulence since non-encapsulated pneumo-
cocci are avirulent3,4. Capsular PS are known to mediate a protective humoral immune
response. Based on the unique antigenic determinants of the capsular PS, pneumococ-
cus can be dened into 90 different serotypes. Strikingly, antibodies that are protective
against one serotype do not necessarily provide protection against another. Furthermore,
the individual serotypes differ in virulence and immunogenicity 5,6. Besides the PS cap-
sule, all pneumococcal serotypes have a cell wall containing polysaccharides (cell wall
polysaccharides, CWPS), which are common to all pneumococci. Unlike capsular PS,
the structure of CWPS is more conserved.
Although major advances have been made in the development of pneumococcal vac-
cines, their efcacy is undermined by the serotype variability and genome plasticity of the
pneumococcus. Moreover, the ever-increasing frequency of antibiotic-resistant S. pneu-
moniae strains severely hampers effective treatments 7. Thus, a better understanding of
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the mechanisms involved in the pathogenesis of pneumococcal disease is needed; in par-
ticular of the initial interactions that take place between the host and the bacterium.
Dendritic cells (DC) are professional antigen presenting cells that are pivotal in or-
chestrating an effective immune response. In order to interact with pathogens, DC ex-
press various kinds of receptors, including C-type lectins, that bind to carbohydrate struc-
tures. Dendritic cell-specic ICAM-3 grabbing non-integrin (DC-SIGN) is a type II C-
type lectin that functions as a pathogen receptor. DC-SIGN contains one carbohydrate
recognition domain (CRD) that binds to carbohydrate structures present on the surface of
many pathogens but also on self-antigens. As a pathogen receptor, DC-SIGN interacts
with a plethora of pathogens, such as HIV, hepatitis C virus, Mycobacterium tuberculo-
sis and Schistosoma mansoni 8–11. Next to its function as a pathogen receptor, DC-SIGN
binds self-proteins and establishes cellular interactions of DC with endothelial cells dur-
ing DC migration, with neutrophils during inammation and with T cells during antigen
presentation12–14.
To further elucidate the in vivo function of DC-SIGN, ve murine DC-SIGN homo-
logues have been cloned 15. The most extensively studied is mSIGNR1, which is ex-
pressed on marginal zone macrophages (MZM) of the spleen and peritoneal macrophages
16,17
. Recently, it has been shown that mSIGNR1 is involved in the in vivo capture of
different pneumococcal capsular serotypes, e.g. serotypes 3, 14, 23 and 26 (also known
as serotypes 3, 14, 23F and 6B, respectively, according to the Danish nomenclature) 18.
Furthermore, mSIGNR1 was shown to be required for immunity against infection with
S. pneumoniae serotype 2 and 14( 19). Similarly, DC-SIGN may also be involved in the
orchestration of the immune response against S. pneumoniae.
We studied the interaction of DC-SIGN with pneumococcal PS serotypes, commonly
causing disease20,21. Strikingly, DC-SIGN interacted only with pneumococcal PS sero-
type 14. However, when the interaction with heat-killed pneumococci was studied, bind-
ing was observed to serotype 3 in addition to serotype 14. This indicates that DC-SIGN
may interact with other antigenic epitopes found on serotype 3.
Moreover, we observed that S. pneumoniae capsular polysaccharides did not alter the
activation of DC by LPS, suggesting that S. pneumoniae capsular polysaccharides do not
target DC-SIGN to evade the immune system. Still, the immunological consequences of
this serotype-specic capacity to interact with DC-SIGN should be further explored and
might result into new insights in the development of new and more potent vaccines.
5.2 Materials and Methods
Antibodies, cells and bacteria
The stable Raji transfectant expressing DC-SIGN was generated by electroporation
of 10 µg pRc/CMV-DC-SIGN as previously described 9. The Raji-1 cells used were pre-
viously called THP-1 cells by mistake 22. Immature DC were cultured from monocytes
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in the presence of IL-4 and GM-CSF (500 and 800 U/ml, respectively; Schering-Plough,
Brussels, Belgium)23,24. All experiments were performed using 5-7 days old immature
DC. S. pneumoniae serotype 3 (ATCC 6303, Rockville, MD), 14 or 19 (CDC, Atlanta,
GA), were cultured in Todd Hewitt broth containing 10% fetal bovine serum and heat-
killed by incubation at 56◦C for 30 minutes. Heat-killed preparations were cultured on
blood agar plates at 37◦C for 20 hours to conrm the absence of viable organisms.
The following antibodies were used: AZN-D1 and AZN-D2 (anti-DC-SIGN) 9; Clone
19 (anti-MR, BD Biosciences).
Soluble DC-SIGN-Fc adhesion assay
DC-SIGN-Fc consists of the extracellular portion of DC-SIGN (amino acid residues
64-404) fused at the COOH terminus to a human IgG1-Fc fragment 25. The soluble DC-
SIGN adhesion assay was performed as follows. Soluble ligands were coated onto ELISA
plates 10 µg/ml for 18 hours at 4◦C followed by blocking with 1% BSA for 30 minutes
at 37◦C. Soluble DC-SIGN-Fc supernatant (0.75 µg/ml) was added and incubated for
2 hours at room temperature. Unbound DC-SIGN-Fc was washed away and binding
was detected by peroxidase-labeled goat anti-human IgG (Jackson). Absorbance was
measured at 450 nm. Specicity of binding was determined in the presence of either 20
µg/ml blocking antibodies or 10 mM EGTA.
Ligand coating of fluorescent beads
Carboxylate-modied TransFluorSpheres (Molecular Probes, Eugene, OR) 75 µl (a-
bout 3.3× 1010/ml) were coated with the capsular polysaccharides of S. pneumoniae
serotype 3, 14, 19 and cell wall polysaccharide by incubation for 15 minutes at room tem-
perature with 10 µg/ml polysaccharides of S. pneumoniae. 1-ethyl-3-(3-dimethylamino-
propyl)-carbodiimide (EDAC) (Sigma Chemie) dissolved (1.33 mg/ml) in MES-buffer
(50 mM MES pH 6.0) was added to the solution and incubated for 2 hours. The reaction
was stopped by addition of glycin to a nal concentration of 100 mM for 30 minutes. The
beads were washed three times with PBS and resuspended in 75 µl PBS, 0.5% BSA. This
suspension remains stable for two months if stored at 4◦C26.
The gp120 coated beads were generated by incubating streptavidin-coated beads with
biotinylated goat F(ab)2 anti-human Fc fragments (Jackson Immunoresearch Laboratories
Inc., Westgrove, PA) for 2 hours at 37◦C. The beads were washed and incubated with cell
supernatant containing gp120-Fc recombinant protein overnight at 4◦C9.
Adhesion of ligand-coated beads to cells was performed as described previously 26.
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Binding assay
DC or Raji cells stably expressing DC-SIGN were pre-incubated in adhesion buffer
(20 mM Tris- (tris(hydroxymethyl)aminomethane)-)HCl, pH 8.0, 150 mM NaCl, 1mM
CaCl2, 2mM MgCl2, 0.5% BSA) with either 1 mg/ml mannan (Saccharomyces cerevisiae,
SIGMA, St. Louis, MO, USA), 10 mM EGTA, 20 µg/ml AZN-D1, 20 µg/ml AZN-D2,
1×108 CFU/ml Escherichia coli (strain AMC B12G1) or 1×108 CFU/ml heat-killed S.
pneumoniae serotype 3, 14 or 19F, for 15 minutes at 37◦C. Gp120 beads or beads coated
with pneumococcal PS serotypes 3, 14, 19F or CWPS were added and the suspension was
incubated for 45 minutes at 37◦C. Cells were washed with adhesion buffer and analyzed
using ow cytometry (FACS Calibur, BD, San Jose, CA).
Maturation assay
Immature DC (5×104 cells/well) were cultured for 24 hours in a total volume of 100
µl RPMI 10% FCS and in the presence of polysaccharides of S. pneumoniae (50 µg/ml)
and LPS (10 ng/ml) unless otherwise noted. The role of DC-SIGN was determined by
preincubating immature DC with AZN-D1 or AZN-D2 (20 µg/ml) for 30 minutes at 37◦C.
DC maturation was determined by analyzing cell-surface expression of the co-stimulatory
molecules CD83 and CD86 using phycoerythrin-conjugated antibodies, which were incu-
bated for 30 minutes at 4◦C.
Cytokines in cell supernatant were measured by sandwich ELISA. The anti-cytokine
antibodies (IL-6, IL-10 and IL-12, 1.0 µg/ml, Biosource) were coated onto ELISA plates
in 0.05 M sodium carbonate for 18 hours at 4◦C. After washing with PBS, 0.02% Tween-
20, the plates were blocked with PBS 2% milk (PBS/milk) for 1 hour. After washing,
samples and standards (Biosource) were incubated for 2 hours together with cytokine
detecting antibody (Biosource). Standards were used to determine the concentration of
cytokine production in the samples. For detecting the cytokine complex, streptavidin
poly-HRP (CLB) was added for 30 minutes at room temperature. The reaction was de-
veloped by TMB and stopped by addition of 0.8 M H2SO4.
5.3 Results
S. pneumoniae is a major cause of morbidity and mortality worldwide. The capsular
polysaccharides are crucial for virulence of the bacterium but are also involved in the
elicitation of protective humoral immunity. DC-SIGN, a C-type lectin, is known for its
dual role in immunity against pathogens. As this C-type lectin is able to interact with
polysaccharides, DC-SIGN may be involved in the immune response against or immune
modulation by S. pneumoniae.
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Figure 5.1: Immature DC express high levels of DC-SIGN
The thin and thick line correspond to the isotype control and specific antibody staining (AZN-D1)
respectively. One representative experiment out of three is shown.
DC-SIGN binds the capsular polysaccharide of S. pneumoniae serotype 14
More than 90 pneumococcal serotypes have been described for pneumococcus, based
on the capsular PS structures, which differ in virulence and immunogenicity 21. We set out
to investigate the binding capacity of DC-SIGN on DC (Fig. 5.1) to a panel of pneumococ-
cal capsular PS and CWPS. The panel is a representation of the pneumococcal serotypes
that are most common cause of pneumococcal disease 20,21. Capsular PS was coated on
ELISA plates and DC-SIGN-Fc binding was analyzed. Strikingly, only serotype 14 was
bound by DC-SIGN and the interaction was specic as it was blocked by anti-DC-SIGN
antibodies and EGTA (Fig. 5.2).
We have demonstrated that DC interact with HIV-1 envelope gp120 through DC-SIGN
previously9. To investigate the interaction of DC-SIGN expressed on DC with pneumo-
coccal PS, a gp120-blocking assay was used. Thus, blocking of gp120 binding to DC in-
dicates binding of PS to DC-SIGN. Strikingly, only capsular polysaccharide derived from
pneumococcal serotype 14 blocked the binding of gp120 to DC-SIGN whereas neither
the other capsular polysaccharides derived from pneumococcal serotype 1, 3, 4, 6B,18C
and 19F (also known as serotype 1, 3, 4, 26, 56 and 19, respectively, according to the
American nomenclature) nor the CWPS demonstrated any substantial block (Fig. 5.3).
DC-SIGN binds heat-killed pneumococci serotype 3 and 14
Since DC-SIGN interacts with the capsular polysaccharide of pneumococcal serotype
14 we set out to investigate the binding capacity to heat-killed pneumococci. In addition
to serotype 14, serotype 3 was analyzed as this serotype has been described to inter-
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Figure 5.2: Soluble DC-SIGN-Fc specifically interacts with capsular PS serotype 14
DC-SIGN Fc binding to the capsular PS was determined by an Fc-specific ELISA. Standard devia-
tion <0.02 OD 450. One representative experiment out of three is shown.
act with the murine homologue of DC-SIGN, mSIGNR1( 18). A gp120-blocking assay
demonstrated that gp120 binding to DC-SIGN expressed on immature DC (Fig. 5.1) was
not only blocked by pneumococcal serotype 14, but also by serotype 3 in contrast to S.
pneumoniae serotype 19 (Fig. 5.4). In addition, preincubation with other bacteria such as
E. coli did not inhibit binding of DC-SIGN to gp120 (Fig. 5.4).
The difference in binding of bacteria compared to polysaccharides of pneumococcal
Figure 5.3: DC-SIGN specifically interacts with capsular PS serotype 14
Both DC-SIGN expressing DC and transfectants specifically bind to capsular PS serotype 14 in
contrast to capsular PS serotype 1, 3, 4, 6B, 18C, 19F and CWPS. Binding of DC-SIGN on DC
(A) or transfectants (B) to the different capsular PS serotypes was determined by the measurement
of the inhibition of the DC-SIGN specific binding to gp120. Standard deviation for the fluorescent
bead adhesion assay was <5%. One representative experiment out of three is shown.
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Figure 5.4: DC-SIGN specifically binds to heat-killed pneumococcal serotype 3 and 14
DC-SIGN expressing DC specifically interact with heat-killed pneumococcal serotype 3 and 14 in
contrast to serotype 19. Binding of DC-SIGN on DC to three different heat-killed pneumococcal
serotypes was determined by the measurement of the inhibition of the DC-SIGN specific binding to
gp120. The standard deviation for the fluorescent bead adhesion assay was <5%. One representa-
tive experiment out of three is shown.
serotype 3 may reect the localization of the specic epitope recognized by DC-SIGN. In
addition, the difference in binding of S. pneumoniae polysaccharide compared to whole
bacteria could also be caused by a difference in the tertiary structure of the capsular
polysaccharide. Next, uorescent beads were coated with pneumococcal PS serotypes
3, 14, 19F and CWPS, respectively, to provide multivalence. Fluorescent beads coated
with PS derived from pneumococcal serotype 14 bind DC-SIGN expressed by immature
DC and DC-SIGN expressed on Raji cells. This binding to DC is DC-SIGN specic,
since binding could be blocked by the DC-SIGN specic blocking antibody AZN-D1
(Fig. 5.5). Fluorescent beads coated with PS derived from pneumococcal serotypes 3,
19F or pneumococcal CWPS did not bind to DC-SIGN. In conclusion, DC-SIGN rec-
ognizes an epitope present on pneumococcal serotype 3, which is not present in the PS
capsule.
Capsular polysaccharides of S. pneumoniae do not influence DC-maturation
Next, the functional implications of the specic binding of S. pneumoniae serotype
14 by DC-SIGN were investigated. Previously, it has been shown that binding of a cell
wall component of M. tuberculosis to DC-SIGN blocks LPS-induced maturation. Specif-
ically, maturing DC exposed to the mycobacterial component ManLAM showed lower
expression of the maturation markers CD80, CD83 and CD86 and secreted increased lev-
5.4 Discussion 89
Figure 5.5: DC-SIGN specifically recognizes capsular PS serotype 14
The adhesion of DC-SIGN expressed by DC or on transfectants was determined using the fluo-
rescent bead adhesion assay. Specificity was determined by the polysaccharide mannan and the
DC-SIGN specific antibody AZN-D1. Standard deviation for the fluorescent bead adhesion assay
was <5%. One representative experiment out of three is shown.
els of the immunomodulatory cytokine IL-10( 27). Thus, DC-SIGN expressing immature
DC were co-cultured with LPS and pneumococcal capsular polysaccharide serotype 14.
However, no immunosuppressive effects such as IL-10 production by DC or a reduction
in the expression of the maturation markers CD83 and CD86 by DC was observed (Fig.
5.6A and B and data not shown). Production of IL-12p40 by DC was not inuenced by
the capsular PS (Fig. 5.6C).
Thus, DC-SIGN displays a clear binding specicity for S. pneumoniae serotype 3 and
14 in contrast to serotype 19 or the polysaccharides of the cell wall. Furthermore, binding
to S. pneumoniae serotype 3 does not seem to be mediated via the capsular polysaccharide.
Overall, we demonstrate that S. pneumoniae binding to DC-SIGN is serotype dependent.
However, the functional implications of the serotype specicity of DC-SIGN remain to
be elucidated.
5.4 Discussion
S. pneumoniae still poses a great threat to human health. Effective vaccines are still
needed and the emergence of antibiotic resistant pneumococci is a large drawback in
the battle against this pathogen. In this study the interaction between S. pneumoniae
and the type II C-type lectin DC-SIGN was investigated. Interaction of this bacterium
with DC that express DC-SIGN could give us more insight into the early events of S.
pneumoniae infection. DC-SIGN, via its cross talk with T cells and neutrophils, is able to
enhance immune activation. In contrast, DC-SIGN has also been described as a target for
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Figure 5.6: Capsular PS serotype 14 binding to DC does not result in immune modulation
Capsular PS serotype 14 and 19 do not induce activation of immature DC. LPS-induced activation
of DC is not blocked by capsular PS serotype 14 or 19. Immature DC were incubated with capsular
PS serotype 14 and 19 for 24 hours and activation was determined by measuring the expression of
CD83 (A) and CD86 (B). (C) Supernatants were harvested after 24 hours and the IL-12 production
was measured by ELISA. One representative experiment out of three is shown. Standard deviation
<0.02 OD 450.
pathogens to escape immunity 11,27.
This report demonstrates that DC-SIGN specically binds capsular polysaccharide
serotype 14 in contrast to the other important capsular PS tested (serotypes 1,3, 4, 6B,
18C, 19F) and pneumococcal CWPS. However, DC-SIGN expressed on human immature
DC also interacts with encapsulated S. pneumoniae serotype 3 in addition to serotype 14.
The epitope bound by DC-SIGN on encapsulated S. pneumoniae serotype 3 was not de-
tected in the PS capsule, but probably involves another unidentied antigen 28. Another
explanation could be that the epitope recognized by DC-SIGN is initially present on the
capsule of pneumococcal serotype 3, but is destroyed upon extraction of the polysac-
charide fraction. This is in concurrence with the fact that upon removal of the capsule,
mSIGNR1 no longer binds pneumococcal serotype 3( 18). However, in that specic exper-
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iment the bacteria were heated at 95◦C, which likely destroys bacterial surface proteins.
Furthermore, Kang et al. have shown that S. pneumoniae serotype 3 capsular polysac-
charide is able to block dextran-FITC binding to mSIGNR1, the murine homologue of
DC-SIGN, although to a lesser extent than serotype 14( 18). This is in contrast to our data
that identify only capsular polysaccharide 14 and not capsular polysaccharide of serotype
3 as a ligand for DC-SIGN, suggesting a difference in binding specicity between the two
homologues. However, this difference in binding might also be reecting a lower binding
afnity of DC-SIGN for pneumococcal serotype 3 capsular PS.
Pneumococcal serotype 14 is a leading cause of invasive pneumococcal disease in
the US and Western Europe 20,29. Strikingly, of a panel of capsular polysaccharides de-
rived from the most common S. pneumoniae serotypes causing disease, only the capsular
polysaccharide of S. pneumoniae serotype 14 is bound by DC-SIGN. Recent studies have
shown that pathogens target DC-SIGN to evade the immune system. For example, M.
tuberculosis is able to down-regulate DC maturation by the ligation of its cell wall com-
ponent ManLAM to DC-SIGN on DC 27. Possibly, the capacity of S. pneumoniae serotype
14 to bind DC-SIGN induces suppression of the immune response against this pathogen,
facilitating the large contribution of this pneumococcal serotype to pneumococcal disease.
To investigate this, DC-SIGN expressing immature DC were co-cultured with LPS and
pneumococcal capsular polysaccharide serotype 14. However, no immunosuppressive ef-
fects such as a down-regulation of IL-12 production by DC or a down-regulation of the
maturation markers CD80 and CD86 were observed. Possibly, S. pneumoniae serotype 14
uses DC-SIGN for dissemination, hereby explaining the invasive nature of this bacterium.
Thus, this study demonstrates that DC-SIGN specically binds to S. pneumoniae
serotype 3 and 14 whereas no binding was observed to S. pneumoniae serotype 19. Fur-
ther experiments are needed to demonstrate the physiological relevance of the binding
specicity of mSIGNR1 and DC-SIGN to different S. pneumoniae serotypes.
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Abstract
The dendritic cell-specic ICAM-3-grabbing nonintegrin (DC-SIGN) homologue, murine
SIGN-related 1 (mSIGNR1) is a pathogen receptor expressed by splenic marginal zone
and peritoneal macrophages, and is essential for clearance of Streptococcus pneumo-
niae by phagocytosis after intraperitoneal infection. Here, we identied an important
in vivo function for mSIGNR1 in S. pneumonia infection induced via its natural en-
trance route. Upon intranasal infection with S. pneumoniae, mSIGNR1-decient mice
did not clear bacteria from lung and blood, and displayed severely enhanced inam-
matory parameters compared to the wild-type mice. However, mSIGNR1 is not ex-
pressed by alveolar macrophages, suggesting that another mechanism than a decrease
in phagocytosis is responsible for this difference. Natural anti-phosphorylcholine IgM
produced by marginal zone B cells is essential for protection against infection with S.
pneumoniae. Strikingly, during infection, mSIGNR1-decient mice failed to produce a
rapid anti-phosphorylcholine IgM response. Marginal zone macrophages have been sug-
gested to capture antigens for presentation to marginal zone B cells. We demonstrate that
marginal zone macrophages from mSIGNR1-decient mice in contrast to wild-type mice
are not able to capture pneumococci from blood, suggesting that mSIGNR1 on marginal
zone macrophages captures S. pneumoniae for antigen presentation to and activation of
marginal zone B cells, resulting in an anti-phosphorylcholine IgM response.
6.1 Introduction
The rst line of defense against invading Streptococcus pneumoniae is provided by the
innate immune system. There is strong evidence that the complement system is important
in pneumococcal infection 1, and the classical pathway, partially mediated by the binding
of natural IgM antibodies to bacteria, is the most important pathway for activation of this
system during innate immunity to S. pneumoniae 2.
Rapid antibody responses to pneumococci are also essential for effective elimination
of the pathogen and, in this context, the spleen, with its highly specialized lymphoid com-
partment, plays a central role in clearing blood-borne pathogens. Pneumococcal polysac-
charides are T-cell independent type 2 (TI-II) antigens and splenic marginal zone B cells
play an important role in such responses 3,4. Splenic marginal zone B cells join B1 B cells
to generate the initial humoral IgM response in the initial 3 days of a primary immune
response to particulate bacterial antigens 5.
A role in the defense against pneumococcal infection may also exist for marginal
zone macrophages that have been shown to capture and concentrate both TI-II and par-
ticulate antigens circulating in the blood 6,7. Encapsulated S. pneumoniae injected in-
travenously were rapidly captured by marginal zone macrophages 7. The dendritic cell-
specic ICAM-3-grabbing nonintegrin (DC-SIGN) homologue, murine SIGN-related 1
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(mSIGNR1) is a C-type lectin involved in the capture of TI-II antigens by marginal
zone macrophages, since the rapid capture of pathogen polysaccharides, such as man-
nan and dextran, by marginal zone macrophages upon intravenous injection is inhibited
by antibodies against mSIGNR1( 8,9). Moreover, using blocking antibodies Kang et al.
demonstrated that mSIGNR1 is involved in the capture of different serotypes of capsu-
lar polysaccharides from S. pneumoniae 10. Recently, Lanoue et al. demonstrated that
mSIGNR1 plays a crucial role in the immune response against intraperitoneal infection
of S. pneumoniae serotype 2 and 14( 11). The authors show that mSIGNR1 expressed
by peritoneal macrophages plays a crucial role in binding and concomitant phagocyto-
sis of the bacteria. However, the natural infection pathway of S. pneumoniae is through
inhalation via the upper airways, and mSIGNR1 is not expressed by the residing alveo-
lar macrophages. Therefore, we have investigated the role of mSIGNR1 in the defense
against pulmonary infection with S. pneumoniae using mice with a genetic deletion of
mSIGNR1 (SIGNR1−/−)11. We demonstrate that SIGNR1−/− mice are more suscep-
tible to pulmonary S. pneumoniae infection than WT mice, and that SIGNR1−/− mice
fail to induce an early IgM response against S. pneumoniae. Furthermore, our data sug-
gest that mSIGNR1 expressed by marginal zone macrophages is pivotal for the capture
of S. pneumoniae from blood, and is involved in the induction of the early IgM response
against S. pneumoniae, which might be necessary for protection against these bacteria.
6.2 Materials and Methods
Mice and bacteria
SIGNR1−/− mice were a generous gift from A. McKenzie (Cambridge, UK). C57BL/
6×129 WT and SIGNR1−/− mice were bred in the animal facility of the VU University
Medical Center under specic pathogen-free conditions, and were kept in the animal fa-
cilities of the VU University Medical Center and the Academic Medical Center in Am-
sterdam, The Netherlands. Age- and sex-matched mice were used in all experiments. The
experiments have been approved by the Animal Care and Use Committee of the Univer-
sity of Amsterdam and the VU University Medical Center.
S. pneumoniae serotype 3 (ATCC 6303, Rockville, MD) were used in mid-logarithmic
phase and concentrations were determined by plating dilutions on sheep-blood agar plates.
Immunofluorescence analysis
Cryosections, 8 µm thick, were xed in dehydrated acetone for 10 minutes, rehy-
drated with PBS and stained for 90 minutes at 37◦C with primary antibodies ED31 (anti-
MARCO), SER-4 (anti-Sialoadhesin) or ERTR-9 (anti-SIGNR1). The appropriate sec-
ondary antibodies were used for detection. Heat-killed S. pneumoniae serotype 3 was de-
tected by a pneumococcal polysaccharide serotype 3-specic rabbit polyclonal (Statens
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Serum Institute, Copenhagen, Denmark).
In vivo antigen capture by marginal zone macrophages
Naive mice were injected intravenously into the tail veins with either 100 µl FITC-
dextran (0.5 mg/ml, 500-kDa dextran-FITC; Molecular Probes, Eugene, OR), or 200 µl
heat killed S. pneumoniae serotype 3 (1.3× 106 CFU/ml). After 45 minutes mice were
sacriced and spleens were isolated and antigens were detected by immunouorescence
analysis.
Binding Assay
Raji-1 cells stably expressing mSIGNR1 or freshly isolated peritoneal macrophages
were preincubated in adhesion buffer (20 mM Tris, pH 8.0, 150 mM NaCl, 1 mM CaCl2,
2 mM MgCl2, 0.5% BSA) with either 2 mg/ml mannan (SIGMA, St. Louis, MO), 50 mM
EGTA, 2.6×107 CFU/ml heat killed S. pneumoniae serotype 3 (ATCC 6303, Rockville,
MD), 1× 109 CFU/ml Escherichia coli (strain AMC B12G1) or 2× 109 CFU/ml heat-
killed non-typeable Haemophilus influenzae (strain 12 kindly donated by S. J. Barenkamp,
St. Louis, MO) for 15 minutes at room temperature. Dextran-FITC (50 µg/ml, 500 kDa;
Molecular Probes, Eugene, OR) was added and after 45 minutes at 37◦C analyzed by ow
cytometry.
Induction of pneumonia
Pneumonia was induced as described previously 12. Mice were inoculated with bacte-
ria in a 50 µl volume (5×104 CFU) intranasally, and 24 or 48 hours after infection, mice
were sacriced. CFU were determined from tissue homogenates.
Cytokines and chemokines were measured using specic ELISA (R&D Systems,
Minneapolis, MN) according to the manufacturers instructions. Lungs for histology were
harvested at 24 and 48 hours after infection, xed in 10% buffered formalin in PBS for
24 hours and embedded in parafn. Lung sections, 4 µm thick, were stained with hema-
toxylin and eosin, and scored by a pathologist who was blinded for groups 13. Lung
inammation and damage were scored by analyzing the entire lung surface with respect
to the following parameters: interstitial inammation, oedema, endothelialitis, bronchitis
and pleuritis. Each parameter was graded on a scale of 0-5; from 0: absent to 5: se-
vere. The total lung inammation score was expressed as the sum of the scores for each
parameter, the maximum being 25.
Plasma samples were analyzed for the presence of anti-PC IgM antibodies by ELISA
on PC-BSA-coated wells. Specicity was determined by subtracting the coating buffer
background levels from the PC coated values. All data are expressed as mean ± SEM
unless indicated otherwise. Comparisons between groups were performed with Mann-
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Whitney U tests using GraphPad Prism version 3.00, GraphPad Software (San Diego,
CA). Values of P<0.05 were considered statistically signicant.
Immunization
Naive animals were injected intraperitoneally with 0.1 mg/ml trinitrophenol-keyhole
limpet hemocyanin (TNP-KLH) in 0.5 ml PBS. Sera were collected before and weekly
after injection for assessment of TNP-KLH specic IgG antibodies by ELISA.
6.3 Results
mSIGNR1 expression and function
The C-type lectin mSIGNR1 is expressed by splenic marginal zone macrophages
and peritoneal macrophages 8,14, but not by alveolar macrophages in the lung (data not
shown). Initially, the lack of mSIGNR1 expression by marginal zone and peritoneal
macrophages of SIGNR1−/− mice was conrmed (Fig. 6.1A and B). mSIGNR1 de-
ciency in marginal zone macrophages from SIGNR1−/− mice did not alter the architec-
ture of the macrophage subsets present in the marginal zone (Fig. 6.1A), since the local-
ization of both the MARCO+ marginal zone macrophages and the sialoadhesin+ marginal
zone metallophilic macrophages were comparable to WT (Fig. 6.1A). An intravenous
injection of the TI-II antigen dextran-FITC results in a rapid capture by marginal zone
macrophages through mSIGNR1 8. As expected, the marginal zone macrophages from
SIGNR1−/− mice failed to capture dextran-FITC after intravenous administration (Fig.
6.1A). Similarly, mSIGNR1+ peritoneal macrophages efciently bound dextran-FITC,
whereas peritoneal macrophages from SIGNR1−/− mice did not (Fig. 6.1C). These data
support an essential role for mSIGNR1 in the capture of TI-II antigens by both marginal
zone and peritoneal macrophages.
mSIGNR1 interacts with S. pneumoniae serotype 3
To investigate the role of mSIGNR1 in infection with the virulent S. pneumoniae
serotype 3, the mSIGNR1 interaction with this pneumococcus was studied using a dextran-
blocking assay. Cell lines expressing mSIGNR1 efciently capture dextran-FITC, and this
interaction was blocked by pre-incubation of the transfectants with S. pneumoniae sero-
type 3 (Fig. 6.2A). In contrast, pre-incubation with other bacteria such as Escherichia coli
and non-typeable Haemophilus influenzae did not inhibit binding of mSIGNR1 transfec-
tants to dextran-FITC (Fig. 6.2A). Thus, while mSIGNR1 binds whole S. pneumoniae
serotype 3, it does not interact with other bacteria such as E. coli and H. influenzae (Fig.
6.2A).
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Figure 6.1: mSIGNR1 captures blood-borne TI-II antigens in vivo
(color reprint: Fig. A.3, pp. 156)
(A) The splenic marginal zone from SIGNR1−/− mice contains both marginal zone macrophage
subsets (marginal zone macrophages (MZM) and marginal metallophilic macrophages (MMM) re-
spectively), but does not capture TI-II antigens. Spleens from naive WT (left) and SIGNR1−/−
(right) mice were stained for MARCO+ MZM in red and SER-4+ MMM in green (upper panel),
for mSIGNR1 with ERTR-9 (middle panel) and for capture of dextran-FITC 45 minutes after intra-
venous administration (lower panel). These data are representative for three animals of both geno-
types. (B and C) Peritoneal macrophages from SIGNR1−/− mice do not capture TI-II antigens.
Peritoneal macrophages were analyzed for mSIGNR1 expression using ERTR-9 (B), and binding
to dextran-FITC was analyzed in the presence and absence of the blocking reagents mannan and
EGTA (C). These data are representative for three independent experiments.
SIGNR1−/− mice are more susceptible to pulmonary infection with S. pneumoniae
serotype 3
Next, WT and SIGNR1−/− mice were challenged by intranasal administration of 5×
104 CFU S. pneumoniae serotype 3. To investigate the role of mSIGNR1 during infection
of S. pneumoniae, we determined the bacterial load in the lungs 24 and 48 hours after
infection. Between 24 and 48 hours after infection, the bacterial load in SIGNR1−/−
mice increased, whereas the WT mice started clearing the bacteria (Fig. 6.2B). Thus,
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Figure 6.2: SIGNR1−/− mice fail to efficiently clear S. pneumoniae from the lungs despite the
induction of a strong inflammatory response in vivo
(A) mSIGNR1 interacts with S. pneumoniae serotype 3. mSIGNR1 transfectants were incubated
with dextran-FITC and the ability of different bacteria to inhibit this interaction was measured. (B
and C) S. pneumoniae are not cleared from the lungs of SIGNR1−/− mice. WT and SIGNR1−/−
mice were inoculated with 5× 104 S. pneumoniae and bacterial outgrowth in lungs (B) and rela-
tive lung wet weight (weight lung/total mouse weight, C) was determined. (D) SIGNR1−/− mice
have a more severe lung inflammation and damage than WT mice due to S. pneumoniae infection.
Lung inflammation and damage were scored with respect to the following parameters: interstitial
inflammation, oedema, endothelialitis, bronchitis and pleuritis. Each parameter was graded on a
scale of 0-5; from 0: absent to 5: severe. The total “lung inflammation score” was expressed as
the sum of the scores for each parameter, the maximum being 25. Horizontal bars represent mean
inflammation scores. (E) Neutrophil influx is increased in lungs from SIGNR1−/− mice due to S.
pneumoniae infection. Representative slides of lung histopathology; original magnification ×10;
insert magnification ×40. ∗P <0.05, ∗∗∗P<0.001.
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Figure 6.3: Upon infection with S. pneumoniae, SIGNR1−/− mice display similar early pul-
monary cytokine responses compared to WT mice
Cytokine production in the lung (A, B and C) was measured 24 and 48 hours after infection. Bacte-
rial outgrowth from the spleen (D) was measured 48 hours after infection. ∗P <0.05, ∗∗∗P<0.001.
SIGNR1−/− mice are unable to clear the pneumococci, suggesting that mSIGNR1 is
involved in the early defense against S. pneumoniae infection.
Clearance of bacteria from the respiratory tract during pneumococcal pneumonia is
strongly dependent on the efcacy in mounting a local inammatory response. To inves-
tigate the role of mSIGNR1 in the inammatory response, we evaluated the inammation
of the lung during infection with S. pneumoniae in vivo after 24 and 48 hours. Relative
lung wet weights were calculated and lung histology sections were scored as described
in Section 6.2. Lungs of SIGNR1−/− mice were enlarged, and SIGNR1−/− mice dis-
played a signicantly increased inammation of the lungs when compared to WT (Fig.
6.2C and D). In accordance, lungs from SIGNR1−/− mice contained more neutrophils
than those from WT and substantial more oedema, as demonstrated by hematoxylin and
eosin staining and increased wet lung weight (Fig. 6.2E and C). Thus, S. pneumoniae
induced a strong inammatory response in SIGNR1−/− mice, which was associated with
an increased inux of neutrophils into the lungs.
Next, we investigated whether SIGNR1−/− mice have different pulmonary cytokine
responses to respiratory tract infection with pneumococci. Therefore, we determined the
concentrations of the pro-inammatory cytokines IL-1β, TNFα and the chemokine KC at
24 and 48 hours after infection. SIGNR1−/− mice did not exhibit an increased immune
response early after infection, since cytokine levels did not differ between SIGNR1−/−
and WT mice after 24 hours of infection (Fig. 6.3A, B and C). However, at 48 hours of
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infection, cytokine levels in the lungs from SIGNR1−/− mice were strongly elevated due
to massive inammation (Fig. 6.3A, B and C).
Furthermore, ve of eight SIGNR1−/− mice developed bacteremia after 24 hours, and
seven of eight after 48 hours, compared to three of eight WT mice after both 24 and 48
hours. Dissemination of bacteria to spleen and subsequent growth was strongly increased
in SIGNR1−/− mice, since they had 100-fold more CFU in spleen after 48 hours than did
WT mice (Fig. 6.3D). These data demonstrate that, although SIGNR1−/− mice are able to
mount a neutrophil-attracting inammatory response upon infection with S. pneumoniae,
the pneumococci are not cleared from the lung. Moreover, SIGNR1−/− mice are not able
to clear the bacteria from blood, suggesting that mSIGNR1 is necessary for clearance of
blood-borne pathogens.
mSIGNR1 is essential for the capture of blood-borne S. pneumoniae serotype 3
Although mSIGNR1 is not expressed by resting alveolar macrophages in the lung,
we investigated whether mSIGNR1 is upregulated after infection with S. pneumoniae.
Immunouorescence analysis of lung tissue demonstrated that mSIGNR1 expression was
not induced upon S. pneumoniae infection (data not shown), indicating that the failure
of the SIGNR1−/− mice to clear the S. pneumoniae is not due to an altered function of
alveolar macrophages. This was supported by a similar cytokine prole compared to WT
after 24 hours (Fig. 6.3A). To further elucidate the role of mSIGNR1 in the clearance of
S. pneumoniae, we studied the capture of S. pneumoniae by marginal zone macrophages.
After intravenous injection, S. pneumoniae were captured by the marginal zone in the WT,
whereas hardly any S. pneumoniae were detected in the marginal zone of SIGNR1−/−
mice (Fig. 6.4A and B). Moreover, S. pneumoniae particles that were observed in the
spleen of the SIGNR1−/− mice were primarily localized in the red pulp (Fig. 6.4C).
Thus, mSIGNR1 is essential for the capture of whole S. pneumoniae by the marginal
zone of the spleen.
mSIGNR1 is pivotal for the induction of a natural IgM response against S. pneumo-
niae
Splenic marginal zone B cells are essential for the rapid antibody response against TI-
II polysaccharides, such as the capsular polysaccharides of S. pneumoniae 15. In the early
phase of pneumococcal infection, IgM antibodies, in particular natural antibodies against
the S. pneumoniae-epitope phosphorylcholine (PC), play an important role in the pro-
tection against pneumococci 16–19. As mSIGNR1 is able to capture S. pneumoniae from
blood, resulting in S. pneumoniae accumulation in the marginal zone, close to marginal
zone B cells, we investigated whether mSIGNR1 is involved in the rapid increase of nat-
ural antibody production by marginal zone B cells. Therefore, we determined the anti-PC
IgM response during infection. Strikingly, whereas in WT mice natural anti-PC IgM lev-
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Figure 6.4: mSIGNR1 is pivotal for the in vivo capture of blood-borne S. pneumoniae serotype
3 by the marginal zone
(color reprint: Fig. A.4, pp. 157)
(A) S. pneumoniae is not captured in vivo by the splenic marginal zone in SIGNR1−/− mice. The
capture of intravenous injected S. pneumoniae was determined in five representative visual fields
of spleen sections of WT (upper) and SIGNR1−/− (lower panel) mice after 45 minutes. Spleens
were stained for MARCO+ marginal zone macrophages (MZM) in red and S. pneumoniae in green.
Inset shows pneumococci colocalizing and in close contact with WT MARCO+ MZM. Inset shows
the absence of pneumococci in the marginal zone of SIGNR1−/− mice. (B) S. pneumoniae is
captured by the marginal zone of the WT spleen whereas the pneumococci are hardly detected in
the marginal zone of the SIGNR1−/− spleen. The amount of S. pneumoniae particles residing in
the marginal zone of either WT or SIGNR1−/− mice was counted and compared. The capture of
intravenously injected S. pneumoniae was determined in five representative visual fields of spleen
sections of WT and SIGNR1−/− mice after 45 minutes. (C) The S. pneumoniae particles present
in the SIGNR1−/− spleen reside mostly in the red pulp (RP) area of the spleen, in contrast to the S.
pneumoniae particles present in the WT spleen which target to the marginal zone (MZ). These data
are representative for three animals of both genotypes. ∗P <0.05.
6.4 Discussion 105
WT SIGNR1
-/-
WT SIGNR1
-/-
C
-0.3
0.0
0.3
0.6
***
48 hrB
-0.3
0.0
0.3
0.6
***
24 hr
WT SIGNR1
-/-
A
-0.3
0.0
0.3
0.6
0 hr
a
n
ti
-P
C
 I
g
M
 (
O
D
4
9
0
)
Figure 6.5: SIGNR1−/− mice fail to raise a rapid anti-PC IgM antibody response in vivo
during infection with S. pneumoniae
The anti-PC IgM levels were measured in plasma before (A) and 24 (B) or 48 hours (C) after
infection with 5× 104 CFU S. pneumoniae. Horizontal bars represent mean anti-PC IgM levels.
∗∗∗P<0.001.
els increased upon infection, no increase in natural anti-PC IgM production was observed
during infection in SIGNR1−/− mice (Fig. 6.5). These data suggest that mSIGNR1-
mediated capture of blood-borne S. pneumoniae is necessary for an efcient anti-PC IgM
response by marginal zone B cells. However, upon administration of an irrelevant antigen
(TNP-KLH), no differences in IgG response were observed between WT and SIGNR1−/−
mice (Fig. 6.6). Hence, SIGNR1−/− mice do display a normal follicular B cell response.
6.4 Discussion
In this study we have identied an important in vivo function for the murine homo-
logue of DC-SIGN in S. pneumoniae infection induced via its natural entrance route.
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Figure 6.6: SIGNR1−/− mice display a normal follicular B cell-mediated immune response
The anti-TNP-KLH IgG levels were measured in serum at day 0, and at 7 and 14 days after in-
traperitoneal administration of 0.1 mg/ml TNP-KLH.
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We demonstrate that SIGNR1−/− mice are more susceptible to intranasally administrated
S. pneumoniae than WT mice. Strikingly, in contrast to infected WT mice, infected
SIGNR1−/− mice fail to induce natural anti-PC IgM antibodies, known to be pivotal
for protection against S. pneumoniae 16–19. Our data suggest that mSIGNR1+ marginal
zone macrophages are essential for the natural anti-PC IgM response by marginal zone B
cells.
The marginal zone of the spleen is a unique compartment that facilitates the capture of
blood-borne antigens for eliciting rapid antibody responses against bacteria 20. Marginal
zone macrophages are strategically situated in the marginal zone to capture antigens from
blood. Recently, it has been demonstrated that mSIGNR1, a murine homologue of DC-
SIGN, is specically expressed by marginal zone macrophages and mediates the capture
of blood-borne TI-II antigens 8,9. Similar to DC-SIGN, mSIGNR1 interacts with dif-
ferent pathogens, including viruses and bacteria 10,14, suggesting that mSIGNR1 might
be an important pathogen receptor on these macrophages. Marginal zone macrophages
efciently capture particulate S. pneumoniae present in blood 7 and our data demon-
strate that mSIGNR1 mediates capture of these particulate bacteria, since marginal zone
macrophages from SIGNR1−/− mice do not capture intravenously injected S. pneumo-
niae serotype 3 (Fig. 6.4). The failure of the SIGNR1−/− mice to clear the bacteria
from blood after infection and the 100-fold increase in splenic bacterial load compared
to WT mice supports the importance of mSIGNR1 as a pathogen receptor on marginal
zone macrophages. Recently, Lanoue et al. demonstrated that mSIGNR1 is involved in
the capture of S. pneumoniae 11. In a peritonitis model using S. pneumoniae serotype 2
and 14, Lanoue et al. demonstrated that mSIGNR1 expressed by peritoneal macrophages
is important in the binding and subsequent phagocytosis of the pneumococci, as peri-
toneal macrophages derived from SIGNR1−/− mice fail to clear injected S. pneumoniae,
which causes severe infection 11. Thus, mSIGNR1 is an important receptor for the defense
against S. pneumoniae and is involved in the clearance of bacteria from the peritoneal
cavity. However, the common route of infection by S. pneumoniae is through the up-
per airways. Strikingly, alveolar macrophages do not express mSIGNR1, suggesting that
mSIGNR1 might not be involved in the defense against S. pneumoniae upon infection
via the natural route. Therefore, we have mimicked the natural route of S. pneumoniae
infection. In our experiments, the SIGNR1−/− mice displayed a signicantly increased
inammation of the lungs when compared to WT mice, characterized by extensive inl-
tration with neutrophils and substantial more oedema (Fig. 6.2). Alveolar macrophages
do not express mSIGNR1, and we did not observe mSIGNR1 expression after infection
(data not shown), indicating that mSIGNR1 is not directly involved as a pathogen recep-
tor on alveolar macrophages in the clearance of the infection. The increased inux of
neutrophils in the SIGNR1−/− mice suggested that neutrophils were unable to clear the
bacteria even though the SIGNR1−/− mice were able to mount an inammatory response.
Interestingly, in pneumococcal infection, natural IgM antibodies against PC play an
important role16–19. Recently Lanoue et al. demonstrated that the levels of anti-PC anti-
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bodies do not differ between naive WT and SIGNR1−/− mice11. In this study we show
that although the SIGNR1−/− mice display a normal follicular B cell-mediated immune
response, intranasal infection of S. pneumoniae serotype 3 results in an elevation of anti-
PC IgM antibodies during infection only in the WT mice. The SIGNR1−/− mice did not
mount an efcient anti-PC IgM response, as no increase in anti-PC IgM was observed in
the blood from SIGNR1−/− mice during infection. These data suggest that the inability
of the SIGNR1−/− mice to clear the infection is due to the lack of early IgM antibodies
against S. pneumoniae.
Marginal zone B cells are essential in the induction of a rapid IgM response against
encapsulated bacteria, such as S. pneumoniae 15,21. Although marginal zone macrophages
are ideally localized to capture blood-borne antigens, their role in the early innate im-
mune response is unclear. Early experiments suggested that marginal zone macrophages,
due to their localization and ability to capture blood-borne antigens, are critical com-
ponents of the TI-II antibody responses 3,22. Recently, Kang et al. demonstrated that
mSIGNR1 on marginal zone macrophages efciently captures pneumococcal polysaccha-
rides10. Marginal zone macrophages might capture polysaccharides for processing and
presentation of the TI-II antigens to the marginal zone B cells. However, in vivo depletion
of marginal zone macrophages did not lead to a decreased TI-II response against soluble
TI-II antigens20,23,24. Our data suggest that the capture of whole encapsulated bacteria by
mSIGNR1+ marginal zone macrophages is essential to induce an early immune response
in vivo, which is pivotal for the protection against S. pneumoniae. It is possible that
whole encapsulated bacteria are not efciently recognized by marginal zone B cells dur-
ing infection in vivo, and that marginal zone macrophages are necessary for capture and
processing of bacteria followed by presentation of bacterial fragments to marginal zone
B cells. The close localization of marginal zone macrophages and B cells suggests that
either whole bacteria or antigens from processed bacteria might be presented by marginal
zone macrophages to marginal zone B cells, reminiscent of the role of the human homo-
logue of mSIGNR1 in HIV-1 transmission; HIV-1 is captured by dendritic cells through
DC-SIGN and transmitted to T cells 25, suggesting that these C-type lectins are able to
capture pathogens to present either whole particulate antigens or components to adjacent
leukocytes.
Moreover, marginal zone macrophage-produced signals following the capture of bac-
teria might be necessary in the activation of marginal zone B cells, since TI-II antigens
alone are not sufcient to induce proliferation of marginal zone B cells, and co-signals
from mitogens present on bacteria as well as from accessory cells such as macrophages
are needed to activate marginal zone B cells 26.
Thus, mSIGNR1+ marginal zone macrophages may be involved in natural antibody
production against S. pneumoniae, which is pivotal for defense against S. pneumoniae.
Further studies are needed to demonstrate whether the lack of anti-PC IgM antibodies is
the only factor involved in the increased susceptibility of the SIGNR1−/− mice and how
mSIGNR1 expressed by marginal zone macrophages is involved in the early humoral
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immune response against S. pneumoniae, either through activation of marginal zone B
cells, or by presentation of captured antigens to marginal zone B cells.
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Abstract
The spleen plays a pivotal role in the immune defense against encapsulated bacteria such
as Steptococcus pneumoniae. Splenic marginal zone macrophages express the C-type
lectin mSIGNR1, which is crucial for the capture of S. pneumoniae from blood. In this
study we demonstrate that mSIGNR1 is able to interact in vitro with the juxtaposing
marginal zone B cell population, which is responsible for the production of the early IgM
response against the S. pneumoniae-epitope phosphorylcholine. Strikingly, mSIGNR1-
decient mice display a reduction in the marginal zone B cell population. In addition,
in vitro assays demonstrate a decrease in phosphorylcholine specicity in the splenic B
cell population derived from mSIGNR1-decient mice. Therefore we hypothesize that
antigens are presented by mSIGNR1, expressed by marginal zone macrophages, to the
developing marginal zone B cell population, thereby inuencing the repertoire of this
B cell population, which is pivotal for the early immune response against encapsulated
bacteria such as S. pneumoniae.
7.1 Introduction
Specic intercellular adhesion molecule-grabbing nonintegrin receptor 1 (mSIGNR1) is
one of the murine homologues of the C-type lectin dendritic cell-SIGN (DC-SIGN) 1.
mSIGNR1 and DC-SIGN bind high mannose-containing ligands such as mannose-capped
lipoarabinomannan (ManLAM), a major cell wall component of M. tuberculosis and
HIV-1 gp120( 2–5). Previously it has been reported that mSIGNR1 is involved in the
immune defense against S. pneumoniae 6,7. Lanoue et al. described that mSIGNR1 ex-
pressed by peritoneal macrophages is involved in the uptake of pneumococci by peritoneal
macrophages and thereby enhances the clearance of this pathogen 7. Using an in vivo in-
fection model where the bacterium was administrated via the lungs, we demonstrated that
mSIGNR1-decient mice are more susceptible to S. pneumoniae-mediated pathology. In
addition, we demonstrated the absence of an increase in early antibodies directed against
the pneumococci in the mSIGNR1-decient mice.
In the early phase of pneumococcal infection, IgM antibodies, in particular those
against the S. pneumoniae-epitope phosphorylcholine (PC), play an important role in the
immune defense against this pathogen 8–11. These antibodies are produced by marginal
zone B cells, a unique IgMhi, CD21hi, CD23lo, IgDlo, CD1dhi B cell population residing
in the marginal zone of the spleen in close contact to marginal zone macrophages ex-
pressing mSIGNR1( 12). For years it has been speculated that marginal zone B cells can
be activated by marginal zone macrophages or that marginal zone macrophages are able to
transfer processed antigens to marginal zone B cells 13. The activation of B cells without
the help of T cells is referred to as the T-independent (TI) immune response. Antigens that
evoke TI immune responses can be divided into two groups; TI-I and TI-II antigens. TI-I
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antigens are polyclonal stimulators which evoke a TI immune response independent of T
cells, whereas TI-II antigens display multiple repeating subunits that need additional T-
cell derived factors to activate B cells 14–16. Upon intravenous injection, TI-II antigens are
captured by the marginal zone of the spleen 17,18. Several studies have been performed to
identify the role of the marginal zone macrophage in the TI-II response, using TI-II anti-
gens such as Ficoll, PC and dextran, with contradictory results 19,20. Here, we set out to
investigate the interaction of mSIGNR1 with marginal zone B cells and the involvement
of this interaction in the development of this specic B cell population. We demonstrate
that mSIGNR1 is able to interact specically with marginal zone B cells. In addition,
mSIGNR1-decient mice display a reduced marginal zone B cell population. Based on
these results we conclude that mSIGNR1 interacts with marginal zone B cells and is in-
volved in the recruitment of marginal zone B cells to the spleen or their survival in this
area. Furthermore, we show that B cells derived from both mSIGNR1-decient and wild-
type (WT) mice display anti-PC specicity. However, the anti-PC response produced by
WT-derived B cells was much more pronounced. In conclusion, mSIGNR1, expressed by
marginal zone macrophages, interacts with marginal zone B cells and is involved in the
production of early antibodies by this unique B cell population.
7.2 Materials and Methods
In vivo antigen capture by marginal zone macrophages
C57BL/6×129 WT and mSIGNR1-decient mice were bred in the animal facility of
the VU University Medical Center under specic pathogen-free conditions, and were kept
in the animal facilities of the VU University Medical Center, Amsterdam, The Nether-
lands. Naive mice were injected intravenously into the tail veins with 200 µl PPS type 3
(0.25 mg/ml; American Type Culture Collection, Manassas, VA). After 45 minutes mice
were sacriced and spleens were isolated and PPS was detected by a PPS serotype 3-
specic rabbit polyclonal (Statens Serum Institute, Copenhagen, Denmark) and analyzed
by immunouorescence analysis.
Immunohistochemistry
Spleens for (double) immunouorescence were isolated and frozen in Tissue-Tekfi
(Sakura Finetek Europe BV, Zoeterwoude, The Netherlands). 8 µm cryosections were
xed in dehydrated acetone for 10 minutes, rehydrated with PBS and stained for 16 hours
at 4◦C with primary antibody MECA 367 (anti-MAdCAM) or ED31 (anti-MARCO), and
subsequently with Alexa Fluorfi 594-conjugated goat anti-rat IgG (Molecular Probes,
Eugene, OR) for 30 minutes at room temperature. Prior to incubation with FITC-labeled
anti-CD1d (CD1.1 Ly-38 1B1, BD Biosciences, Pharmingen, USA) the sections were
incubated with 20% normal rat serum in PBS. Culture supernatant of the mAb MadCAM
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was used, ED31 was puried from culture supernatant from hybridoma cells with protein
G-Sepharose (Amersham Pharmacia Biotech, Uppsala, Sweden) and anti-CD1d was a
kind gift from Prof.Dr. R. Schepers.
Flow cytometry and cell sorting
CHO transfectants expressing mSIGNR1 were generated by transfection with 10 µg
pRc/CMV-mSIGNR1 plasmid by electroporation as previously described 2. Expression
was conrmed by FACS analysis using the antibody ERTR-9 (anti-SIGNR1) 21.
Splenocyte single cell suspensions were incubated with PBS supplemented with 20%
normal goat serum before staining with biotin-conjugated rabbit anti-mouse IgM (Zymed
Laboratories Inc., San Fransisco, CA) and rat anti-mouse IgD (Southern Biotechnol-
ogy Associates Inc., Birmingham, USA) and subsequently with PE-conjugated strepta-
vidin (BD Biosciences Pharmingen) and 488-conjugated anti-rat IgG (Jackson Immunore-
search, USA). Next, the samples were blocked with PBS supplemented with 50% normal
rat serum before adding PerCP-labeled CD19 (BD Biosciences, Pharmingen, USA). The
CD19pos, IgMhi, IgDlow cells were considered marginal zone B cells and CD19pos, IgMhi,
IgDhi cells were considered follicular B cells. Flow cytometry was performed on a FACS
Calibur (BD, USA).
Splenocyte single cell suspensions derived from 3 C57Bl6 mice were stained with PE-
conjugated anti-mouse CD21 and FITC-conjugated anti-mouse CD23 purchased from BD
Biosciences, Pharmingen, USA. CD21hi, CD23low cells were considered marginal zone B
cells. CD21hi, CD23hi cells were assigned follicular B cells. The sorted populations had
a purity of at least 80%. Cells were sorted with a MoFlow (Dako Cytomation, Denmark).
Plate adhesion assay
CHO transfected with mSIGNR1 and parental CHO cells were seeded at 3×104 cells
per well in a 96-well at-bottom cell culture plate (Cellstar, Greiner Bio-one, Germany)
and cultured overnight. The supernatant was removed from the monolayer and the cells
were washed with TSA and were incubated with TSA, 4× 104 sorted marginal zone B
cells or sorted follicular B cells labelled with calceine-AM (25 µg/107 cells/ml; Molecular
Probes Inc., Eugene, OR) for 45 minutes at 37◦C. After vigorous washing, cells were al-
lowed to adhere for 90 minutes at 37◦C. The control plate was lysed by the addition of 50
µl lysis buffer (50 mmol/l Tris, 0.1% Triton X-100) immediately to gain the maximal and
minimal uorescent values. The test plate was carefully washed to remove non-adherent
cells. The remaining adherent cells were lysed with 100 µl lysis buffer and the uo-
rescence was measured using the FluoStar Galaxy (BMG Labtechnologies, Germany).
Results are expressed as the mean percentage of cells binding from triplicate wells i.e.
cell adhesion percentage of maximal binding minus background uorescence.
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In vitro IgM production
Splenocyte single cell suspensions were allowed to adhere to a culture ask for 2
hours. The nonadherent cells were harvested and seeded in a 96-well plate. Next, the
cells were stimulated with LPS (5 µg/ml, puried LPS from H. pylori, M. Monteiro,
National Research Council, Ottawa, Canada), supernatant was harvested at the indicated
time points. Total IgM and PC-specic IgM levels were determined by ELISA.
ELISA
Goat anti-mouse IgM (Jackson Immunoreasearch, USA) or PC-BSA (Biosearch Tech-
nologies Inc., Novato, CA, USA) were coated onto 96-well maxisorb plates (NUNC A/S,
Roskilde, Denmark) in coating buffer (0.2 M NaHCO3, pH 9.2) overnight at 4◦C, fol-
lowed by blocking with PBS 1% BSA (La Jolla, CA, USA) for 30 minutes at 37◦C.
The supernatants were added. After two hours of incubation at room temperature, PO-
conjugated goat anti-mouse IgM (Nordic Immunology Laboratories, NL) was added for
30 minutes. The ELISA was developed using TMB (Sigma-Aldrich, USA) substrate and
stopped with 0.8 M H2SO4. Absorption was measured using a Benchmark microplate
reader (Biorad) at 450 nm.
7.3 Results
mSIGNR1 specifically captures S. pneumoniae capsular polysaccharides
In order to investigate the role of mSIGNR1 in the TI-II humoral immune response we
rst tested whether pneumococcal capsular polysaccharides, which are classied as TI-II
antigens, target mSIGNR1 on marginal zone macrophages similar to whole pneumococci
14
. Indeed, the capsular polysaccharides of S. pneumoniae were efciently captured by
the marginal zone of WT mice, whereas these polysaccharides were not captured by the
marginal zone of mSIGNR1-decient mice (Fig. 7.1). Thus, besides the capture of whole
S. pneumoniae, mSIGNR1 is also essential for the capture of S. pneumoniae capsular
polysaccharides by the marginal zone of the spleen 6,22.
Decreased numbers of marginal zone B cells in mSIGNR1-deficient mice
Previously we have demonstrated a decreased early antibody production in mSIGNR1-
decient mice upon S. pneumoniae infection 6. Possibly, mSIGNR1 is involved in the ac-
tivation of marginal zone B cells. In addition, mSIGNR1 may be involved in the recruit-
ment or survival of the marginal zone B cell population. Therefore, this specic B cell
population was identied in mSIGNR1-decient mice. Furthermore, the amount and lo-
cation of the marginal zone B cell population was compared between WT and mSIGNR1-
decient mice using immunohistochemistry and ow cytometry. Marginal zone B cells,
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Figure 7.1: mSIGNR1 is pivotal for the in vivo capture of blood-borne S. pneumoniae serotype
3 polysaccharide by the marginal zone
(color reprint: Fig. A.5, pp. 158)
S. pneumoniae serotype 3 polysaccharides are retained by the marginal zone after intravenous in-
jection in WT (upper) whereas it is dispersed throughout the spleen in mSIGNR1-deficient mice
(SIGNR1−/−, lower panel). Intravenously injected S. pneumoniae serotype 3 polysaccharide was
detected in spleen sections of WT mice (upper) and mSIGNR1-deficient mice (lower panel) after
45 minutes. Spleens were analyzed for the expression of MARCO+ marginal zone macrophages
(MZM) in red and pneumococcal polysaccharide serotype 3 (PPS3) in green.
identied as the CD1d-positive cells located outside the MadCAM-positive vascular en-
dothelial cells of the marginal sinus, could be identied in both WT and mSIGNR1-
decient mice (Fig. 7.2). However, the CD1d positive population located outside the
MadCAM positive rim appeared to be reduced in the mSIGNR1-decient mice (Fig. 7.2).
Similarly, the CD1d positive marginal zone B cells located in close approximation to the
macrophage scavenger receptor with a collagenous structure (MARCO) positive marginal
zone macrophages were also present in reduced amounts in the mSIGNR1-decient mice
(Fig. 7.2). Using ow cytometry we quantied the decreased marginal zone B cell pop-
ulation, identied as the IgMhiIgDlow population, in the mSIGNR1-decient mice (Fig.
7.3A and B).
Based on these results we conclude that in both WT and mSIGNR1-decient mice,
marginal zone B cells are present in the marginal zone of the spleen. However, the
mSIGNR1-decient mice have a reduced number of marginal zone B cells.
mSIGNR1 interacts with marginal zone B cells in contrast to follicular B cells
The decreased marginal zone B cell population in mSIGNR1-decient mice could be
explained by mSIGNR1 being involved in the homing or survival of this cell population
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Figure 7.2: Decreased numbers of marginal zone B cells in mSIGNR1-deficient mice
(color reprint: Fig. A.6, pp. 159)
The splenic marginal zone from mSIGNR1-deficient mice contains a decreased amount of marginal
zone B cells. Spleens from naive WT (left) and mSIGNR1-deficient mice (SIGNR1−/−, right)
were analyzed for the presence of MadCAM+ sinus-lining endothelial cells in red (upper panel) or
MARCO+ marginal zone macrophages in red (lower panel) and the expression of CD1d in green.
Marginal zone B cells were identified as the CD1d-postitive cells located outside the MadCAM+
rim and juxtaposed to the MARCO+ marginal zone macrophages. These data are representative for
three animals of both genotypes.
through a direct interaction. Therefore we investigated the interaction between mSIGNR1
expressed by CHO cells (Fig. 7.4A) and marginal zone B cells. Using a plate adhesion
assay we tested the adhesion of sorted marginal zone B cells and their follicular counter-
parts (Fig. 7.4B) to CHO cells expressing mSIGNR1. The binding of follicular B cells
was similar between CHO and mSIGNR1 expressing CHO cells indicating that mSIGNR1
does not bind follicular B cells (Fig. 7.4C). However, the marginal zone B cells adhered
to a larger extent to the mSIGNR1 expressing CHO cells (Fig. 7.4C). Hence, mSIGNR1
specically binds to the marginal zone B cell population.
The B cell population derived from mSIGNR1-deficient mice displays a lower PC-
specificity in vitro
We previously observed a decreased anti-PC IgM production in mSIGNR1-decient
mice upon S. pneumoniae infection 6. Now that it has been established that marginal zone
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Figure 7.3: Decreased numbers of marginal zone B cells in mSIGNR1-deficient mice
Splenocytes derived from mSIGNR1-deficient mice contain less marginal zone B cells. (A) Spleno-
cyte single cell suspensions from naive WT (A, upper panel) and mSIGNR1-deficient mice (KO,
A, lower panel) were analyzed for CD19pos, IgMhi, IgDlow marginal zone B cells (MZB) and
CD19pos, IgMhi, IgDhi follicular B cells (FOB). (B) A comparison of the percentage of follicular
(FOB) and marginal zone B cells (MZB) in the spleen between WT and mSIGNR1-deficient mice.
These data are representative for three animals of both genotypes. ∗P <0.05.
B cells can interact with the juxtaposed marginal zone macrophages through mSIGNR1,
we next investigated the capacity of the B cell population in the mSIGNR1-decient mice
to produce anti-PC IgM. Splenic B cells were polyclonally stimulated with LPS resulting
in antibody production and both total IgM and anti-PC IgM levels were measured 23.
Strikingly, we observed that, although the B cells derived from mSIGNR1-decient mice
produce similar total IgM levels (Fig. 7.5A), there was a decreased level of anti-PC IgM
produced by the mSIGNR1-decient B cell population compared to WT B cells (Fig.
7.5B). This indicates that the splenic B cell population derived from mSIGNR1-decient
mice displays a lower anti-PC specicity compared to the WT B cell population.
7.4 Discussion
Using S. pneumoniae infection models, it has been described that mSIGNR1-decient
mice are more affected by this pathogen 6,7. In both models, e.g. intraperitoneal versus in-
tratracheal infection with S. pneumoniae, a higher outgrowth of bacteria and more severe
pathology in the mSIGNR1-decient mice was observed in comparison to WT mice.
Lanoue et al. postulated that the binding of S. pneumoniae to mSIGNR1 expressed
by resident peritoneal macrophages leads to phagocytosis of the pathogen resulting in
the clearance of the pathogen and concomitantly to less pathology in the WT mice com-
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Figure 7.4: mSIGNR1 interacts with marginal zone B cells in contrast to follicular B cells
CHO-cells expressing mSIGNR1 interact with marginal zone B cells. CHO cells expressing
mSIGNR1 or non-transfected parental cells (A) were analyzed for the binding of sorted marginal
zone B cells (MZB) and follicular B cells (FOB) (B) using a plate adhesion assay. (A) The open his-
togram represents the isotype control, the dotted line represents the mock transfectant and the filled
histogram indicates specific antibody staining. (C) Depicted is the percentage of specific binding
relative to the maximal value. These data are representative for three independent experiments. ∗P
<0.05.
pared to mSIGNR1-decient mice that could not efciently clear S. pneumoniae 7. In
the intraperitoneal infection model exerted by Lanoue et al. the role of phagocytosis of
the pneumococci by the residing peritoneal macrophages and concomitant clearance of
the pathogen dominates 7. The role of the early humoral immune response in which an-
tibodies are raised against PC was addressed by Lanoue et al. 7. The anti-PC levels of
uninfected WT and mSIGNR1-decient mice were determined, and no difference was
observed. Strikingly, the amount of anti-PC antibody in both mice strains was similar to
the titer of pneumovax-immunized mice.
In our intratracheal infection study, the early anti-PC levels were monitored during in-
fection and striking differences were found. While the anti-PC levels were raised in WT
mice during the course of infection, anti-PC levels of mSIGNR1-decient mice remained
unchanged. Marginal zone B cells, which reside in close proximity to the mSIGNR1-
expressing marginal zone macrophages, are able to produce these early anti-PC IgM an-
tibodies12.
Anti-PC IgM antibodes play an important protective role in the immune defense
against S. pneumoniae infection 8–11. Since the capture of S. pneumoniae is mediated
by marginal zone macrophages and the early antibody response is mediated by marginal
zone B cells we focused on the interaction between these two specialized cell populations
120 Chapter 7 The interaction of marginal zone B cells with mSIGNR1. . .
WT
mSIGNR1-deficient
0.0
0.2
0.4
0.6
0.8
1.0
mSIGNR1-deficient
WT
medium LPS
Day 3 Day 6 Day 3 Day 6
a
n
ti
-P
C
 I
g
M
 O
D
 4
5
0
*
*
A B
0.0
0.4
0.8
1.2
1.6
to
ta
l 
Ig
M
 O
D
 4
5
0
 n
m
medium LPS
Figure 7.5: B cells derived from mSIGNR1-deficient mice produce less PC-specific IgM com-
pared to WT derived B cells
Non-adherent splenocytes were stimulated with LPS in vitro. The production of total IgM at day
6 (A) and PC-specific IgM at day 3 and 6 (B) was measured. (A) The total IgM production was
comparable between B cells derived from WT and mSIGNR1-deficient mice. (B) Upon stimulation,
WT B cells produced more PC-specific IgM compared to B cells derived from mSIGNR1-deficient
mice. ∗P <0.05.
located in the marginal zone of the spleen.
Marginal zone B cells are a unique B cell population, known to be long-lived and to
display an activated phenotype 24–26. Several studies have been performed to investigate
the role of cells in the marginal zone of the spleen in T-independent immune responses.
It has been described that marginal zone B cells are pivotal for the T-independent im-
mune response against the TI-II antigen Ficoll 27. Upon elimination of marginal zone
macrophages the anti-Ficoll response was diminished 19. Hence both marginal zone mac-
rophages and marginal zone B cells are crucial for a TI immune response. However, spe-
cic depletion of marginal zone macrophages using the anti-SIGNR1 antibody ERTR-9
did not induce a decrease in the TI immune response 20,28.
MARCO, a scavenger receptor that is also expressed by marginal zone macrophages
has been described to interact with marginal zone B cells 29. The interaction between
MARCO and an unknown ligand on marginal zone B cells is pivotal for the localization
of the marginal zone B cells since disruption of the interaction leads to the migration of
marginal zone B cells into the follicle. In addition, Chen et al. observed a lower amount
of resident peritoneal macrophages and splenic marginal zone macrophages in MARCO-
decient mice30. Hence, the interaction of MARCO with juxtaposing marginal zone B
cells is important for both marginal zone macrophage and marginal zone B cell localiza-
tion. However, during ontogeny the absence of MARCO does not affect the localization
of marginal zone B cells in the spleen 30.
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In this study it was observed that the marginal zone of mSIGNR1-decient mice con-
tains marginal zone B cells, however their number was decreased in comparison to WT
mice. In addition, marginal zone B cells were found to adhere to mSIGNR1 expressed by
transfectants, whereas follicular B cells did not interact with mSIGNR1.
The interaction of marginal zone macrophages with marginal zone B cells through
mSIGNR1 can have multiple effects. Marginal zone B cells are long-lived and display
an activated phenotype 24–26. In general, activated B cells are prone to go into apoptosis,
unless they receive the proper signals for their proliferation. Possibly, marginal zone
B cells receive survival signals from neighboring marginal zone macrophages. Since
we observed that the marginal zone B cell population is still present in the mSIGNR1-
decient mice, although at a lower level, the absence of mSIGNR1 in these mice could be
the cause of a decreased survival signal.
Another explanation for the diminished anti-PC IgM production in the mSIGNR1-
decient mice upon infection with S. pneumoniae could be a lack of specicity within
the B cell population. Survival signals may also be involved in the composition of the
marginal zone B cell repertoire. It has been postulated that marginal zone B cell speci-
city for antigens such as PC on S. pneumoniae arises from the encounter of self-antigens
31,32
. To test the presence of PC-specicity in the mSIGNR1-decient mice we stimulated
splenic B cells and measured both total and PC-specic IgM levels. Strikingly, we ob-
served a decreased level of anti-PC IgM in the mSIGNR1-decient mice despite a normal
value of total IgM.
Based on these results we conclude that mSIGNR1 is involved in the composition of
the specicity of the juxtaposed marginal zone B cells. Perhaps mSIGNR1 is involved
in the capture and/or presentation of self- and non-self-antigens, resulting in the devel-
opment of the marginal zone B cell repertoire. However the mechanism behind this phe-
nomenon remains unclear. Recently, Bergtold et al. described FcγRIIb-mediated antigen
uptake and retention by DC 33. A proportion of the antigen did not end up in the lysosomal
pathway but was retained and conserved for antigen presentation to B cells, facilitating
the TI immune response. Possibly antigen uptake by mSIGNR1 may also lead to antigen
retention and presentation to the marginal zone B cells, to optimize a swift and accurate
early immune response upon infection.
Antigen transfer by marginal zone macrophages to marginal zone B cells has been
postulated by van Rooijen et al. 13. Antigen transfer by marginal zone macrophages to
marginal zone B cells may optimize the activation status of the marginal zone B cells and
may play a role in marginal zone B cell retention in the marginal zone or marginal zone B
cell survival, explaining the lower amount of marginal zone B cells in mSIGNR1-decient
mice.
Further research is needed to investigate the cascade of events involved in the early
immune response against blood-borne TI-II antigens such as S. pneumoniae. Mice de-
cient for both mSIGNR1 and MARCO and mice decient for mSIGNR1 but transgenic
for PC-specic marginal zone B cells would be powerful tools to analyze the role of
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pathogen receptors expressed by marginal zone macrophages in the development of the
marginal zone B cell repertoire and marginal zone B cell activation.
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8.1 The in vivo role of mSIGNR1 during infection with
M. tuberculosis
C-type lectin receptors (CLR) are expressed by antigen presenting cells and recognize
specic carbohydrate structures on self-antigens or pathogens. Upon recognition, anti-
gen is internalized, processed and presented 1,2. In addition, CLR are involved in im-
mune modulation and the induction of tolerance against self-antigens 3. Hence, specic
pathogens target CLR such as DC-SIGN to evade and suppress the immune system 4,5.
The shared binding specicity of DC-SIGN, L-SIGN and mSIGNR1 for mannose-
containing structures hinted at the capacity of these molecules to interact with ManLAM,
a Mycobacterium tuberculosis capsule component with a mannose cap 6. Indeed all three
SIGN molecules specically interacted with ManLAM and the ara-(man)3 structure was
identied as the ligand for DC-SIGN, L-SIGN and mSIGNR1 on M. tuberculosis 7. Man-
LAM is known as a virulence factor of M. tuberculosis and is expressed by slow-growing
yet highly pathogenic mycobacteria strains. Previously, ManLAM was identied as an
immunomodulating factor responsible for the inhibition of DC maturation and the induc-
tion of IL-10 production by DC through DC-SIGN 8. Therefore, we set out to investigate
the in vivo function of mSIGNR1 in an in vivo M. tuberculosis infection model (Chapter
4, submitted for publication).
Upon in vitro stimulation of peritoneal macrophages with ManLAM, IL-10 produc-
tion was induced. In contrast, IL-10 production was abolished in the mSIGNR1-decient
macrophages, indicating that ManLAM binding to mSIGNR1 induces the production of
the anti-inammatory cytokine IL-10. Hence, M. tuberculosis is able to induce immuno-
suppression through mSIGNR1, which may contribute to its survival. Strikingly, IL-10
production upon ligation of DC-SIGN by ManLAM is only induced upon concomitant
triggering of TLR4 by LPS 8. Thus, mSIGNR1 can mediate immune modulation on its
own, whereas DC-SIGN-mediated immune modulation through ManLAM is dependent
on additional signaling through TLR.
Despite the observed in vitro immune modulation upon ligation of mSIGNR1 with
ManLAM, both mice strains succumbed to infection and no differences were observed in
the cytokine levels within the lungs. In addition, no expression of mSIGNR1 was induced
in the lung upon infection with M. tuberculosis. This is in contrast to DC-SIGN, which
expression in human lung alveolar macrophages was induced upon infection with M. tu-
berculosis9. Therefore, probably due to the lack of mSIGNR1 expression in the lungs,
immune modulation does not result in a difference in pathology. Nonetheless, ManLAM
may exert modulation of the immune response through mSIGNR1. In the early phase
of infection, mSIGNR1 inuences the Th1/Th2 balance of the immune response evoked
by M. tuberculosis. In the mSIGNR1-decient mice, a Th1 prone response was detected
whereas the wild-type mice displayed a mixed Th1/Th2 response. Thus the ManLAM
induced IL-10 production by macrophages expressing mSIGNR1 leads to the modulation
of the cytokine production by T cells resulting in a mixed Th1/Th2 response. The Th1
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prone response observed in the mSIGNR1-decient mice indicates a Th2-skewing role
for mSIGNR1. Perhaps when using a lower dose of M. tuberculosis, immune modulation
mediated by the interaction of ManLAM and mSIGNR1 will have an effect on the course
of the infection.
8.2 mSIGNR1-mediated signaling
DC-SIGN and its homologues are involved in many pivotal functions of the immune sys-
tem. However, it is still unclear how these C-type lectins are able to exert their function
besides the binding to self- and pathogen ligands. It has been shown that DC-SIGN is
targeted by pathogens to modulate the immune response and evade their destruction 4.
DC-SIGN is thought to modulate the signaling cascades induced by TLR4 triggering.
However, the signaling pathways involved in this mechanism are not clear. Recently, Ca-
parros et al. demonstrated using a monoclonal antibody as a ligand for DC-SIGN, that
ligation of DC-SIGN induces the phosphorylation of both ERK and Akt 10. In addition, a
transient inux of calcium was induced. These ndings t with the mechanism described,
in which DC-SIGN-induced signaling promotes a Th2 prone, more tolerogenic immune
response8,10.
In contrast, Nagoaka et al. described that upon concomitant ligation of both TLR4
and mSIGNR1 by LPS from Gram-negative bacteria, mSIGNR1 enhanced the induced
cytokine response suggesting a pro-inammatory role for mSIGNR1( 11). It remains un-
clear how mSIGNR1 mediates this response and whether the effect can be attributed solely
to mSIGNR1. Possibly the capture of Gram-negative bacteria LPS by mSIGNR1 facil-
itates other receptors to interact with the pathogen-derived LPS, leading to additional
signaling. In addition, the observed pro-inammatory role of mSIGNR1 by Nagaoka et
al. is in contrast to the production of the anti-inammatory cytokine IL-10 observed upon
ManLAM stimulation in vitro in Chapter 4.
8.3 The in vivo role of mSIGNR1 during infection with
S. pneumoniae
The lack of expression of mSIGNR1 by alveolar macrophages probably added to the
minor role of mSIGNR1 in the immune response against M. tuberculosis. mSIGNR1 is
expressed in spleen, liver and lymph node 12. Since the spleen plays a major role in the
immune response against the Gram-negative bacterium Streptococcus pneumoniae and
pneumococci have been described to target the marginal zone of the spleen, a role for
mSIGNR1 in the immune response against S. pneumoniae was investigated.
Upon investigation of the binding characteristics of DC-SIGN for a panel of capsular
polysaccarides derived from the most common S. pneumoniae serotypes causing disease,
DC-SIGN displayed specicity for only S. pneumoniae serotype 14 polysaccaride. Strik-
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ingly, S. pneumoniae serotype 14 is a leading cause of invasive pneumococcal disease in
the US and Western Europe 13,14. In addition, DC-SIGN also interacts with encapsulated
S. pneumoniae serotype 3. The structure on encapsulated serotype 3 that was specically
recognized by DC-SIGN was not detected in the polysaccharide capsule and remains to
be identied.
In Chapter 7 we found that the polysaccharide of S. pneumoniae serotype 3 does
specically target mSIGNR1 expressing marginal zone macrophages upon intravenous
injection in vivo. Hence, mSIGNR1 may bind a specic ligand on the capsule of S. pneu-
moniae serotype 3 that does not bind DC-SIGN, or mSIGNR1 interacts with an epitope
that is exposed only in vivo by for example the binding of complement or antibodies.
The specic binding of DC-SIGN to only two of the tested serotypes may add new in-
sights in the pathology of these two pneumococci. The interaction between DC-SIGN and
S. pneumoniae does not seem to have immunomodulatory consequences. Upon stimula-
tion of DC with S. pneumoniae serotype 14 polysaccaride, no modulation of DC biology
was observed. Moreover, no immunomodulatory effect to suppress the immune response
against pneumococci, similar to the IL-10 production induced by M. tuberculosis-derived
ManLAM, was detected 8. Still, the specic binding of S. pneumoniae serotype 14 may
serve as a tool for the optimization of the vaccines that are currently used. Possibly, the
binding specicity of DC-SIGN expressed by immature DC can be used as a tool to target
vaccines to the DC. The currently licensed pneumococcal vaccine is based on 23 most
common serotypes, and has an overall protective efcacy of about 60-70% 15. The target-
ing of such a vaccine to the DC via the specic binding of serotype 14 polysaccharides
to DC-SIGN may enhance the immune response against all 23 pneumococcal serotypes.
Future research should look into the use of such an approach.
The spleen plays an important role in the immune defense against S. pneumoniae
16
. In addition, S. pneumoniae and its polysaccharides have been described to target
the marginal zone of the spleen. Possibly, mSIGNR1 is involved in the specic uptake
and clearance of blood-borne S. pneumoniae by the spleen, resulting in effective immu-
nity. Indeed, mSIGNR1 specically interacts with both S. pneumoniae serotype 3 and
14( 17,18). Moreover, Lanoue et al. describe that mSIGNR1 is benecial for the immune
defense against pneumococci 18. The intraperitoneal infection model used by Lanoue et
al. demonstrated the pivotal role for mSIGNR1 as a pathogen receptor expressed by peri-
toneal macrophages, facilitating the clearance of the bacteria in the peritoneal cavity.
In Chapter 6 the role of mSIGNR1 during infection with S. pneumoniae serotype 3
was investigated using an infection model resembling the natural route of entry 19. Similar
to the intraperitoneal infection model, mSIGNR1-decient mice succumb to infection
with S. pneumoniae in contrast to wild-type mice. Investigation of the sera of the mice
during infection demonstrated that in wild-type mice antibodies against the S. pneumoniae
capsular component phosphorlycholine (PC) were raised, in contrast to the levels of early
anti-PC antibodies in mSIGNR1-decient mice.
Marginal zone B cells together with peritoneal B-1 cells are involved in the produc-
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tion of these early antibodies that are protective upon S. pneumoniae infection 20,21. Upon
investigation of the capture of blood-borne S. pneumoniae, we observed that S. pneumo-
niae was not captured by marginal zone macrophages of SIGNR1-decient mice. Thus,
mSIGNR1 expressed by marginal zone macrophages captures blood-borne S. pneumo-
niae and can be involved in the production of early antibodies by marginal zone B cells.
Marginal zone B cells reside in close proximity to marginal zone macrophages in the
marginal zone of the spleen 22. mSIGNR1 may mediate antigen transfer to the marginal
zone B cell population or directly activate marginal zone B cells to produce these early an-
tibodies. Indeed, marginal zone macrophages are important for the function of marginal
zone B cells since Karlsson et al. described that the interaction between MARCO ex-
pressed by marginal zone macrophages and marginal zone B cells is pivotal for marginal
zone B cell localization in the marginal zone 23. Strikingly, mSIGNR1-decient mice dis-
play a reduction in the marginal zone B cell population, suggesting that mSIGNR1 is in-
volved in either retention or survival of marginal zone B cells in the marginal zone. More-
over, an in vitro cell-cell adhesion assay demonstrated that mSIGNR1 specically inter-
acts with marginal zone B cells in contrast to follicular B cells, suggesting a direct interac-
tion between marginal zone macrophages and marginal zone B cells through mSIGNR1.
Furthermore, the response to LPS by mSIGNR1-decient and wild-type mice-derived
splenic B cells resulted in a similar production of IgM. However, the mSIGNR1-decient
mice-derived splenic B cells produced a reduced amount of anti-PC IgM upon poly-
clonal stimulation. These ndings indicate that mSIGNR1 expressed by marginal zone
macrophages is involved in the composition of the marginal zone B cell population and
repertoire.
8.4 The role of mSIGNR1 in the early immune response
against blood-borne pathogens
Marginal zone B cells form a B cell population distinct from peritoneal B-1 and follicular
recirculating B-2 cells. This compartmentalization may be crucial for the specialized
function of marginal zone B cells; the execution of the early immune response against
blood-borne antigens. The marginal zone B cell repertoire is not a random repertoire;
certain B cell receptors are enriched in this population 24. The mechanism behind this
enrichment of certain clones has not been elucidated completely but there is a role for B
cell receptor associated Brutons tyrosine kinase and coreceptor CD19. In addition, these
B cell receptors display a specicity for autoantigens or commensal ora 24–26. Possibly,
(auto)antigens play a role in the enrichment and recruitment of certain specicities into
the marginal zone population.
It has been described that S. pneumoniae displays molecular mimicry with the au-
toantigen oxidized low-density lipoprotein and some antibodies against oxidized low-
density lipoprotein recognize S. pneumoniae phosphorylcholine 27. In addition, DC-SIGN
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specically binds to oxidized low-density lipoprotein in contrast to the non-oxidized form
28
. Hence, mSIGNR1 may also be involved in the capture of oxidized low-density lipopro-
tein resulting in the manifestation of anti-phosphorylcholine specicity in the marginal
zone B cell repertoire. Thus, mSIGNR1 may be involved in the capture of (auto)antigens
pivotal for the recruitment and stimulation of marginal zone B cells reactive to these anti-
gens. This mechanism provides a marginal zone B cell repertoire that despite the low
afnity for certain autoantigens is equipped to respond fast to blood-borne pathogens by
recognition of common structures expressed by these pathogens. However, upon distor-
tion of this balance, autoimmunity may ensue. Thus, mSIGNR1 could be involved in
the development of the marginal zone B cell repertoire resulting in a reduced population
with less specicities in the mSIGNR1-decient mouse strain and may be involved in the
prevention of autoimmunity. More research is needed to elucidate the functional conse-
quences of the interaction of mSIGNR1 expressed by marginal zone macrophages and
marginal zone B cells on both the marginal zone B cell population and repertoire. Identi-
cation of the ligand expressed on the marginal zone B cells may provide more insight in
this interaction.
8.5 Concluding remarks
In this thesis the in vivo function of mSIGNR1 was investigated. Besides its similarities
to both DC-SIGN and L-SIGN, leading to its function as a model to study the in vivo role
of these two C-type lectins, mSIGNR1 displays a unique function as a pathogen receptor
pivotal for the early immune response against blood-borne antigens. Recently Kang et
al. described that mSIGNR1 binds the complement component C1q which results in the
xation of C3. Possibly, this mechanism contributes to the clearance of S. pneumoniae
and may be involved in the activation of marginal zone B cells 29.
In contrast, DC-SIGN has been described to be targeted by pathogens to modulate
and concomitantly evade the immune response 4. The fact that mSIGNR1 plays a crucial
role in the early immune response against S. pneumoniae poses the question whether
DC-SIGN is also involved in the immune defense against pathogens. Possibly, immune
modulation by pathogens through DC-SIGN should be regarded as an exception. Thus far,
research has focused on the interaction of DC-SIGN with T cells, endothelial cells, and
neutrophils30–35. The interaction between mSIGNR1 and marginal zone B cells suggests
that also DC-SIGN may interact with specic B cells populations. Thus, DC-SIGN might
also have a functional role in autoimmunity and T-independent immune responses.
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Summary
Several studies have been performed to investigate the function of both human DC-SIGN
and L-SIGN. However, thus far, research was limited to in vitro and ex vivo studies. To
understand the potential functions of these molecules in vivo, we set out to investigate the
function of the murine homologue SIGNR1.
The carbohydrate binding characteristics of mSIGNR1 were compared to DC-SIGN
and L-SIGN in Chapter 2( 1). For the large part, DC-SIGN, L-SIGN and mSIGNR1 dis-
play similar binding characteristics such as the binding to high mannose structures. It has
been described that viruses such as HIV-1, lymphocytic choriomeningitis virus (LCMV)
and the severe acute respiratory syndrome (SARS) coronavirus bind DC-SIGN through
high mannose structures. Thus, it is likely that mSIGNR1 also binds these viruses. Con-
sequently, mSIGNR1 can be used as a model for both DC-SIGN and L-SIGN to study
the functional consequences of the binding of high mannose structures expressed by both
host and pathogen. DC-SIGN and L-SIGN display a difference in the ability to bind to
Lewisx. mSIGNR1 has the capacity to bind Lewisx, similar to DC-SIGN and in contrast
to L-SIGN2,3. Hence, we concluded that the binding capacity of mSIGNR1 is more sim-
ilar to DC-SIGN than to L-SIGN and that pathogens such as the Gram-negative H. pylori
and the worm parasite Schistosoma mansoni may also interact with mSIGNR1 through
the expression of Lewis antigens. Indeed, mSIGNR1 interacts with H. pylori LPS rich in
Lewisx and Lewisy( 1).
We also demonstrated a unique binding specicity of mSIGNR1 for sialated-Lewisx
in contrast to both DC-SIGN and L-SIGN. Sialated-Lewisx is an L-, E- and P-selectin
ligand and mSIGNR1 may share their afnity for sialylated Lewis antigens. Therefore,
the interaction with sialyl Lewisx may facilitate the binding of sialyl Lewisx-expressing
lymphocytes with mSIGNR1.
mSIGNR1, similar to DC-SIGN and L-SIGN, binds the capsular component of My-
cobacterium tuberculosis ManLAM (Chapter 3) 4. The interaction of ManLAM with DC-
SIGN expressed by immature DC results in the arrest of DC maturation and enhanced
IL-10 production5. ManLAM, which is also shed by the mycobacterium into the blood,
uses the binding to DC-SIGN to modulate the immune response for its own benet 5. We
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identied the structure expressed by ManLAM that is recognized by DC-SIGN, L-SIGN
and mSIGNR1. Using synthesized structures, we demonstrated that the SIGN molecules
specically target the mannosylated cap of ManLAM, with the highest afnity for the
(man)3-ara structure compared to (man)2-ara and man-ara structures.
Since mSIGNR1 specically binds ManLAM and M. tuberculosis, the in vivo func-
tion of mSIGNR1 during infection with M. tuberculosis was investigated (Chapter 4, sub-
mitted for publication). Although mSIGNR1 is not expressed by alveolar macrophages
6
, systemically secreted ManLAM may exert immune modulation through mSIGNR1. In
addition, expression of DC-SIGN was described to be induced upon infection with M.
tuberculosis7. Possibly, mSIGNR1 expression by alveolar macrophages is also induced
upon infection, facilitating a scavenging role for mSIGNR1 in the lung during infection.
In vitro stimulation of peritoneal macrophages of both wild-type and mSIGNR1-
decient mice demonstrated that mSIGNR1 induced an increase in IL-10 production by
these cells. These in vitro results suggested that mSIGNR1, similar to DC-SIGN, can be
used by M. tuberculosis to modulate the immune system, to enhance its propagation and
pathology. However, upon infection with M. tuberculosis, both mice strains succumbed
to this pathogen and no differences in local IL-10 or other cytokine production was ap-
parent during infection. More T cell activation in mSIGNR1-decient mice was observed
early during infection. In addition, the mSIGNR1-decient mice displayed an increase
in the Th1 associated cytokine IFNγ and a trend towards a lower production of the Th2
associated cytokine IL-4 upon restimulation of splenocytes with PPD. Hence, mSIGNR1
expressed by macrophages may be involved in the production of cytokines by T cells.
However, no difference in T cell recruitment was observed. Thus, M. tuberculosis is ca-
pable to bind mSIGNR1, and this C-type lectin may be involved in the orchestration of
the Th1/Th2 immune balance. However, mSIGNR1 does not play a signicant role in
M. tuberculosis pathology, probably due to the expression pattern of mSIGNR1 at remote
sites such as the splenic marginal zone but not by alveolar macrophages.
In contrast to M. tuberculosis, the spleen plays an important role in the defense against
Streptococcus pneumoniae 8. First the interaction of DC-SIGN with a panel of S. pneu-
moniae polysaccharides of various serotypes was investigated (Chapter 5) 9. DC-SIGN
selectively binds S. pneumoniae serotype 3 and 14, and the polysaccharide of S. pneumo-
niae serotype 14. In vitro experiments showed that serotype 14 polysaccharides do not
modulate DC biology and do not suppress the immune response against pneumococci as
is the case for M. tuberculosis-derived ManLAM 5. Thus the implications of the binding
of S. pneumoniae to DC-SIGN are currently unknown. In vivo experiments have shown
that S. pneumoniae polysaccharides specically target to the marginal zone of the spleen
10,11
. In addition, the spleen is pivotal for an appropriate immune response against this
pathogen12. Therefore, the expression of mSIGNR1 by marginal zone macrophages hints
to a role of this C-type lectin in the immune response against S. pneumoniae. Indeed, sim-
ilar to DC-SIGN, mSIGNR1 also specically interacts with both S. pneumoniae serotype
3 and 14 (Chapter 6)11,13,14. The role of mSIGNR1 during infection with S. pneumo-
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niae serotype 3 was investigated using an mSIGNR1-decient mouse strain (Chapter 6)
14
. Infection was induced by the administration of the serotype 3 pneumococci in the up-
per airways, resembling the natural route of entry. Strikingly, mSIGNR1-decient mice
succumb to infection with S. pneumoniae, in contrast to wild-type mice. Upon inves-
tigation of the sera of the mice during pneumococcal infection, the wild-type levels of
early antibodies against the pneumococcal antigen phosphorylcholine (PC) were raised
during infection, in contrast to the levels of early anti-PC IgM in mSIGNR1-decient
mice, which remained low. Marginal zone B cells together with peritoneal B-1 cells are
involved in the production of these early antibodies. Marginal zone B cells reside in close
proximity to marginal zone macrophages in the marginal zone of the spleen. Therefore,
we hypothesized that mSIGNR1, through the capture of S. pneumoniae, is involved in the
production of early antibodies by marginal zone B cells. mSIGNR1 may mediate anti-
gen transfer to the marginal zone B cell population or directly activate marginal zone B
cells to produce these early antibodies. This subject was further explored in Chapter 7,
and it was found that marginal zone B cells specically bind mSIGNR1, in contrast to
follicular B cells. In addition, mSIGNR1-decient mice displayed a reduction in their
marginal zone B cell population, suggesting that mSIGNR1 is involved in the retention
or survival of marginal zone B cells in the marginal zone. Upon polyclonal stimulation,
mSIGNR1-decient mice-derived splenic B cells produced a reduced amount of anti-PC
IgM whereas the total amount of IgM was similar to their wild-type counterparts.
The reduced marginal zone B cell population, with a lower amount of PC-specic
cells observed in the mSIGNR1-decient mice, indicates that mSIGNR1 is involved in the
development of the marginal zone B cell repertoire. However, the underlying mechanism
remains to be elucidated. Possibly mSIGNR1 expressed by marginal zone macrophages
provides survival signals or mediates retention of the marginal zone B cells.
In conclusion, mSIGNR1 is involved in the early immune defense against S. pneumo-
niae infection. Thus far, DC-SIGN was demonstrated to be hijacked by pathogens in order
to evade an immune response but our data suggest that members of the SIGN family can
also be involved in the immune defense against pathogens. In addition, we describe that
mSIGNR1 is involved in the immune defense against pneumococcal infection through the
interaction with marginal zone B cells. DC-SIGN expressed by DC has been described
to interact with T cells in both the immunological and infectious synapse where viruses
are transmitted15,16. Future studies should look into the interaction between mSIGNR1
and DC-SIGN with B cells and the concomitant functional consequences such as antigen
presentation to B cells and B cell activation.
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Samenvatting in het Nederlands voor
niet-immunologen
Het menselijk lichaam is in staat om zichzelf te beschermen tegen een groot aantal ziek-
teverwekkers, zoals bacteri¤en, schimmels, parasieten en virussen; dit worden ook wel
pathogenen genoemd. De cellen en processen die hierbij betrokken zijn vormen samen
het afweersysteem, ook wel immuunsysteem genaamd. Een belangrijk proces binnen het
immuunsysteem is het herkennen van ziekteverwekkers in een vroeg stadium van een
eventuele infectie.
Overal in ons lichaam en vooral op plaatsen waar ziekteverwekkers het lichaam binnen
kunnen komen, zoals de mond, de neus, de longen, bij de darmen, maar ook in de huid,
liggen cellen van het immuunsysteem te wachten op ziekteverwekkers. Deze cellen, zo-
gezegd de poortwachters van het immuunsysteem, zijn in staat een groot aantal ziekte-
verwekkers te herkennen en te binden. De herkenning van pathogenen is mogelijk doordat
deze cellen specieke eiwitten op het celmembraan hebben, de receptoren, die structuren
die veel voorkomen bij ziekteverwekkers kunnen herkennen. Deze structuren, die kunnen
worden gebonden door receptoren, worden liganden genoemd.
De poortwachtercellen van het immuunsysteem zijn niet allemaal hetzelfde. Een van
de soorten poortwachtercellen zijn de dendritische cellen. Deze cellen hebben lange uit-
lopers (dendron is Grieks voor boom) waarmee ze continu de omgeving aftasten om ziek-
teverwekkers op te sporen. Wanneer ze een ziekteverwekker herkennen en binden, ver-
plaatsen ze zich naar de lymfeklieren om de afweerreactie op gang te brengen door witte
bloedcellen, de T-cellen, te activeren.
Een van de receptoren waarmee de dendritische cel een ziekteverwekker kan herken-
nen heet DC-SIGN. Dit is een receptor die alleen voorkomt op de dendritische cel. Naast
het herkennen van ziekteverwekkers heeft deze receptor nog andere functies. Wanneer
dendritische cellen net aangemaakt zijn en zich in het bloed bevinden speelt DC-SIGN
een belangrijke rol bij de migratie uit het bloed richting weefsels zoals de huid. Zoals
al eerder is beschreven, vertrekken de dendritische cellen zodra ze een ziekteverwekker
hebben herkend naar de lymfeklieren om hier T-cellen te activeren. DC-SIGN is ook
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betrokken bij het contact maken met deze T-cellen.
Echter, DC-SIGN is vooral bekend vanwege het feit dat het speciek kan binden aan
het Humane Immunodeci¤entie Virus (HIV). Dendritische cellen met DC-SIGN op het
oppervlak bevinden zich bij de slijmvliezen van de geslachtsorganen, de mond en de
anus; plaatsen waar HIV door seksueel contact kan worden overgedragen van mens tot
mens. Wanneer HIV door de slijmvliezen heen het lichaam binnen probeert te komen kan
de dendritische cel via DC-SIGN HIV binden. Vervolgens migreert de dendritische cel
naar de lymfeknoop om T-cellen te activeren. Echter, de binding van DC-SIGN aan HIV
leidt niet tot een verbeterde immuunrespons en het voorkomen van HIV-infectie: HIV
proteert juist van de binding aan DC-SIGN op de dendritische cel. HIV verstopt zich
in de dendritische cel en laat zich meevoeren richting de T-cellen in de lymfeklieren. De
T-cellen zijn namelijk de slachtoffercellen van HIV. Door speciek deze T-cellen aan
te vallen zorgt HIV ervoor dat het immuunsysteem van de pati¤ent stil komt te liggen met
de ziekteverschijnselen van AIDS tot gevolg. Onze groep heeft aangetoond dat DC-SIGN
het niet alleen mogelijk maakt dat HIV mee kan liften naar de T-cellen maar dat DC-SIGN
ook nog helpt bij het infecteren van de T-cel met HIV. Wanneer DC-SIGN aanwezig is
kan HIV meer T-cellen infecteren dan bij de afwezigheid van DC-SIGN.
Sinds de ontdekking van DC-SIGN door onze groep is er al veel onderzoek gedaan
naar de functie van DC-SIGN. Ook wordt er door onze groep onderzoek gedaan naar een
homoloog van DC-SIGN in de mens; L-SIGN. Deze homoloog komt voor op bepaalde
cellen in de lever en de lymfeklier. Echter, het onderzoek bestaat voornamelijk uit expe-
rimenten die met losse cellen in kweekesjes (in vitro) worden uitgevoerd. Experimenten
met mensen zijn wel mogelijk maar alleen als er al heel veel voorwerk is verricht met
experimenten in dieren. Een voor de hand liggend dier om experimenten mee te doen in
de immunologie is de muis. Er zijn namelijk heel veel ziektes die ook kunnen worden
opgewekt in de muis en vervolgens worden bestudeerd: de infectiemodellen. Ook is er
veel kennis op het gebied van het maken van muizen die een bepaald gen missen, de
knock-outmuizen.
Het doel van dit promotieonderzoek was het onderzoeken van DC-SIGN in de muis.
Er bleken wel 5 DC-SIGN-achtige moleculen (DC-SIGN homologen) te zijn in de muis
(mDC-SIGN, mSIGNR1, mSIGNR2, mSIGNR3 en mSIGNR4) waarvan mDC-SIGN en
mSIGNR1 tot expressie komen op immunologisch interessante cellen; respectievelijk de
dendritische cel en de macrofaag. Hoewel mDC-SIGN een veelbelovende kandidaat voor
onderzoek aan DC-SIGN was doordat het net als DC-SIGN speciek tot expressie komt
op de dendritische cel, bleek dat deze receptor de liganden die DC-SIGN kon binden alle-
maal niet bond. Een andere homoloog, mSIGNR1, kon wel binden aan dezelfde liganden
als DC-SIGN. Vandaar dat dit promotieonderzoek zich heeft gericht op de functie van
mSIGNR1, een homoloog van DC-SIGN in de levende muis (in vivo).
Zoals al eerder genoemd, komt mSIGNR1 niet voor op het oppervlak van de dendriti-
sche cel, maar op een specieke groep macrofagen in de milt. Macrofagen (vrij vertaald
veelvraten) zijn immuuncellen die net als dendritische cellen door het hele lichaam
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verspreid liggen, en dode of beschadigde cellen, maar ook pathogenen kunnen opnemen
en verteren.
Om zo snel mogelijk een effectieve immuunreactie te genereren zijn er op diverse
plaatsen in ons lichaam verschillende organen van het immuunsysteem gesitueerd. Een
aantal van die organen zijn de honderden lymfeklieren die zich op strategische plekken
in het lichaam bevinden. De milt is een ander orgaan van het immuunsysteem en is veel
groter dan een lymfeklier. Het is een vuistgroot, zeer goed doorbloed orgaan dat ligt on-
der het middenrif, achter de maag. Zoals lymfeklieren de huid controleren op indringers,
zo controleert de milt het bloed op pathogenen. Naast deze immunologische functie is
de milt ook belangrijk voor het afbreken van verouderde rode bloedcellen en het recyclen
van het ijzer dat vrijkomt bij deze afbraak. Aangezien de meeste taken van de milt kun-
nen worden overgenomen door andere organen, is het mogelijk dat individuen bij wie de
milt operatief is verwijderd een relatief normaal leven kunnen leiden. Echter, de afweer
tegen bacteri¤en die zijn omgeven door een kapsel met suikerstaarten, zoals Streptococcus
pneumoniae, is verminderd wanneer de milt is verwijderd. Streptococcus pneumoniae
is een ziekteverwekker die verantwoordelijk is voor onder andere hersenvliesonststeking
(nekkramp), longontsteking en oorinfecties. Vandaar dat pati¤enten, bij wie de milt zal
worden verwijderd, gevaccineerd worden.
De structuur van het miltweefsel laat witte bolvormige structuren zien binnen een rode
sponzige massa. De witte structuur wordt de witte pulpa genoemd. Deze structuur bevat
de witte bloedcellen; de T- en B-cellen, die verantwoordelijk zijn voor de immunologi-
sche functie van de milt. De rode massa is rood vanwege de rijke doorbloeding en wordt
de rode pulpa genoemd. In de rode pulpa worden de verouderde rode bloedcellen uit het
bloed gelterd en afgebroken. De rode en witte pulpa worden van elkaar gescheiden door
de marginale zone. Deze marginale zone bestaat uit een bloedvat waar een deel van het
arteri¤ele bloed in terecht komt maar waar de snelheid van de bloedsomloop drastisch is
verlaagd, en diverse immuuncelpopulaties. De marginale zone macrofagen liggen tussen
het bloedvat en de rode pulpa. Door specieke technieken waarbij specieke eiwitten op
het celmembraan van cellen zichtbaar gemaakt kunnen worden, de immunohistochemie,
kunnen we diverse populaties macrofagen van elkaar onderscheiden.
De marginale zone macrofaagpopulatie werd al in de jaren ’80 ontdekt doordat zij
speciek reageerde met de antistof ERTR-9. Heel lang was het onbekend wat ERTR-9
precies herkende op het celmembraan van de marginale zone macrofaag. Vlak voor de
start van dit promotieonderzoek heeft onze groep ontdekt dat ERTR-9 speciek mSIGNR1
(een muis-homoloog van DC-SIGN) herkent. Het doel van het promotieonderzoek was
het vergroten van het inzicht in de functie van mSIGNR1. Door de eigenschappen van
mSIGNR1 te onderzoeken en te vergelijken met DC-SIGN en L-SIGN, kunnen we er-
achter komen in hoeverre mSIGNR1 in de muis te vergelijken is met DC-SIGN in de
mens. Vervolgens kunnen muismodellen, waarbij de functie van mSIGNR1 wordt onder-
zocht in het levende dier, ons meer informatie geven over de functie van DC-SIGN en
L-SIGN in de mens.
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In hoofdstuk 1 wordt een overzicht gegeven van de literatuur op het gebied van DC-
SIGN en de homologen van DC-SIGN in mens en muis. Aangezien mSIGNR1 op een
specieke macrofaagpopulatie in de milt tot expressie komt, wordt in dit hoofdstuk de
anatomie van de milt uitgebreid besproken.
In hoofdstuk 2 worden de bindingseigenschappen van mSIGNR1 bestudeerd. Aange-
zien het hoofddoel van het promotieonderzoek is om door in vivo experimenten met een
muis-homoloog van DC-SIGN meer kennis te verkrijgen over de in vivo functie van
DC-SIGN worden de bindingseigenschappen vergeleken met DC-SIGN. Ook L-SIGN
wordt in deze studie betrokken aangezien studies aan mSIGNR1 wellicht ook meer infor-
matie zouden kunnen geven over L-SIGN. De binding van diverse suikerstructuren aan
mSIGNR1, DC-SIGN en L-SIGN wordt vergeleken. De drie homologen vertonen in grote
lijnen hetzelfde bindingspatroon. Ze binden bijvoorbeeld alledrie stucturen met een groot
aantal mannosegroepen. Door deze kennis weten we dat mSIGNR1 gebruikt kan worden
als model voor zowel DC-SIGN als L-SIGN bij het bestuderen van de in vivo functie
van deze moleculen, bij het binden aan deze structuren op lichaamseigen structuren of op
pathogenen. Naast overeenkomsten zijn er echter ook verschillen. DC-SIGN bindt aan
de suikerstructuur Lewisx terwijl L-SIGN deze structuur niet bindt. mSIGNR1 kan net
zoals DC-SIGN wel binden aan Lewisx. Dus kan mSIGNR1 model staan voor DC-SIGN
bij het bestuderen van de interactie met Lewisx. Echter, qua expressie lijkt mSIGNR1
meer op L-SIGN dan op DC-SIGN aangezien mSIGNR1 net als L-SIGN tot expressie
komt op specieke cellen in de lever en de lymfeklier, en niet op dendritische cellen zoals
DC-SIGN. Ook blijkt uit deze bindingsstudie dat mSIGNR1 kan binden aan Lewisx met
een siaalzuurgroep terwijl zowel DC-SIGN als L-SIGN dit niet doen. Dit suggereert dat
mSIGNR1 ook functies zou kunnen hebben die niet vergelijkbaar zijn met DC-SIGN of
L-SIGN.
Nu we meer weten over de bindingseigenschappen van mSIGNR1 kunnen we probe-
ren te voorspellen welke ziekteverwekkers deze receptor zal kunnen binden. Het binden
aan Lewis-antigenen wijst er bijvoorbeeld op dat mSIGNR1 zal kunnen binden aan de pa-
rasitaire worm Schistosoma mansoni of de bacterie Helicobacter pylori (die maagzweren
kan veroorzaken), aangezien het bekend is dat deze ziekteverwekkers Lewis-structuren
op hun oppervlak hebben.
Ook zijn DC-SIGN, L-SIGN en mSIGNR1 alledrie in staat om ManLAM, een on-
derdeel van het kapsel van Mycobacterium tuberculosis te binden. Mycobacterium tuber-
culosis veroorzaakt tuberculose bij de mens. Onze groep heeft al eerder laten zien dat
ManLAM-binding aan DC-SIGN op humane dendritische cellen in vitro ertoe leidt dat
dendritische cellen uitgeschakeld worden en een stofje (interleukine-10) gaan produceren
dat de immuunrespons afremt. De kapselcomponent ManLAM wordt expres door de my-
cobacterie uitgescheiden om via DC-SIGN de afweerreactie te onderdrukken, waardoor
Mycobacterium tuberculosis beter kan gedijen.
In hoofdstuk 3 hebben we uitgezocht welke structuur op ManLAM nu precies gebon-
den wordt door DC-SIGN. Het zijn de mannosegroepen van ManLAM. ManLAM bestaat
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uit een polymeer van arabinose waar op drie plekken verschillende hoeveelheden man-
nosegroepen gebonden kunnen zijn. De binding aan DC-SIGN, L-SIGN en mSIGNR1
is het beste als er meer dan 1 mannosegroep per plek aanwezig is. Nu we weten welke
structuren verantwoordelijk zijn voor de binding van ManLAM aan DC-SIGN is het mo-
gelijk om middelen te verzinnen om deze interactie te blokkeren zodat Mycobacterium
tuberculosis niet langer in staat is het immuunsysteem te onderdrukken. Echter het on-
derdrukken van het immuunsysteem door ManLAM-binding aan DC-SIGN is tot dusver
alleen in vitro aangetoond.
Om de rol van DC-SIGN tijdens een infectie met Mycobacterium tuberculosis verder
te onderzoeken hebben we in hoofdstuk 4 een Mycobacterium tuberculosis infectiemodel
bestudeerd met mSIGNR1 knock-outmuizen. In vitro stimulatie van macrofagen met en
zonder mSIGNR1 laten zien dat mSIGNR1 net als DC-SIGN ook interleukine-10 aan-
maakt na stimulatie. Dit is een aanwijzing dat ook mSIGNR1 door Mycobacterium tu-
berculosis gebruikt kan worden om de afweerreactie te remmen. Echter, na infectie van
normale (wild-type-) en knock-outmuizen met Mycobacterium tuberculosis waren er geen
verschillen in het ziektebeeld van de muizen te meten. Wel hebben we een aantal aanwij-
zingen dat mSIGNR1 een rol speelt in de aard van de immuunreactie. Een verklaring
voor het ontbreken van grote verschillen in ziektebeeld tussen de wild-type- en knock-
outmuizen is dat mSIGNR1 tot expressie komt in de milt, de lever en in de buikholte, ter-
wijl Mycobacterium tuberculosis vooral actief is in de long. Hierdoor kan een eventuele
invloed van mSIGNR1 uiteindelijk geen meetbare invloed hebben op het ziektebeeld van
de muizen.
Het is bekend dat de milt een belangrijke rol speelt bij de afweer tegen de bacterie
Streptococcus pneumoniae. In hoofdstuk 5 laten we zien dat DC-SIGN in staat is om
deze bacterie te binden maar deze binding leidt, in tegenstelling tot de binding van Man-
LAM op Mycobacterium tuberculosis, niet tot onderdrukking van het immuunsysteem.
In hoofdstuk 6 bestuderen we een infectiemodel met Streptococcus pneumoniae. De
muizen worden ge¤nfecteerd door ze kleine druppeltjes met bacterie op te laten snuiven,
wat vergelijkbaar is met een besmetting die je oploopt doordat iemand anders hoest. Nu
waren er grote verschillen tussen de wild-type- en knock-outmuizen waar te nemen; de
knock-outmuizen waren veel zieker dan de wild-typemuizen. Toen we het bloed van de
muizen nader gingen onderzoeken bleek dat de wild-typemuizen tijdens de infectie een
bepaalde antistof hadden aangemaakt; anti-fosforylcholine, terwijl deze antistof amper
aanwezig was in de knock-outmuizen. Het is bekend dat deze anti-fosforylcholine anti-
stof de Streptococcus pneumoniae speciek kan herkennen en zo een onderdeel vormt van
de afweerreactie tegen deze ziekteverwekker. De antistof wordt gemaakt door specieke
B-cellen in de buikholte en de marginale zone van de milt. Deze B-cellen zijn bijzonder
omdat ze zonder hulp van T-cellen antistoffen kunnen produceren. Het voordeel hier-
van is dat er binnen zeer korte tijd een antistof geproduceerd kan worden waardoor de
ziekteverwekker snel onschadelijk kan worden gemaakt.
Marginale zone B-cellen bevinden zich vlakbij de marginale zone macrofagen met
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mSIGNR1 op het oppervlak. Wellicht dat mSIGNR1 door het binden en wegvangen
van Streptococcus pneumoniae betrokken is bij de produktie van de vroege antistoffen
door marginale zone B-cellen. In hoofdstuk 7 hebben we een begin gemaakt met het
onderzoek naar de rol van mSIGNR1 bij de productie van antistoffen door marginale
zone B-cellen. Ons onderzoek wijst uit dat mSIGNR1 kan binden aan marginale zone
B-cellen. Bovendien waren er veel minder marginale zone B-cellen aanwezig in de milt
van mSIGNR1 knock-outmuizen dan in de milt van wild-typemuizen. Deze resultaten
wijzen er op dat mSIGNR1 betrokken kan zijn bij het aantrekken van B-cellen naar
de marginale zone: dat in de afwezigheid van mSIGNR1 de marginale zone B-cellen de
marginale zone niet kunnen vinden en hier dus niet terecht komen. Ook is het mogelijk
dat marginale zone B-cellen afhankelijk zijn van een overlevingssignaal van mSIGNR1
waardoor ze in de knock-outmuis sneller doodgaan.
Wanneer B-cellen uit de milt van knock-out- of wild-typemuizen in vitro gestimuleerd
werden om antistof te produceren was er wederom een verschil te meten in de hoeveelheid
anti-fosforylcholine antistof. De B-cellen uit de milt van de knock-outmuis produceerden
wel wat anti-fosforylcholine antistof maar dit was veel minder dan de hoeveelheid ge-
produceerd door de B-cellen uit de milt van de wild-typemuis. Wellicht is mSIGNR1
betrokken bij het samenstellen van het repertoire van de B-cellen door fosforylcholine-
specieke B-cellen aan te trekken en/of in leven te houden.
Samenvattend beschrijft dit proefschrift de complexe rol van mSIGNR1 in vitro en in
vivo. mSIGNR1 is een homoloog van DC-SIGN en kan model staan voor deze receptor.
Echter doordat mSIGNR1 niet zoals DC-SIGN tot expressie komt op de dendritische cel
maar op specieke macrofaagpopulaties in de milt, lymfeklier, buikholte en op endotheel-
cellen van de lever is mSIGNR1 geen ideale, maar tot dusver wel de enige kandidaat voor
het verkrijgen van informatie over de in vivo functie van DC-SIGN. Juist vanwege dit
expressiepatroon is mSIGNR1 een zeer geschikte kandidaat voor het onderzoeken van de
in vivo functie van L-SIGN. Er is een stuk minder bekend over de functie van L-SIGN
dan die van DC-SIGN; waarschijnlijk zal verder onderzoek naar mSIGNR1 ook nieuwe
invalshoeken genereren voor het onderzoek naar L-SIGN en de immunologie in het alge-
meen.
Tijdens dit promotieonderzoek is duidelijk geworden dat mSIGNR1, naast de overeen-
komsten met DC-SIGN en L-SIGN, een unieke functie heeft als pathogeenreceptor en
betrokken is bij de snelle afweerreactie tegen ziekteverwekkers in het bloed.
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A B
C D
Figure A.1: In both WT and mSIGNR1 KO mice a similar degree of inflammation was ob-
served in the lung
(color reprint of Fig. 4.3, pp. 73)
Representative lung histology of WT (A and C), and mSIGNR1 KO (B and D) mice, 2 (A, B) and
5 (C, D) weeks after intranasal infection with 105 CFU of M. tuberculosis. The lung sections are
representative for 6-8 mice per group per time point. H&E staining, magnification ×10.
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Figure A.2: No expression of mSIGNR1 in lungs of infected WT mice
(color reprint of Fig. 4.4, pp. 74)
Representative mSIGNR1 stainings of lung (A) and spleen (B) from WT mice 2 weeks after in-
tranasal infection with 105 CFU of M. tuberculosis. No mSIGNR1 positive cells were detectable in
the lung whereas marginal zone macrophages are stained positively. Sections are representative for
6-8 mice per group. Original magnification ×10.
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Figure A.3: mSIGNR1 captures blood-borne TI-II antigens in vivo
(color reprint of Fig. 6.1, pp. 100)
(A) The splenic marginal zone from SIGNR1−/− mice contains both marginal zone macrophage
subsets (marginal zone macrophages (MZM) and marginal metallophilic macrophages (MMM) re-
spectively), but does not capture TI-II antigens. Spleens from naive WT (left) and SIGNR1−/−
(right) mice were stained for MARCO+ MZM in red and SER-4+ MMM in green (upper panel),
for mSIGNR1 with ERTR-9 (middle panel) and for capture of dextran-FITC 45 minutes after intra-
venous administration (lower panel). These data are representative for three animals of both geno-
types. (B and C) Peritoneal macrophages from SIGNR1−/− mice do not capture TI-II antigens.
Peritoneal macrophages were analyzed for mSIGNR1 expression using ERTR-9 (B), and binding
to dextran-FITC was analyzed in the presence and absence of the blocking reagents mannan and
EGTA (C). These data are representative for three independent experiments.
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Figure A.4: mSIGNR1 is pivotal for the in vivo capture of blood-borne S. pneumoniae serotype
3 by the marginal zone
(color reprint of Fig. 6.4, pp. 104)
(A) S. pneumoniae is not captured in vivo by the splenic marginal zone in SIGNR1−/− mice. The
capture of intravenous injected S. pneumoniae was determined in five representative visual fields
of spleen sections of WT (upper) and SIGNR1−/− (lower panel) mice after 45 minutes. Spleens
were stained for MARCO+ marginal zone macrophages (MZM) in red and S. pneumoniae in green.
Inset shows pneumococci colocalizing and in close contact with WT MARCO+ MZM. Inset shows
the absence of pneumococci in the marginal zone of SIGNR1−/− mice. (B) S. pneumoniae is
captured by the marginal zone of the WT spleen whereas the pneumococci are hardly detected in
the marginal zone of the SIGNR1−/− spleen. The amount of S. pneumoniae particles residing in
the marginal zone of either WT or SIGNR1−/− mice was counted and compared. The capture of
intravenously injected S. pneumoniae was determined in five representative visual fields of spleen
sections of WT and SIGNR1−/− mice after 45 minutes. (C) The S. pneumoniae particles present
in the SIGNR1−/− spleen reside mostly in the red pulp area (RP) of the spleen, in contrast to the S.
pneumoniae particles present in the WT spleen which target to the marginal zone (MZ). These data
are representative for three animals of both genotypes. ∗P <0.05.
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Figure A.5: mSIGNR1 is pivotal for the in vivo capture of blood-borne S. pneumoniae serotype
3 polysaccharide by the marginal zone
(color reprint of Fig. 7.1, pp. 116)
S. pneumoniae serotype 3 polysaccharides are retained by the marginal zone after intravenous in-
jection in WT (upper) whereas it is dispersed throughout the spleen in mSIGNR1-deficient mice
(SIGNR1−/−, lower panel). Intravenously injected S. pneumoniae serotype 3 polysaccharide was
detected in spleen sections of WT mice (upper) and mSIGNR1-deficient mice (lower panel) after
45 minutes. Spleens were analyzed for the expression of MARCO+ marginal zone macrophages
(MZM) in red and pneumococcal polysaccharide serotype 3 (PPS3) in green.
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Figure A.6: Decreased numbers of marginal zone B cells in mSIGNR1-deficient mice
(color reprint of Fig. 7.2, pp. 117)
The splenic marginal zone from mSIGNR1-deficient mice contains a decreased amount of marginal
zone B cells. Spleens from naive WT (left) and mSIGNR1-deficient mice (SIGNR1−/−, right)
were analyzed for the presence of MadCAM+ sinus-lining endothelial cells in red (upper panel) or
MARCO+ marginal zone macrophages in red (lower panel) and the expression of CD1d in green.
Marginal zone B cells were identified as the CD1d-postitive cells located outside the MadCAM+
rim and juxtaposed to the MARCO+ marginal zone macrophages. These data are representative for
three animals of both genotypes.
